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Preeclampsia is a pregnancy specific disorder which complicates about 5 to 7% of all 
pregnancies and is characterized by the presence of hypertension (blood pressure systolic 
≥ 140 mmHg and/or diastolic ≥ 90 mmHg) and proteinuria after the 20th week of pregnancy 
in a previously normotensive woman.1 Although the pathophysiology of preeclampsia has 
been the focus of many studies, the exact mechanism underlying the disease remains 
unclear. Currently leading hypotheses concern poor placentation followed by oxidative 
stress and release of substances from the intervillous space into the maternal circulation 
such as soluble endoglin, soluble fms-like tyrosine kinase-1 (sFlt-1) and syncytiotrophoblast 
microparticles. These substances may subsequently lead to a maternal inflammatory 
response and generalized endothelial dysfunction resulting in a decreased circulating 
volume and altered vascular reactivity.1 
Preeclampsia is a systemic disorder that can affect several maternal organs, including 
the kidneys, liver and brain. Involvement of the brain is most evident in case of eclampsia 
which is characterized by tonic-clonic convulsions or coma, and may develop before, 
during or after labor.2, 3 Several other neurological symptoms can be seen including severe 
and persistent headache, nausea, vomiting, altered mental status and photophobia.4, 5 In 
addition, visual disturbances may accompany (pre)eclampsia and are reviewed in Chapter 
6. 
Eclampsia is a relatively rare but serious complication of preeclampsia, and largely 
contributes to preeclampsia-related maternal and neonatal mortality and morbidity 
worldwide. In the Netherlands, eclampsia occurs in 6.2 per 10,000 deliveries and is 
responsible for death in 1 out of 74 eclamptic cases (1.4%).6 In the period 1993-2005, the 
overall Dutch maternal mortality ratio was 12.1 per 100,000 live births. The preeclampsia-
related mortality ratio was 3.5 per 100,000, which makes preeclampsia the leading cause 
of maternal mortality in the Netherlands. Of all preeclampsia-related deaths, 61% is due to 
cerebral complications.7 In other developed countries, incidence rates of eclampsia vary 
from 2.4 to 8.0 per 10,000 deliveries8-11 and case fatality rates range from 0.5 to 1.8 %.3, 10 
Unfortunately, eclampsia is more common in developing countries12 with incidence rates 
of 29 to 220 per 10,000 deliveries and maternal outcome is worse with case fatality rates 
of 5.0 to 26.5 %.13-16 
Animal models of preeclampsia
Both preeclampsia and eclampsia spontaneously occur only in the human and in primates.17 
During the last decades, much effort has been put into the development of animal models 
for preeclampsia. Ideally, such a model should exhibit the full spectrum of biochemical 
and clinical features of human preeclampsia. However, so far no model has been able to 
reproduce all preeclampsia aspects, but several models have been identified to mimic at 
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least part of the syndrome. These models in several species include reduced uteroplacental 
perfusion by clipping the aorta or uterine arteries, chronic nitric oxide synthase inhibition, 
adriamycin-induced nephropathy, insulin resistance, renin angiotensin or sympathetic 
nervous system overactivity, antagonism of angiogenic factors by sFlt-1 and inflammatory 
models with low-dose endotoxin or tumor necrosis factor α administration.17 
In Chapter 4 and 5, the low-dose endotoxin-infused pregnant rat was used as a 
model for preeclampsia to study the effects of this disease on the brain. Pregnant rats 
in this model become hypertensive after low-dose endotoxin infusion through a jugular 
vein cannula at day 14 of pregnancy.18 Furthermore, these rats have been shown to exhibit 
proteinuria, disseminated intravascular coagulation with decreased platelet numbers and 
endothelial cell activation,18-21 which are all features of human preeclampsia. In addition, 
the syndrome is pregnancy-specific since nonpregnant rats treated with endotoxin remain 
asymptomatic.18, 19 The underlying mechanism of the development of the preeclamptic-like 
syndrome in this model is considered to be a generalized low-grade inflammatory response 
induced by endotoxin,19, 22 which is similar to the systemic intravascular inflammatory state 
observed in preeclamptic patients.1 Additionally, oxidative stress may have a role as well, 
which seems also the case in human preeclampsia.23
Pathophysiology of eclampsia
The pathophysiology of eclampsia has not been completely elucidated. Nowadays, two 
opposing theories exist about the mechanism underlying the occurrence of eclampsia, 
both concerning failure of autoregulation of cerebral blood flow. 
The first theory proposes that eclampsia arises from cerebral ischemia. In this 
theory, acute hypertension leads to vasospasm due to cerebral “overautoregulation”. As 
a result, cerebral hypoperfusion may induce ischemia, cytotoxic edema formation and 
eventually cerebral infarction. Evidence for this theory comes from catheter angiography 
and MR angiography demonstrating focal or diffuse vasoconstriction of the cerebral 
vasculature.24-26 
The second theory entails loss of cerebral autoregulation, in which, in the presence 
of some degree of endothelial dysfunction, an increase in blood pressure is thought to 
exceed the upper autoregulatory limit. This may cause forced dilatation of the cerebral 
vasculature leading to cerebral hyperperfusion, blood-brain barrier disruption and cerebral 
vasogenic edema formation.27-29 This edema is considered to be the underlying cause of 
the neurological symptoms in eclampsia and resolves upon recovery of endothelial cell 
dysfunction and lowering of blood pressure to values within the autoregulatory limits.30-32
Since the emergence of advanced cranial imaging techniques, it has become apparent 
that cerebral edema in eclampsia is consistent with vasogenic edema.33-35 Therefore, the 
first theory which held ischemia as the sole mechanism underlying eclampsia seems 








In 1996, Hinchey et al described a syndrome in a series of patients which all had 
neuroimaging findings consistent with cerebral edema, mainly in the posterior regions of 
the brain.30 Furthermore, these patients demonstrated similar neurological symptoms, 
including headache, visual disturbances, altered mental status and seizures. This syndrome, 
named ‘reversible posterior leukoencephalopathy syndrome’, was associated with a variety 
of disorders, one of which was eclampsia. Since that time, eclampsia is considered to be 
a form of this syndrome, which is nowadays mostly referred to as ‘posterior reversible 
encephalopathy syndrome’ (PRES).36, 37 
Posterior Reversible Encephalopathy Syndrome
PRES is a clinicoradiological entity, which is associated with a wide range of clinical 
problems in both the adult as well as the pediatric population.38 PRES has most commonly 
been reported in patients with eclampsia, immunosuppression after organ transplantation, 
and severe hypertension but is also associated with renal inflammatory conditions, 
chemotherapy and several autoimmune diseases.30, 38, 39 
PRES can present with various neurological symptoms, of which headache, nausea 
and vomiting, seizure, altered mental state and visual disturbances such as blurred vision 
and cortical blindness are most common.30 As its name suggests, the classical radiologic 
imaging pattern in PRES consists of bilateral edema predominantly in the posterior portion 
of the cerebral hemispheres, especially the parieto-occipital regions. However, frontal and 
temporal lobe, cerebellum, basal ganglia and brainstem involvement is also seen in PRES 
patients.30, 38-40 While the subcortical white matter is mainly affected by edema, gray matter 
involvement and hemorrhage may also occur.39, 41 Although the edema is often apparent on 
computed tomography (CT) imaging as hypointense lesions, the edema is best depicted 
by magnetic resonance imaging (MRI). On MRI, PRES lesions appear as hypointensities 
on T1 sequence and hyperintensities on T2 and fluid attenuation inversion recovery 
(FLAIR) sequences.30, 38 Using diffusion weighted imaging (DWI), these areas have normal 
or decreased signal intensity while they show increased apparent diffusion coefficients 
(ADC).33, 35 This MRI imaging pattern of PRES is consistent with vasogenic edema. However, 
in some cases DWI demonstrate small areas of cytotoxic edema within areas of vasogenic 
edema, which has been suggested to result from extensive vasogenic edema leading to 
decreased cerebral perfusion, impaired cerebral blood flow and ischemia.35, 39, 42
The exact mechanism leading to cerebral edema in PRES is not completely understood. 
While acute hypertension is considered to play a central role in the pathophysiology of 
PRES, evident hypertension is not always present.43 In fact, 20-30% of patients developing 
PRES are normotensive or have hypertensive values which do not exceed the generally 
accepted upper limit of cerebral autoregulation,43-45 which is the capacity of the cerebral 
vasculature to keep cerebral blood flow relatively constant in the presence of changes in 
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cerebral perfusion pressure (see below). Interestingly, in pathological conditions associated 
with PRES a certain degree of endothelial dysfunction is usually present.43 While the role 
of endothelial dysfunction in the development of PRES has not been elucidated, it may 
influence cerebral autoregulation and the blood-brain barrier. 
The cerebral vasculature seems to play a crucial role in the pathophysiology of PRES, 
and eclampsia in particular. In this context, several aspects of the cerebral circulation 
are of interest and will be discussed in the following paragraphs, including cerebral 
autoregulation and the blood-brain barrier.
Cerebral autoregulation
Under normal conditions, cerebral blood flow is maintained at a relatively constant level 
despite changes in cerebral perfusion pressure. The ability of the brain to maintain this 
relatively constant blood flow during changes in perfusion pressure is called autoregulation 
and is brought about by changes in arterial diameter and cerebrovascular resistance (Figure 
1).46 Between arterial pressures of about 50-60 to 150-160 mmHg, cerebral blood flow is kept 
constant and is called the autoregulatory plateau.47 However, in case of blood pressures 
below or above these limits, autoregulation may be lost.46 During acute hypertension, as in 
eclampsia, the upper limit of cerebral autoregulation is exceeded and the myogenic tone 
of cerebral arteries and arterioles is overcome due to excessive intravascular pressure.46,48 
In this state of forced dilatation, cerebral blood flow increases linearly with increases in 
blood pressure.48, 49 Consequently, the blood-brain barrier can be disrupted due to excessive 
hydrostatic pressure leading to vasogenic edema formation.29, 50, 51 When blood pressure is 
reduced to values within the autoregulatory range, cerebral blood flow normalizes and 
edema is thought to resolve.30, 52
Figure 1. The cerebral autoregulation curve. Adapted from Chillion and Baumbach 1997 47 and used 







Several mechanisms have been proposed to cause changes in cerebral artery 
diameter in order to maintain a constant cerebral blood flow, including neurogenic, 
metabolic and myogenic mechanisms.53, 54 Concerning the neurogenic mechanism, 
neuronal innervation of the cerebral vasculature may control cerebral blood flow and 
comprises extrinsic innervation arising from the peripheral nervous system, and intrinsic 
innervation originating from within the brain. Although under resting conditions extrinsic 
sympathetic and trigeminal innervation appears to have little effect on cerebral blood 
flow, a role for extrinsic parasympathetic and intrinsic innervation has been suggested.46, 
55-57 The metabolic mechanism is thought to be flow-dependent: reduction of cerebral 
blood flow results in accumulation of metabolic substances that cause vasodilatation.53 
This way, higher metabolic demand leads to increased cerebral blood flow. In contrast, 
the myogenic control mechanism suggests a pressure-dependent mechanism by which 
vascular wall smooth muscle cells respond to changes in transmural pressure.46, 58 This 
intrinsic response induces vascular constriction when transmural pressure increases and 
relaxation during pressure decreases. In addition to these three mechanisms underlying 
cerebral autoregulation, endothelial-derived factors are also thought to influence cerebral 
autoregulation by exerting relaxing or constrictive influences on vascular smooth muscle 
cells. Release of these factors can be induced by various stimuli, including shear stress, 
hormones and neuronal signals.59 
Chronic hypertension influences cerebral autoregulation by inducing remodeling and 
hypertrophy of the cerebral arteries and arterioles, thereby normalizing wall stress by 
increasing wall thickness and reducing vascular diameter.60, 61 These structural changes of 
the vascular wall are considered to be protective mechanisms for the cerebral circulation 
by inducing a rightward shift of the cerebral autoregulation curve.62 This way, the pressure 
at which loss of cerebral autoregulation occurs increases to higher values, i.e., the cerebral 
blood flow autoregulatory curve shifts to the right.
Since impaired cerebral autoregulation seems to have a crucial role in the 
pathophysiology of PRES/eclampsia, a number of studies have focused on the influence of 
pregnancy per se on cerebral autoregulation. A considerable number of eclamptic women 
never reach blood pressures that exceed the upper limit of autoregulation.3, 10 Therefore, 
it has been suggested that pregnancy may shift the upper limit of the autoregulation curve 
to the left, thereby leading to breakthrough of autoregulation and hyperperfusion at lower 
blood pressure compared to nonpregnant subjects. In support of this hypothesis, Cipolla et al 
found that posterior cerebral arteries from late-pregnant rats in vitro exhibit less myogenic 
reactivity and undergo forced dilatation at lower pressures compared to nonpregnant 
animals.63, 64 However, in contrast to these findings, pressure of forced dilatation did not 
differ between late-pregnant and nonpregnant animals in vivo.65 Therefore, whether there 




Although studies in normal pregnancy may certainly add to our understanding of the 
cerebrovascular pathophysiology of preeclampsia, the influence of preeclampsia on the 
cerebral circulation is of particular interest. Studies addressing structure and function of 
cerebral arteries in rat models of pregnancy hypertension are limited. In Dahl salt-sensitive 
rats, that become hypertensive due to a high-salt diet, myogenic reactivity was diminished 
during pregnancy, regardless of presence of hypertension.64 In addition, while hypertension 
in nonpregnant rats causes inward remodeling and medial hypertrophy of posterior cerebral 
arteries, arteries from late-pregnant rats lacked this response.64 This lack of hypertensive 
remodeling was also shown in a study using nitric oxide synthase inhibition to raise blood 
pressure in nonpregnant and late-pregnant rats.66 Both diminished myogenic reactivity and 
lack of hypertensive remodeling may predispose the brain to breakthrough of autoregulation 
when blood pressure is increased, as observed in eclampsia. How preeclampsia, induced 
by low-dose endotoxin infusion in pregnant rats, affects the function and structure of the 
cerebral circulation has not been elucidated and was investigated in Chapter 4.  
Blood-brain barrier and vasogenic edema
Another unique feature of the cerebral circulation is the presence of the blood-brain 
barrier (BBB). This BBB is formed by the cerebral endothelium and distinguishes the brain 
from other tissues pertaining to the processes of extravasation of water and solutes 
from the blood stream. In other tissues, plasma proteins are kept within the capillaries 
but water and solutes can freely move between the vascular endothelial cells into the 
surrounding tissue.67 In the brain, however, the BBB prevents extravasation of both small 
and large solutes including ions and plasma proteins.67 This is established by the presence 
of high electrical resistance tight junctions between the endothelial cells which prevent 
paracellular flux.68, 69 In addition, cerebral endothelial cells lack fenestrations and have a 
low rate of pinocytosis, which both restrict transcellular transport.68, 70 In this way, the BBB 
protects the brain against formation of vasogenic edema since water movement due to 
hydrostatic pressure in the capillaries is immediately opposed by the osmotic pull of both 
plasma proteins and ions.67
It is of importance to understand the influence of pregnancy on the BBB since the 
vasogenic edema seen in eclamptic patients is considered to be a consequence of BBB 
disruption.71 Apparently, during acutely increased hydrostatic pressure, the BBB can be 
disrupted with resultant vasogenic edema formation.71, 72 An in vivo study in nonpregnant 
and late-pregnant rats with acute hypertension showed that while pregnancy did not affect 
the pressure at which breakthrough of cerebral autoregulation occurred, only the late-
pregnant animals developed significant brain edema in response to this autoregulatory 
breakthrough.65 These results suggest that pregnancy predisposes to cerebral edema 
formation during acute hypertension. In Chapter 2, we aimed to provide insight into the 







greater edema formation in response to increased hydrostatic pressure, we investigated 
the effect of pregnancy on hydraulic conductivity (permeability to water in response to 
hydrostatic pressure) and endothelial cell permeability to Lucifer Yellow of rat posterior 
cerebral arteries. Furthermore, we assessed whether estrogen has a role in the effects of 
pregnancy on BBB permeability.
Aquaporins
Also aquaporins (AQPs) have been proposed to have a role in brain water homeostasis 
and cerebral edema formation and resolution.73 AQPs are a family of channel forming 
transmembrane proteins consisting of 13 members, AQP0 through AQP12.73 These proteins 
all facilitate bidirectional movement of water through cell membranes in a variety of cell 
types.74, 75 Some AQPs are also permeable to glycerol, urea or other solutes.73 Currently, 
seven of the AQP family members have been identified in the rodent brain, of which three 
are well described in vivo, namely AQP1, AQP4, and AQP9.73
AQP1 is permeable only to water and has been localized within epithelial cells of the 
choroid plexus.76, 77 Given its location and the finding that AQP1-deficient mice have reduced 
cerebrospinal fluid (CSF) formation, AQP1 is proposed to have a role in CSF formation.78 
AQP4 is the most abundant AQP in the brain, and its permeability is restricted to water.73 
Expression of AQP4 is found in several brain regions including the cortex, hippocampus, 
magnocellular hypothalamic nuclei, cerebellum and brain stem.75, 79 In these regions AQP4 
is expressed in astrocytic endfeet bordering the ventricles, subarachnoid space, and the 
blood vessels.80 Some studies have also demonstrated endothelial AQP4 expression,81, 82 
however, others did not.80, 83 Given its location at the blood-brain and brain-CSF interfaces, 
AQP4 is proposed to have a role in brain water homeostasis. Furthermore, colocalization 
with the potassium channel Kir4.1 suggests involvement of APQ4 in potassium homeostasis.
84 
AQP9 facilitates diffusion of both water and several solutes such as glycerol, urea and 
monocarboxylates.85 Expression of AQP9 is found in glia and catecholaminergic neurons.86, 
87 One study also showed AQP9 in endothelial cells of pial vessels.87 The localization of 
AQP9 suggests involvement in cerebral water homeostasis. In addition, a role in brain 
energy metabolism by facilitating diffusion of glycerol and monocarboxylates has been 
proposed.87
Since cerebral edema formation is basically an expression of loss of water homeostasis 
in the brain, AQPs have been proposed to play a role in cerebral edema formation. In 
fact, several studies in different animal models have focused on the role of AQP1, AQP4 
and AQP9 in cerebral edema formation and resolution. For example, in a rodent model 
of subarachnoid hemorrhage, which is accompanied by cerebral edema formation, AQP1 
expression appears increased.88 In a mouse model of transient focal cerebral ischemia, 
also accompanied by cerebral edema, AQP9 is upregulated in astrocytes around the infarct 
border.89 However, this upregulation was not correlated with brain swelling, suggesting a 
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lack of an important role for AQP9 in water movement associated with vasogenic edema 
formation in ischemic brain injury.90 
Of the cerebral AQPs, AQP4 has been most extensively studied in relation to cerebral 
edema. Its role in cerebral edema formation was first described when AQP4 knockout 
mice were found to have reduced cytotoxic edema after ischemic stroke and acute 
hyponatremia.91 Later studies have confirmed this concept, with altered AQP4 expression in 
animal models of trauma and ischemia as well as in human subarachnoid hemorrhage and 
brain tumour, all conditions that are associated with cerebral edema.90, 92-97 In addition to its 
role in edema formation, a contribution of AQP4 in edema resolution has been proposed. 
In studies using a freeze injury model of vasogenic edema, AQP4 knockout mice exhibited 
increased brain water content compared to wild type mice.98, 99
Since cerebral AQP expression may have a role in cerebral edema during eclampsia, 
the regional expression of AQP1, 4 and 9 in the brain during pregnancy was evaluated in 
Chapter 3.
Biomarkers of brain injury
Once preeclamptic patients start to seize, the presence of central nervous system (CNS) 
involvement is clear. However, this is not always the case in the period preceding the 
seizures. Since these difficulties in diagnosing the presence of CNS involvement are faced 
in several patient categories, identification of non-invasive biomarkers of neuronal and 
BBB injury has become of interest. Ideally, these biomarkers are brain specific substances 
released into cerebrospinal fluid and/or peripheral blood in which elevated levels can 
be measured during the manifestation of CNS disorders. Several candidate biomarkers 
have been proposed, including neuron-specific enolase (NSE), glial fibrillary acidic protein 
(GFAP) and S100B.100,101 
S100B is member of a family of acidic calcium-binding proteins and is mainly 
expressed in astrocytes and Schwann cells within the CNS.102 Outside the CNS, S100B is 
expressed in a variety of cell types including melanocytes, chondrocytes and Langerhans 
cells, however, approximately 95% of S100B is located in the CNS.102-104 Therefore, several 
studies have related increased peripheral S100B levels and S100B brain expression to the 
process of neuroinflammation, a key component of several CNS disorders involved in both 
neural tissue damage and regeneration.101, 104-107 While the exact mechanism by which such 
level or expression increases has not been completely elucidated, proposed mechanisms 
include astrocytic death, reactive gliosis and BBB dysfunction.104, 105, 107-110 
In preeclampsia, there may also be a place for use of neuroinflammatory biomarker 
levels, including S100B, in the diagnosis of (impending) cerebral involvement. In addition to 
early recognition, cerebrovascular complications might eventually even be prevented when 
cerebral involvement in preeclampsia is diagnosed at an early stage. However, knowledge 







scarce.104 In contrast, many studies have assessed S100B in various neuropathological states 
in nonpregnant subjects. For instance, elevated S100B serum levels were observed in 
both animal and human studies of cerebral hemorrhage, ischemic stroke, traumatic injury 
and iatrogenic BBB disruption.102, 105-107, 111 In addition, increased S100B brain expression 
was demonstrated in stroke-prone spontaneously hypertensive rats,112 chronic cerebral 
hypoperfusion in rats108 and septic encephalopathy in pigs.113 
In Chapter 5, the presence and extent of brain injury was assessed in the low-dose 
endotoxin-treated pregnant rat, a preeclampsia animal model, using the neuroinflammatory 
marker S100B.
Long-term consequences of eclampsia
Eclampsia and/or PRES have long been held to be reversible disorders, of which patients 
could expect to recover completely. However, during the last decade doubts have been 
raised concerning this full recovery. Approximately 25% of formerly eclamptic women 
appeared to have persistent white matter lesions (WML) consistent with tissue loss or 
gliosis on cerebral MRI several weeks postpartum.33, 35 In addition, on long-term MRI follow-
up formerly eclamptic women had significantly more WML compared to healthy parous 
controls.114 Two theories concerning the etiology of these lesions following eclampsia have 
been proposed. The first theory suggests a causal relationship between WML and PRES 
in which vasogenic edema progresses to such an extent that regional cerebral perfusion 
pressure decreases and blood flow diminishes to ischemic levels leading to areas of 
cytotoxic edema and infarction.42 On the other hand, such WML have been suggested to 
develop independently of pregnancy as an early expression of increased susceptibility for 
cerebro-/cardiovascular disease in these women. Epidemiological studies have shown an 
increased risk for cerebro-/cardiovascular disease later in life in women with a history of 
preeclampsia, including risk for hypertension, ischemic heart disease, stroke and venous 
thromboembolism.115 While the mechanism behind this association remains to be unraveled, 
preeclampsia and atherosclerosis have several risk factors in common.116, 117 Therefore, 
preeclampsia and WML might both simultaneously develop because of the predisposition 
to cerebro-/cardiovascular disease in these women.
The clinical implications of WML in formerly eclamptic women are largely unknown. 
In the elderly population, WML have been related to cognitive decline and dementia.118, 
119 In a follow-up study, a substantial part of formerly eclamptic women report several 
neurocognitive limitations months to years after eclampsia, including problems with 
concentrating and recalling.120 These results are in line with a study by Aukes et al 
demonstrating impaired subjective cognitive functioning years following eclampsia.121 
In addition to subjective cognitive impairment, visual disturbances are reported by a 
significant number of the formerly eclamptic women.120 While most women recover from 
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the visual disturbances seen during the acute phase of eclampsia, incidental permanent 
visual field loss due to cerebral infarction has been described after both obstetric and non-
obstetric PRES.122, 123 This raised the question whether WML in formerly eclamptic women 
may cause visual field loss, and is subject of Chapter 7. To gain further insight into the 
possible consequences and etiology of WML after eclampsia, evaluation of the location of 
these lesions may be elucidating, and is therefore assessed in Chapter 8.
Aims of thesis
Part I – Animal studies
- To investigate the underlying mechanism by which pregnancy increases blood-brain 
barrier permeability. (Chapter 2)
- To determine the regional distribution of aquaporin 1, 4 and 9 in brain and possible 
pregnancy-related changes in distribution. (Chapter 3)
- To assess how preeclampsia influences the function and structure of cerebral 
resistance arteries and to investigate whether peripheral resistance arteries are 
similarly affected. (Chapter 4)
- To assess the presence and extent of brain injury during preeclampsia using a 
neuroinflammatory biomarker. (Chapter 5) 
Part II – Human studies
- To review the visual disturbances that can be encountered in patients with (pre)
eclampsia. (Chapter 6)
- To assess whether cerebral white matter lesions in formerly eclamptic women 
influence visual functioning in the long term. (Chapter 7)
- To provide insight into the regional distribution of cerebral white matter lesions 
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Eclampsia is similar to posterior reversible encephalopathy syndrome in which acutely 
elevated blood pressure causes autoregulatory breakthrough, blood-brain barrier (BBB) 
disruption, and edema formation. We previously showed that late-pregnant (LP) animals 
developed cerebral edema during breakthrough, a response that was absent in nonpregnant 
(NP) animals. The current study hypothesized that pregnancy predisposes to cerebral 
edema during acute hypertension by enhanced cerebral endothelial cell permeability 
in response to hydrostatic pressure and that the underlying effect of pregnancy on BBB 
permeability is due to elevated estrogen levels. Permeability coefficients to Lucifer 
Yellow (LY) were compared in four groups of Sprague-Dawley rats: NP (n=7), LP (d20; n=7), 
ovariectomized (OVX; n=6), and estrogen treated OVX (OVX+E; n=7). Posterior cerebral 
arteries (PCA) were isolated, pressurized in an arteriograph, and perfused with 0.5mg/
ml LY in saline. Concentration changes of LY outside the vessel wall were determined at 
pressures from 60-200 mmHg. The slope of the pressure versus permeability curve is the 
permeability coefficient to LY. Further, hydraulic conductivity (Lp) was determined in NP 
(n=6) and LP (n=6) PCAs using a modified Landis technique. The permeability coefficient to 
LY was increased in LP versus NP animals (P<0.05), an effect that may predispose the brain 
to edema formation during acute hypertension. However, pregnancy did not increase Lp, 
suggesting that pregnancy differentially affects BBB permeability to LY and water. Estrogen 
treatment prevented an increase of the permeability coefficient in OVX animals (P<0.05), 
suggesting that estrogen is protective of BBB permeability and that pregnancy increases 




Eclampsia is a serious complication of pregnancy accounting for a substantial part of 
maternal and fetal mortality throughout the world.1, 2 Eclampsia occurs when the brain 
is affected by pregnancy-induced hypertension, manifesting with classic neurologic 
symptoms, including seizures, headache, nausea, vomiting, visual disturbances, and coma.3
The primary explanation for the pathogenesis of eclampsia is that it is a form of 
posterior reversible encephalopathy syndrome (PRES).4 This syndrome can arise from a 
sudden increase in blood pressure that causes forced dilatation of the cerebrovasculature, 
breakthrough of autoregulation, and hyperperfusion. As a result, blood-brain barrier (BBB) 
disruption can occur, leading to cerebral edema formation.5, 6 This type of edema, deriving 
from an unfavorable pressure gradient between vasculature and brain tissue, is called 
hydrostatic edema and is thought to be the underlying cause of the neurologic symptoms 
in PRES and eclampsia.7, 8
Under normal conditions, the brain is protected against formation of hydrostatic 
brain edema by the unique features of the BBB. These include the coupling of endothelial 
cells by high electrical resistance tight junctions, the lack of capillary fenestrations, and a 
low rate of pinocytosis, resulting in essentially no extravasation of solutes.9 Together with 
the very low hydraulic conductivity of the BBB, this arrangement of the BBB makes the 
effect of hydrostatic pressure on capillary filtration minimal.10 However, under conditions 
with acutely elevated blood pressure that causes decreased cerebrovascular resistance, 
hydrostatic pressure in the cerebrovasculature increases, resulting in BBB permeability. 
As a consequence, brain edema develops driven by the hydrostatic pressure gradient, i.e. 
hydrostatic edema.7, 11
In a previous study, we found that the blood pressure at which breakthrough 
of autoregulation occurred was similar in late-pregnant (LP) and nonpregnant (NP) 
rats. However, only LP rats developed cerebral edema in response to autoregulatory 
breakthrough,12 suggesting that pregnancy alone predisposes the brain to edema formation 
during acute hypertension. Because increases in BBB permeability are considered the 
major mechanism by which hydrostatic edema forms,13 this study tested the hypothesis 
that pregnancy predisposes the brain to edema formation through enhanced cerebral 
endothelial cell permeability in response to hydrostatic pressure. Therefore, BBB 
permeability was assessed by determining the permeability coefficient to Lucifer Yellow 
(LY), as well as the hydraulic conductivity (Lp), in posterior cerebral arteries (PCAs) from 
NP and LP animals. Permeability coefficients are determined by the regression of the 
pressure versus permeability curves, allowing for comparison of permeability in response 
to hydrostatic pressure. The advantage of this in vitro methodology is that it eliminates 
changes in hemodynamics that can affect the BBB in vivo. Furthermore, since plasma 
estrogen levels are significantly elevated during pregnancy,14 it was hypothesized that the 







To investigate this, the permeability coefficient to LY in PCAs from ovariectomized (OVX) 
and estrogen treated OVX animals was also assessed.
Materials and methods
Animals
For all experiments female Sprague-Dawley rats (N=45) (Charles River, St. Constant, QU, 
Canada) were used. All animals were housed in the University of Vermont Animal Care 
Facility, an American Association for the Accreditation of Laboratory Animal Care (AAALAC) 
accredited facility. Animals had access to food and water ad libitum and were maintained at 
a 12 hour light-dark cycle. All the procedures were approved by the University of Vermont 
Institutional Animal Care and Use Committee and complied with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
Four different groups of rats were used: virgin NP (proestrus stage; n=7 for 
permeability coefficient experiments and n=6 for Lp experiments), LP (day 20; n=7 for 
permeability coefficient experiments and n=6 for Lp experiments), OVX with estrogen 
therapy (OVX+E; n=7), and OVX (n=6). For the OVX+E animals, ovariectomy was performed 
14 days before experimentation and pellets (Innovative Research of America, Sarasota, FL, 
USA) containing 17β-estradiol (0.5 mg 21-day release) and estriol (5.0 mg 21-day release) 
were subcutaneously implanted in the lateral side of the neck at the time of ovariectomy. 
For the OVX animals, ovariectomy was performed 28-29 days before experimentation 
and placebo pellets (Innovative Research of America) were implanted at the time of 
ovariectomy. All surgical procedures were performed by Charles River (Kingston, NY, USA). 
An extra group of female rats (n=6) was used to validate the technique for measuring Lp.
Preparation of arteries 
The animals were anesthetized with isoflurane in oxygen and decapitated. The brain was 
quickly removed and placed in physiologic salt solution (HEPES solution). A third-order 
branch of the posterior cerebral artery (PCA) was carefully dissected, cleared of connective 
tissue, and placed in an arteriograph chamber (Living Systems, Burlington, VT, USA) for 
isolated vessel experiments, described below. The PCA was used because cerebral edema 
in eclampsia is most commonly found in the posterior brain region.15 For pregnant animals, 
the abdomen was opened to count the number of pups in utero. For OVX and OVX+E 
animals the abdomen was opened to verify complete removal of ovaries and to assess the 
morphologic appearance of the uterus (e.g. edema). For the Lp validation experiments, a 
PCA and a similar-sized mesenteric artery were dissected from the same animal.
Pressurized arteriograph chamber
A segment of the dissected artery was mounted on two glass cannulas with nylon ties and 
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pressurized, as previously described.16, 17 The chamber was attached to a heat exchanger 
to maintain the temperature of the HEPES solution at 37 ± 0.5ºC and pH at 7.4 ± 0.5. The 
proximal cannula was attached to an in-line pressure transducer with a peristaltic pump 
and controller that allowed intravascular pressure to be maintained at a constant pressure 
or changed at a variable rate. The distal cannula was connected to a peristaltic pump that 
allowed for flow through the vessel at a set flow rate and intravascular pressure. The whole 
chamber was placed on an inverted microscope attached to a video camera and monitor. 
Lumen diameter was measured through an optical window in the bottom of the chamber, 
using a video dimension analyzer (VDA). 
For experiments assessing Lp, some adjustments in the experimental setup described 
above were made. The peristaltic pump on the distal cannula was removed and the distal 
cannula closed off so there was no flow through the vessel. Furthermore, the distal end 
of the vessel was closed off by placing two nylon ties around the vessel before the distal 
cannula, i.e. the vessel was mounted on the proximal cannula only.
Experimental protocol for permeability coefficient experiments
The arteries were equilibrated for 45 minutes at 60 mmHg after which the HEPES was 
replaced by fresh HEPES. After perfusing the vessel with 0.5 mg/ml LY-CH (Molecular 
Probes, Eugene, OR, USA) in HEPES for three minutes, the HEPES outside the vessel wall was 
sampled to measure baseline fluorescence intensity using a fluorescent spectrophotometer 
(Photon Technology International, Birmingham, NJ, USA). After 15 minutes at 60 mmHg the 
HEPES was sampled again to determine the change in fluorescence. The concentration of 
LY in the HEPES outside the vessel wall was quantified from a linear standard curve plotted 
from known amounts of LY in HEPES. The HEPES was then replaced by fresh HEPES. This 
procedure, except for the equilibration step, was repeated at intravascular pressures from 
80-200 mmHg in steps of 20 mmHg. 
For each animal, intravascular pressure was graphed versus permeability 
(concentration change of LY during 15 minutes) and a regression line was drawn using 
Sigmaplot graphing software; the slope of the regression line is the rate of flux.18 For each 
group, the average slope, or permeability coefficient to LY, was calculated and an average 
regression line was drawn.
Measuring hydraulic conductivity using a modified landis technique
To determine Lp, a modified Landis technique was used.
18 This technique was validated 
by comparing Lp in a mesenteric artery and PCA from the same rat. Briefly, the arteries 
were equilibrated for 1 hour at 75 mmHg after which the HEPES was replaced by fresh 
HEPES. After increasing intravascular pressure to 200 mmHg, the vessel was allowed to 







servo, allowing the pressure transducer to read intravascular pressure without correcting 
for the drop in pressure. This allowed determination of fluid filtration by assessing the 
drop in intravascular pressure over one hour. After this hour, the intravascular pressure 
was increased back to 200 mmHg, after which the stopcock between the proximal cannula 
and the transducer was closed and the procedure described above was repeated, allowing 
measurement of the pressure drop of the transducer alone. This number was subtracted 
from the intravascular pressure drop found in the first part of the experiment to determine 
the drop in pressure resulting from fluid filtration in the vessel.
After validation, this technique was used to compare Lp in NP and LP PCAs. One 
modification was made; the intravascular pressure drop was measured over one hour at 150 
mmHg, a pressure that PCAs would experience during breakthrough in vivo.12, 19 
Determination of estrogen levels 
Immediately after the OVX and OVX+E animals were decapitated, trunk blood was collected 
and serum isolated by centrifuging for 10 minutes at 2500 rpm. Serum was stored at -80 
ºC until analysis. Serum 17β-estradiol and estriol levels were determined using commercial 
ELISA kits (Cayman Chemical, Ann Arbor, MI, USA).
Statistical analysis
Data are presented as mean ± SEM. Differences in body weight, estradiol and estriol serum 
levels, Lp, and permeability coefficients to LY between NP and LP animals and between 
OVX and OVX+E animals were determined by one-way ANOVA. Differences were considered 
significant at P<0.05. 
Results
The average body weight of the LP animals was significantly greater than that of the NP 
animals (280.0 ± 6.3 versus 338.6 ± 8.8 g for permeability coefficient experiments and 
302.5 ± 8.4 versus 375.0 ± 5.0 g for Lp experiments; P<0.001). There was also a significant 
difference in body weight between OVX and OVX+E animals, with the body weight of OVX 
animals being greater than that of OVX+E animals (366.7 ± 9.6 versus 238.6 ± 5.9; P<0.001). 
The mean serum 17β-estradiol level of OVX+E animals was 97.1 ± 23.1 pg/mL, which was 
significantly higher than that of the OVX animals being 23.4 ± 1.2 pg/mL (P<0.05). The mean 
serum estriol level was 778.2 ± 150.9 pg/mL in the OVX+E animals, which was significantly 
higher compared to 2.9 ± 0.7 pg/mL in the OVX animals (P<0.001). It is worth noting that 
the serum estriol level of the OVX group was below the detection level (8 pg/mL) of the 
ELISA kit. 
Figure 1 shows the permeability coefficients to LY for NP and LP animals. While 
the basal permeability at 60 mmHg was not significantly different between the groups, 
37
Chapter 2
LP animals had a significantly higher permeability coefficient to LY (x103), which increased 
257% in LP compared to NP animals. Therefore, PCAs from LP animals had a significantly 
greater increase in permeability in response to increased hydrostatic pressure.
Although the permeability coefficient to LY was increased in LP animals, there was 
no increase in Lp in those animals. Figure 2A shows the Lp in PCAs from NP and LP animals. 
No significant difference in Lp was found between the groups.
To verify that we could detect a difference in Lp with this technique, we compared 
a peripheral (mesenteric) vessel to the PCA. Figure 2B shows the Lp in mesenteric arteries 
and PCAs from female rats. The mesenteric arteries had a Lp of 35.70 ± 5.18 mmHg/hour 
which was significantly higher than the Lp of the PCAs, being 4.45 ± 1.39 mmHg/hour 
(P<0.001).
To determine the influence of estrogen on permeability, permeability coefficients 
to LY were compared between OVX and OVX+E animals. Figure 3 shows the permeability 
coefficients for the OVX and OVX+E group. Again, no significant difference in basal 
permeability at 60 mmHg between OVX and OVX+E animals was found. However, the 
OVX animals had a permeability coefficient to LY (x103) that was significantly increased 
compared to OVX+E animals (P<0.05). In fact, there was a 229% increase in permeability in 
response to hydrostatic pressure in OVX compared to OVX+E animals.
Discussion
The major findings of this study were that pregnancy significantly increased the permeability 
coefficient to LY in PCAs, indicating that this state causes increased cerebral endothelial cell 
permeability in response to hydrostatic pressure. Interestingly, pregnancy did not increase 
Figure 1. Average regression lines of intravascular pressure versus permeability for posterior cerebral 
arteries (PCAs) from nonpregnant (NP) and late-pregnant (LP) Sprague-Dawley rats. The slope of 







Lp, suggesting a differential effect on permeability to water versus LY. In addition, it does 
not appear that elevated levels of estrogen during pregnancy are responsible for increased 
permeability since OVX+E animals had a permeability coefficient to LY more similar to NP 
than LP animals. In fact, OVX animals had the greatest permeability coefficient to LY of all 
the groups.
The increased permeability coefficient in PCAs from pregnant animals suggests 
that pregnancy alone increases BBB permeability in response to hydrostatic pressure. In 
a previous study, we found that only LP rats developed cerebral edema in response to 
autoregulatory breakthrough compared to NP animals.12 Since increases in BBB permeability 
are considered the major mechanism by which hydrostatic edema forms,13 the results of the 
present study suggest that one mechanism behind this predisposition might be increased 
cerebral endothelial cell permeability.
In contrast to LY, we did not find a difference in Lp between PCAs from NP and 
LP animals, suggesting that pregnancy does not increase BBB permeability to water. 
The differential effect of pregnancy on BBB permeability to water and LY suggests that 
transcellular transport is increased without increasing Lp. In fact, transcellular transport 
is a primary mechanism of BBB permeability in response to acute hypertension.20,21 
Alternatively, the lack of an increase in Lp during pregnancy may be related to the sensitivity 
of the Lp measurements. Although we were able to detect a significant difference in Lp 
between PCAs and mesenteric arteries, this technique may not be sensitive enough to 
detect a much smaller difference in Lp between NP and LP PCAs.
In order to explore an underlying mechanism by which pregnancy increases the 
permeability coefficient to LY, we measured permeability coefficients to LY in OVX 
and OVX+E animals. Since plasma estrogen levels are elevated during pregnancy,14 we 
hypothesized that the underlying effect of pregnancy on BBB permeability to LY was due 
to elevated estrogen plasma levels. Estrogen has been shown to increase BBB permeability 
Figure 2. A. Hydraulic conductivity of posterior cerebral arteries (PCAs) from nonpregnant (NP) and 
late-pregnant (LP) Sprague-Dawley rats at 150 mmHg. B. Hydraulic conductivity of posterior cerebral 




to water,22 albumin,23 inulin and sucrose.24 However, it is not known how estrogen, in 
plasma levels seen during pregnancy, affects BBB permeability. Interestingly, we found 
a significantly lower permeability coefficient to LY in OVX+E compared to OVX animals, 
suggesting that estrogen has a protective effect on BBB permeability. This is in agreement 
with studies showing that estrogen treatment attenuated edema formation in traumatic 
brain injury and focal cerebral ischemia.25, 26 In addition, Bake et al reported decreased 
Evans Blue extravasation in the olfactory bulb and hippocampus in estrogen treated young 
adult OVX versus untreated OVX animals.27 Increased BBB permeability in the cortex, brain 
stem, and cerebellum was also found by Saija et al. in OVX animals compared to animals 
in proestrus when estrogen is the lowest.28 These results suggest that pregnancy increases 
BBB permeability by a mechanism other than elevated estrogen levels. However, it should 
be noted that the OVX+E animal model used in this study might not exactly mimic the 
effects of estrogen during pregnancy because of the large variability in estrogen levels 
during pregnancy. Animals in this study were treated for 14 days with timed-release pellets 
which might not have had the same effect of estrogen on BBB permeability as seen during 
late-pregnancy. Furthermore, pregnancy is a state with numerous physiologic adaptations 
other than increased estrogen plasma levels. Therefore, the effects of estrogen on BBB 
permeability may take place in conjunction with other pregnancy related changes that are 
not seen in OVX+E animals such as changes in sFlt-1 and VEGF levels.29,30
Since an unfavorable hydrostatic pressure gradient between the cerebral vasculature 
and brain tissue is the driving force of hydrostatic edema formation,7 this study assessed 
BBB permeability to LY in response to hydrostatic pressure. It is important to note that we 
did not find a difference in permeability at 60 mmHg, a pressure within the physiologic 
Figure 3. Average regression lines of intravascular pressure versus permeability for posterior cerebral 
arteries (PCAs) from ovariectomized (OVX) and estrogen treated ovariectomized (OVX+E) Sprague-
Dawley rats. The slope of these regression lines is the permeability coefficient (x103) to Lucifer 







range. However, the permeability coefficient for LP animals was significantly increased 
in response to hydrostatic pressure suggesting that elevated pressure causes greater 
permeability in pregnancy. LY was chosen as a dye because of its polarity, which means 
that it does not pass through the high electrical resistance tight junctions of the BBB, 
and is a marker of transcellular transport.9 It is therefore likely that pregnancy enhances 
transcellular transport in response to acute hypertension similar to other studies20, 21 and 
that this mechanism underlies the edema formation.
In summary, the present study demonstrated that pregnancy increased the 
permeability coefficient to LY, an effect that may predispose the brain to hydrostatic edema 
formation during acute hypertension. However, pregnancy did not increase Lp suggesting 
that pregnancy differentially affects BBB permeability to LY and water. Furthermore, it 
was found that estrogen treatment prevented the increase of the permeability coefficient 
to LY in OVX animals suggesting that estrogen is protective of BBB permeability and that 
pregnancy increases BBB permeability by a mechanism other than elevated estrogen levels.
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Pregnancy is a state of physiologic adaptation, with significant changes in cardiovascular, 
renal, and hemodynamic systems. Aquaporins (AQPs) may play a role in facilitating these 
changes. While AQP expression has been assessed in several organs during pregnancy, little 
is known about its expression in the brain during pregnancy. Therefore, this study assesses 
the regional expression of AQP1, 4, and 9 during pregnancy and the postpartum period 
using real-time quantitative polymerase chain reaction. The authors show that AQP1, 4, 
and 9 are expressed in the anterior and posterior cerebrum, cerebellum, and brainstem of 
nonpregnant, midpregnant, late pregnant, and postpartum rats. The regional distribution 
pattern of AQP4 and 9 remained similar during gestation, whereas this pattern changed 
for AQP1. The expression levels of AQP1, 4, and 9 in the brainstem did not change with 
gestation, whereas changes were found in the anterior cerebrum for AQP4 and in the 




Aquaporins (AQPs) are a family of transmembrane channel-forming proteins that facilitate 
water movement across plasma membranes.1 In addition to water transport, some AQPs 
also have permeability to small solutes including glycerol, urea, and monocarboxylates.2,3 
To date, 13 AQPs have been identified in mammalian tissues4; however, only 3 have been 
shown to be expressed in brain in vivo and include AQP1, 4, and 9.5
AQP1 is permeable only to water and is expressed in the epithelial cells of the 
choroid plexus.6,7 Given this location and the finding that AQP1–deficient mice have reduced 
cerebrospinal fluid (CSF) formation,8 AQP1 is proposed to play a role in CSF production. 
AQP4 is the most abundant AQP in the brain, and its permeability is restricted 
to water.5 Expression of AQP4 is found in several brain regions, including the cortex, 
hippocampus, magnocellular hypothalamic nuclei, cerebellum, and brainstem.5,9 In 
these regions, expression of AQP4 is restricted to the endfeet of astrocytes, bordering 
the ventricles, the subarachnoid space, and the blood vessels.10 While some studies have 
reported AQP4 expression in the endothelium,11,12 other studies did not find AQP4 at this 
location.10,13 Several physiologic roles have been proposed for AQP4. Given its location at the 
blood-brain and brain-CSF interfaces, it is thought that AQP4 has a role in cerebral water 
homeostasis. In addition, co-localization in astrocytes with the potassium channel Kir4.1 
suggests that AQP4 may be involved in potassium homeostasis.14 Lastly, AQP4 expression in 
the magnocellular hypothalamic nuclei suggests a role for AQP4 in central osmoregulation 
by transferring variations in plasma osmotic pressure from blood to the osmosensitive 
neurons in these nuclei.10,15
AQP9 facilitates the diffusion of both water and several small solutes such as 
glycerol, urea, purines, pyrimidines, and monocarboxylates.2 It is expressed in tanycytes, 
ependymal cells, and astrocytes lining the ventricles, in astrocytes of the glia limitans, 
and endothelial cells of pial vessels.16,17 The expression of AQP9 at these locations suggests 
its involvement in cerebral water homeostasis. Moreover, AQP9 expression is found in 
catecholaminergic neurons, suggesting a role for AQP9 in brain energy metabolism by 
facilitating transport of small metabolites such as glycerol and lactate.17 
We have previously shown that expression of AQP4 protein is increased in the brain 
from late pregnant rats.18 Pregnancy is a state of physiologic adaptation during which 
significant changes in cardiovascular, renal, and hemodynamic systems occur.19,20 These 
changes include a 45% increase in plasma volume and a 30% to 50% increase in cardiac 
output.19 How AQP expression changes during pregnancy to facilitate these adaptations has 
been studied in several organs. For example, AQP2 mRNA and protein expression are shown 
to increase more than 100% in rat kidneys during pregnancy.21 This upregulation of AQP2 
may contribute to the water retention seen in pregnancy. Furthermore, the expression 
profile of AQP0 through 9 has been assessed in mice uteri during the peri-implantation 







by facilitating the formation of uterine edema.22 While the effect of pregnancy on these 
organ systems has been well studied, how pregnancy affects the brain, including AQP 
expression, is not well understood. Our previous study investigated AQP4 expression in 
the brain during pregnancy and found a significant increase in AQP4 protein in the whole 
brain. However, nothing is known about the regional distribution during pregnancy or how 
the expression of other AQPs in the brain changes during gestation. Therefore, this study 
investigates the expression of AQPs 1, 4, and 9 in different brain regions during pregnancy 
and the postpartum state using real-time quantitative polymerase chain reaction (RQ-PCR).
Materials and methods
Animals
For all experiments, female Sprague-Dawley rats (Charles River, St Constant,QC, Canada) 
were used. All animals were housed in the University of Vermont Animal Care Facility, a 
facility accredited by the American Association for the Accreditation of Laboratory Animal 
Care. Animals had access to food and water ad libitum and were maintained at a 12-
hour light/dark cycle. All of the procedures were approved by the University of Vermont 
Institutional Animal Care and Use Committee and complied with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. Four different groups of animals 
were studied: virgin nonpregnant (NP; proestrus stage), midpregnant (MP; day 10 of a 22-
day gestation), late pregnant (LP; day 20), and postpartum (PP; day 4).
Real-time quantitative reverse transcription PCR
To obtain tissue for real-time quantitative reverse transcription PCR (RQ-PCR) analysis, 
a sample size of 4 to 6 rats was used for each group. Animals were anesthetized with 
isoflurane (Abbott, North Chicago, IL) and decapitated. Brains were quickly removed from 
the skull and split into right and left hemispheres. The cerebral cortex, cerebellum, and 
brainstem were separated from each other; the cerebral cortex was further divided into 
the anterior and posterior cerebrum by a coronal cut at the level of the optic chiasm. 
Sections were snap frozen in liquid nitrogen and stored at –80°C until analysis. 
For total RNA extraction, brain sections were placed in a FastPrep instrument (MP 
Biomedicals, Solon, OH) for 45 seconds after adding 1 ml TRIzol Reagent (Invitrogen, 
Carlsbad, CA) and 0.2 g silicon carbide and aluminum oxide mix (Washington Mills, Niagara 
Falls, NY). Following centrifugation at 12000 rcf for 10 minutes at room temperature, cleared 
homogenate solutions were incubated for 5 minutes at room temperature. After addition 
of 0.2 mL of chloroform, samples were shaken for 15 seconds, incubated for 2 to 3 minutes 
at room temperature, and centrifuged for 15 minutes under the same conditions. RNA was 
precipitated from the aqueous phase by adding 0.5 mL isopropyl alcohol, incubating for 10 
minutes at room temperature, and then centrifuging for 30 minutes at 4°C. After washing 
with 1 mL 75% ethanol, RNA pellets were briefly dried and finally dissolved in RNAse-
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free water. Isolated RNA was then quantified using the NanoDrop spectrophotometer and 
checked for integrity in a Bioanalyzer (Bio-Rad, Hercules, CA).
Synthesis of cDNA was accomplished by adding 2 μg of total RNA, 1 μL of 50 μM 
random primers (ABI Research, Oyster Bay, NY), and 1 μL 10 μM dNTP Mix (Invitrogen) 
in a 13 μL total volume. The mixture was heated for 5 minutes at 65°C and incubated 
on ice for at least 1 minute. Next, 4 μL 5X First-Strand Buffer (Invitrogen), 1 μL 0.1 M 
dithiothreitol (Invitrogen), 1 μL RNaseOUT Recombinant RNase Inhibitor (Invitrogen), and 
1 μL of Superscript III RT (Invitrogen) were added to the reaction. Following incubation for 
5 minutes at 25°C, the temperature was increased to 50°C for another 30 minutes. The 
reaction was inactivated by heating to 70°C for 15 minutes.
The resulting reverse-transcribed cDNA was amplified using Assays-on-Demand 
(AOD) gene expression products kits for AQP1, 4, and 9 (assay IDs Rn00562834_m1, 
Rn00563196_m1, and Rn00576331_m1; Applied Biosystems, Foster City, CA). One microliter 
of cDNA was mixed with 10 μL TaqMan Universal PCR Master Mix (Applied Biosystems), 1 μL 
AOD, and 8 μL water. The PCR was carried out in a 7900HT  Sequence Detection System 
(Applied Biosystems) for 2 minutes at 50°C and 10 minutes at 95°C followed by 15 seconds 
at 95°C and 1 minute at 40°C for 40 cycles. MapK6 was used as an endogenous control. All 
samples were run in technical duplicates. Data were analyzed using Sequence Detection 
2.2 software (Applied Biosystems).
Comparison of groups
Two sets of normalization were done to assess both the regional distribution of AQPs at 
each gestational stage and also how gestation affected expression in the different brain 
regions. To assess the regional distribution of AQP expression at different gestational ages, 
data were normalized to the values found for the anterior cerebrum for each AQP in each 
gestational group. To assess how gestation affected the expression of AQPs within the brain 
regions, data were normalized to the NP values for each AQP in each region.
Statistical analysis
All data are expressed as the mean ± SEM. Differences in AQP mRNA expression were 
determined using a Wilcoxon signed-rank test with comparison to a hypothetical value. 
Differences between unnormalized data were determined using an analysis of variance 
with a post hoc Student-Newman-Keuls test for multiple comparisons. Differences were 
considered significant if P<.05.
Results
Regional distribution of AQPs
To assess the regional distribution of AQPs, expression levels were normalized to the levels 







Regional distribution of AQP1
AQP1 was expressed in all brain regions in all 4 groups of animals (Figure 1). The NP and 
PP animals showed a similar distribution pattern in the brain, with higher expression in 
the posterior cerebrum and cerebellum compared with the anterior cerebrum (Figure 1A 
and D). However, this was significant only in the PP group (Figure 1D; P<.05 vs anterior). 
The MP animals had lower expression in the cerebellum and brainstem compared with 
the posterior cerebrum (Figure 1B; P<.01). The LP animals also had lower expression in 
the brainstem compared with the posterior cerebrum (Figure 1C; P<.01). In addition, the 
posterior cerebrum revealed higher expression versus the anterior cerebrum (P<.05), and 
there was more expression in the cerebellum compared with the brainstem (P<.05).
Regional distribution of AQP4
AQP4 was also expressed in all brain regions in all 4 groups of animals (Figure 2). Unlike the 
distribution of AQP1, the distribution pattern of AQP4 within the brain was similar in all 
groups. All groups showed the highest expression in the brainstem (Figure 2A, NP: P<.05 vs 
anterior and posterior; Figure 2B, MP: P<.01 vs anterior and posterior, P<.05 vs cerebellum; 
Figure 1. Graphs showing regional aquaporin 1 (AQP1) mRNA distribution between anterior and 
posterior cerebrum, cerebellum, and brainstem in brains from (A) nonpregnant (NP), (B) midpregnant 
(MP; day 10), (C) late-pregnant (LP, day 20), and (D) postpartum (PP; day 4) rats. AQP1 expression was 
normalized to the expression found in the anterior cerebrum. 
*P<.05 versus anterior. ††P<.01 vs posterior. ‡P<.05 vs brainstem. ‡‡P<.01 versus brainstem.
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Figure 2C, LP: P<.05 vs anterior, posterior, and cerebellum; Figure 2D, PP: P<.01 vs anterior 
and cerebellum, P<.05 vs posterior), followed by the cerebellum (Figure 2B, MP: P<.01 vs 
anterior; Figure 2C, LP: P<.05 vs anterior), posterior cerebrum (Figure 2C and D, LP and PP: 
P<.05 vs anterior), and anterior cerebrum.
Regional distribution of AQP9
AQP9 was also expressed in all brain regions in all 4 groups of animals (Figure 3). Similar 
to AQP4, the regional distribution of AQP9 in the brain was similar in all groups, with no 
significant difference between the anterior and posterior cerebrum and less expression 
in both the cerebellum (Figure 3A, NP: P<.05; Figure 3B, MP:P<.05 vs anterior, P<.01 vs 
posterior; Figure 3C, LP: P<.05; Figure 3D, PP: P<.05 vs anterior, P<.01 vs posterior) and 
brainstem compared with the anterior and posterior cerebrum (Figure 3A, NP: P<.05; 
Figure 3B, MP: P<.05 vs anterior, P<.01 vs posterior; Figure 3D, PP: P<.05 vs posterior).
Gestational changes in AQP expression
To assess how gestation affected the expression of AQPs within the brain regions, data 
Figure 2. Graphs showing regional aquaporin 4 (AQP4) mRNA distribution between anterior and 
posterior cerebrum, cerebellum, and brainstem in brains from (A) nonpregnant (NP), (B) midpregnant 
(MP; day 10), (C) late pregnant (LP; day 20), and (D) postpartum (PP; day 4) rats. Expression of AQP4 
was normalized to the expression found in the anterior cerebrum. 







were normalized to the NP values for each AQP in each region (Figures 4, 5, and 6).
Gestational changes in AQP1 expression
AQP1 expression compared to NP animals did not significantly change with gestation in 
the anterior cerebrum and brainstem (Figure 4A and D). However, expression did change 
significantly in the posterior cerebrum and cerebellum (Figure 4B and C). In the posterior 
cerebrum, expression decreased in MP and LP compared with NP animals (P<.05). Expression 
in the cerebellum was lower in MP, LP, and PP compared with NP animals (P<.05), with the 
expression in the PP animals being higher than in the MP animals (P<.01).
Gestational changes in AQP4 expression
AQP4 expression compared to NP animals in the anterior cerebrum did not change in 
pregnant animals but was lower in PP animals compared with NP animals (Figure 5A; 
P<.05). Expression increased in both the posterior cerebrum and cerebellum in MP and LP 
animals compared to NP animals (Figure 5B and C; P<.05). In the brainstem, no changes in 
Figure 3. Graphs showing regional aquaporin 9 (AQP9) mRNA distribution between the anterior and 
posterior cerebrum, cerebellum, and brainstem in brains from (A) nonpregnant (NP), (B) midpregnant 
(MP; day 10), (C) late pregnant (LP; day 20), and (D) postpartum (PP; day 4) rats. AQP9 expression was 
normalized to the expression found in the anterior cerebrum. 
*P<.05 versus anterior. †P<.05 versus posterior. ††P<.01 versus posterior.
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expression were seen with gestation (Figure 5D).
Gestational changes in AQP9 expression
No changes in AQP9 expression with gestation were found in the anterior cerebrum and 
brainstem (Figure 6A and D). However, expression did change with gestation in the posterior 
cerebrum and cerebellum (Figure 6B and C). In the posterior cerebrum, expression was 
decreased in LP versus NP animals (P<.05). In the cerebellum, expression decreased in both 
MP and LP compared with NP animals (P<.05) and increased in PP versus MP and LP animals 
(P<.01 vs MP; P<.05 vs LP).
Discussion
In this study, we assessed the expression of AQPs 1, 4, and 9 in different brain regions 
during pregnancy and the postpartum state using real-time quantitative PCR. We showed 
that AQP 1, 4, and 9 are expressed in the anterior and posterior cerebrum, cerebellum, 
and brainstem of NP, MP, LP, and PP rats. The regional distribution pattern of AQP4 and 9 
Figure 4. Graphs showing aquaporin 1 (AQP1) mRNA expression levels at different gestational ages 
in (A) anterior (B) posterior cerebrum, (C) cerebellum, and (D) brainstem. Expression of AQP1 was 
normalized to the expression found in nonpregnant (NP) animals. 








remained similar during gestation, whereas this pattern changed for AQP1. The expression 
levels of AQP1, 4, and 9 in the brainstem did not change with gestation, whereas changes 
were seen in the anterior cerebrum for AQP4 and in the posterior cerebrum and cerebellum 
for all AQPs. To our knowledge, this is the first study to assess the regional distribution of 
AQPs 1, 4, and 9 in the brain during pregnancy.
AQP1 mRNA expression was found in all brain regions, namely, the anterior and 
posterior cerebrum, cerebellum, and brainstem in all groups (Figure 1), and AQP1 is thought 
to play a role in the formation of CSF. This is suggested by its location in the epithelial 
cells of the choroid plexus6,7 and the finding that AQP1-deficient mice have reduced CSF 
formation.8 Since the choroid plexus is located in the posterior cerebrum, finding AQP1 
in all brain regions suggests that AQP1 expression is not restricted to the choroid plexus 
epithelium. This is in agreement with results from Dolman et al.,23 who showed the presence 
of AQP1 mRNA and protein at very low levels in primary rat brain microvessel endothelial 
cells in culture. 
Even though we found AQP1 expression in all brain regions, the relative level of 
expression is not known. In the NP animals, no difference in expression was found between 
the regions, although the distribution showed a similar pattern to that of the PP animals, 
Figure 5. Graphs showing aquaporin 4 (AQP4) mRNA expression levels at different gestational ages in 
(A) anterior and (B) posterior cerebrum, (C) cerebellum, and (D) brainstem. Expression of AQP4 was 
normalized to the expression found in nonpregnant (NP) animals. 
*P<.05 versus NP. †P<.05 versus postpartum (PP). LP indicates late pregnant; MP, midpregnant.
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with higher expression in both the posterior cerebrum and cerebellum compared with 
anterior cerebrum. The MP animals showed a different pattern, with no difference between 
the anterior and posterior cerebrum and decreased expression in both the cerebellum and 
brainstem compared with the posterior cerebrum. In LP animals, a distribution pattern with 
higher expression in the posterior versus anterior cerebrum and the lowest expression level 
in the brainstem compared with posterior cerebrum and cerebellum was found. Together, 
these results suggest that pregnancy changed the distribution pattern of AQP1 regionally in 
the brain. The significance of this is not clear for this study, and further studies are needed 
to assess any functional consequence of this gestation-induced redistribution of AQP1.
When assessing gestational changes in AQP1 expression (Figure 4), no significant 
differences were seen in the anterior cerebrum and brainstem. However, although not 
significant, the mean expression level in the brainstem increased ~2- to 3-fold during 
pregnancy and the postpartum period, suggesting that pregnancy does affect the expression 
of AQP1 in this region. In both the posterior cerebrum and cerebellum, a significant 
decrease in AQP1 expression was found in brains from MP and LP versus NP animals. Since 
AQP1 is thought to be involved in CSF formation, the decrease in expression noted in the 
posterior region during pregnancy may have an influence on this CSF formation. However, 
Figure 6. Graphs showing aquaporin 9 (AQP9) mRNA expression levels at different gestational ages 
in (A) anterior and (B) posterior cerebrum, (C) cerebellum, and (D) brainstem. Expression of AQP9 
was normalized to the expression found in nonpregnant (NP) animals. *P<.05 versus NP. †P<.05 versus 







it is also possible that expression changes take place at locations other than the choroid 
plexus since AQP1 expression was found in all brain regions. 
AQP4 is the most abundant AQP in the brain and is expressed in several brain regions, 
including the cortex, hippocampus, magnocellular hypothalamic nuclei, cerebellum, and 
brainstem.5,9 This is in agreement with the current study, which shows AQP4 expression 
in the anterior and posterior cerebrum, cerebellum, and brainstem (Figure 2). The same 
distribution pattern was seen between these brain regions in all gestational groups. AQP4 
expression was lowest in the anterior cerebrum, followed by the posterior cerebrum, 
cerebellum, and brainstem. This expression in the anterior cerebrum and brainstem did 
not change significantly with gestation, except for a decrease in the anterior cerebrum in 
PP animals (Figure 5). In the posterior cerebrum and cerebellum, however, expression did 
change during pregnancy. In both MP and LP animals, increased expression of AQP4 was 
found in these regions. This is in agreement with our previous study, which found that 
AQP4 protein expression was increased in LP animals in the whole brain.18 
AQP4 is thought to have several functions in the brain. Given its location at 
the blood-brain and brain-CSF interfaces, it is thought that AQP4 has a role in brain 
water homeostasis and in cerebral edema formation and resolution under pathologic 
conditions.24-27 In several brain disorders associated with cerebral edema, regulation of 
the level of AQP4 expression was found, including cerebral ischemia,24-27 brain tumors,28 
and brain trauma.29-31 Furthermore, a study using AQP4 knockout mice found that these 
mice had less edema following acute water intoxication and ischemic stroke compared 
with wild type mice, suggesting involvement of AQP4 in edema formation.32 On the other 
hand, involvement of AQP4 in the resolution of vasogenic edema has also been suggested.33 
Thus, although the role of AQP4 in cerebral edema formation is not completely clear, being 
the most abundant AQP in the brain, its role in edema formation may be important under 
pathologic conditions. 
One pathologic condition during pregnancy that involves cerebral edema formation 
is posterior reversible encephalopathy syndrome and eclampsia. Eclampsia is a serious 
complication of pregnancy in which neurologic symptoms arise from the development 
of vasogenic brain edema following an acute elevation of blood pressure.34 Since edema 
formation in eclampsia is mainly found in the posterior brain regions,35,36 it is interesting 
that we found higher expression of AQP4 in the posterior versus the anterior cerebrum in 
both LP and PP animals, 2 states during which eclampsia usually develops.34,37
AQP4 is also expressed in the magnocellular nuclei of the hypothalamus, and a 
role for this water channel has been proposed in central osmoregulation by transferring 
variations in plasma osmotic pressure from blood to the osmosensitive neurons in these 
nuclei.10,15 However, we did not find any changes in expression in the brainstem, where the 
hypothalamus is located, with gestation.
AQP9 is the only aquaporin in the brain that facilitates diffusion of both water and 
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several small solutes such as glycerol, urea, purines, pyrimidines, and monocarboxylates.2 
Expression is found in tanycytes, ependymal cells and astrocytes lining the ventricles, 
astrocytes of the glia limitans, and endothelial cells of pial vessels.16,17 Like AQP4, this 
localization suggests involvement of AQP9 in cerebral water homeostasis. Moreover, AQP9 
expression is found in catecholaminergic neurons, suggesting a role for AQP9 in brain energy 
metabolism by facilitating transport of small metabolites such as glycerol and lactate.17 
We found AQP9 in all brain regions investigated, corresponding to the locations 
described previously (Figure 3). All gestational groups revealed a similar pattern of 
distribution between the regions, showing no significant difference between the anterior 
and posterior cerebrum and a lower expression level in both the cerebellum and brainstem 
compared with the anterior and posterior cerebrum. When assessing the changes in AQP9 
expression with gestation (Figure 6), no significant changes were found in the anterior 
cerebrum and brainstem. However, expression in the posterior cerebrum decreased in LP 
versus NP animals, and in the cerebellum, expression was decreased in MP and LP versus 
NP. These decreased levels went back to the NP levels in PP animals, suggesting a direct 
effect of pregnancy on this AQP. 
It is worth noting that we assessed the expression of AQPs 1, 4, and 9 using RQ-PCR, 
which is the most sensitive and accurate method to assess changes in mRNA expression. 
While other techniques such as Western analysis for protein levels and immunohistochemistry 
may provide further information regarding changes in AQPs in the brain during gestation, 
the results from this study provide a basis of our understanding of how pregnancy alters 
AQP gene expression in the brain. Because of the large number of groups and brain regions, 
we did not pursue other techniques but focused on expression level changes for which 
other studies can follow.
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Since the cerebrovasculature likely plays a prominent role in the pathophysiology of 
eclampsia, we assessed effects of low-dose endotoxin-induced experimental preeclampsia 
on function and structure of rat posterior cerebral arteries (PCA) and mesenteric arteries 
(MA).
Methods
Nonpregnant (NP) and pregnant (P) rats were infused with saline (NP-CTL, n=9; P-CTL, n=9) 
or low-dose endotoxin (NP-endotoxin, n=9; P-endotoxin, n=10). Myogenic activity, pressure 
of forced dilatation (FD) and structural properties were evaluated in PCA and MA.
Results
PCA underwent FD between 125-150 mmHg in P-endotoxin (repeated measures ANOVA 
versus 75 mmHg; P<0.05) and between 150-175 mmHg in P-CTL and NP animals (repeated 
measures ANOVA versus 75 mmHg; P<0.05). PCA myogenic tone was unaffected by 
pregnancy or endotoxin, however, pregnancy decreased MA myogenic tone (P<0.05 versus 
NP). Passive characteristics of PCA and MA were unaffected by pregnancy or endotoxin.
Conclusion
Low-dose endotoxin-infusion during pregnancy, but not pregnancy alone, decreased 
pressure of FD in PCA. This may predispose to cerebral autoregulatory breakthrough and 




Preeclampsia can affect several maternal organs, including the brain in the form of 
eclampsia.1 The pathophysiology of eclampsia is still largely unclear but is considered to 
be a form of the posterior reversible encephalopathy syndrome (PRES).2 This syndrome 
can arise from a sudden increase in blood pressure that causes forced dilatation of the 
cerebrovasculature and breakthrough of autoregulation.3,4 As a result, blood-brain barrier 
disruption can occur, leading to cerebral edema formation which is thought to be the 
underlying cause of the neurological symptoms of PRES/eclampsia.3,4 Interestingly, eclamptic 
patients may show minimal hypertension, suggesting pregnancy or preeclampsia induced 
changes in the cerebrovasculature, which predispose to cerebral edema development.5,6
Several studies have focussed on the effect of pregnancy and preeclampsia on the 
peripheral vasculature. For example, pregnancy has been shown to decrease myogenic 
reactivity and blunt responses to vasoconstrictor agents in rats.7-10 While these changes 
may add to the decreased peripheral resistance during pregnancy, preeclampsia seems 
to inhibit these adaptations to pregnancy. For instance, mesenteric arteries (MA) from 
the reduced uterine perfusion pressure model of preeclampsia have been shown to have 
increased myogenic reactivity and responses to vasoconstrictor agents compared to 
healthy pregnant rats.11,12
Despite a large body of knowledge on the effect of pregnancy and preeclampsia 
on the peripheral vasculature, only few studies have focussed on pregnancy-induced 
adaptations of the cerebral vasculature. In rat posterior cerebral arteries (PCA), Cipolla et 
al have demonstrated that pregnancy diminishes myogenic tone and decreases the pressure 
at which forced dilation (FD) occurs.13,14 Furthermore, hypertension and low-dose endotoxin 
treatment have been shown to have differential effects in pregnant and nonpregnant 
animals.14-16 For example, during pregnancy, in contrast to the nonpregnant situation, 
hypertension does not induce protective remodeling of PCA.14,15 These findings suggest 
that during pregnancy, the cerebrovasculature may be more vulnerable to breakthrough of 
autoregulation and edema formation. 
It is of particular interest to explore how preeclampsia affects the cerebral blood 
vessels and predisposes to PRES.  Therefore, this study assesses the function and structure 
of PCA in a well established preeclampsia rat model, the low-dose endotoxin-infused 
pregnant rat.17-20 In this model, a low grade inflammatory response results in hypertension, 
proteinuria and disseminated intravascular coagulation similar to human preeclampsia.17,21 
As a control, we used pregnant rats infused with saline. To evaluate the effect of pregnancy, 
we also included nonpregnant rats infused with either endotoxin or saline. Furthermore, to 
investigate whether low-dose endotoxin infusion and pregnancy influence the cerebral and 









Female Wistar outbred rats (Harlan Inc, Horst, the Netherlands), 200-220 grams, were used 
for all experiments. Animals had access to food and water ad libitum and were maintained 
at a 12 hour light-dark cycle. All animal experiments were conducted in accordance with 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals and 
approved by the Committee for Animal Experiments of the University of Groningen.
Vaginal smears were taken daily to follow estrous cyclicity until selection for 
experiments. Rats were rendered pregnant by housing them on pro-estrus with fertile 
male Wistar rats for 1 night. When spermatozoa were detected in the vaginal smear the 
next day, this was designated as day 0 of pregnancy.
In cyclic and (day 0) pregnant rats a cannula was surgically inserted into the right 
jugular vein under isoflurane/oxygen anaesthesia according to standard methods.22 This 
cannula allows stress-free infusion of saline or endotoxin. 
As described previously,18 endotoxin (Escherichia coli, 0.55:B5, Whittaker MA 
Bioproducts inc., Walkerville, MD) (1.0 μg/kg body weight) was dissolved in 2 ml pyrogen-
free saline and infused through the jugular vein cannula, using an infusion pump at an 
infusion rate of 2.0 ml/hour.
Pregnant rats were infused on day 14 of pregnancy with either saline (P-CTL) or 
endotoxin (P-endotoxin). Nonpregnant rats received infusion of either saline (NP-CTL) 
or endotoxin (NP-endotoxin) 14 days after cannulation. The low-dose endotoxin-treated 
pregnant rat is an established model of preeclampsia, characterized by hypertension, 
proteinuria, disseminated intravascular coagulation, generalized activation of the 
inflammatory response and endothelial cell activation.17-20 Recently, also aortic endothelial 
dysfunction has been demonstrated in these rats.23 The development of the preeclamptic-
like syndrome in this model is considered to result from a systemic inflammatory response 
induced by endotoxin.17,21,24 In addition to studies focussing on the pathophysiology of 
preeclampsia, studies concerning therapeutic options for preeclampsia have also been 
performed in this model.20,25,26 
Solutions
Krebs solution of the following composition was used for the vessel experiments (mM): 120 
NaCl, 5.9 KCl, 25.2 NaHCO3, 1.2 NaH2PO4, 10.4 glucose, 1.21 MgCl2•6H2O and 2.52 CaCl2 (E. 
Merck Darmstadt, Germany).
Pressurized arteriograph system
Six days after infusion, pregnant (day 20 of pregnancy) and nonpregnant rats were 
anesthetized with isoflurane in oxygen and decapitated. The brain and part of the 
mesentery were quickly removed and placed in ice cold Krebs. Third-order branches of 
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the PCA and MA were carefully dissected, cleared of connective tissue, and transferred 
to an arteriograph chamber for pressurized arteries (Living Systems, Burlington, VT, USA). 
Then they were mounted on two glass micropipettes with nylon ties and pressurized, 
as previously described.13 The arteriograph chamber was continuously recirculated with 
warmed (37.0±0.5ºC) and oxygenated (5% CO2 in O2) Krebs solution with a pH of 7.4.
The proximal cannula was attached to an in-line pressure transducer with a peristaltic 
pump and controller that adjusted intravascular pressure. The distal cannula was closed 
off to eliminate flow-induced responses (blind sac). To determine lumen diameter and wall 
thickness, a video dimension analyzer (Living Systems, Burlington, VT, USA), attached to 
a monitor, was used. On the monitor, the artery in the arteriograph chamber was shown, 
using a video camera connected to an inverted microscope.
Experimental protocol
For active measurements, arteries were allowed to equilibrate for 45 minutes at 50 mmHg 
for PCA and 60 mmHg for MA, after which Krebs was refreshed. For PCA, intravascular 
pressure was then increased in 25 mmHg increments to 175 mmHg. For MA, intravascular 
pressure was set at 40 mmHg and increased in 20 mmHg increments to 160 mmHg. After 
maintaining each pressure step for ~10 minutes to reach a stable contractile response, 
lumen diameter and wall thickness were measured.
Following myogenic protocols, calcium-containing Krebs was replaced with calcium-
free Krebs supplemented with ethyleneglycol-bis-(b-aminoethylether)tetraacetic acid 
(EGTA, 2 mmol/l) to obtain passive measurements of lumen diameter and wall thickness of 
PCA and MA at pressures from 5-175 mmHg and 5-160 mmHg, respectively.
Data calculations
The active measurement myogenic tone was calculated as percent decrease in active 
diameter from the maximally dilated diameter in calcium-free Krebs at each intravascular 
pressure, i.e., myogenic tone (%) = [(DCa-free -DCa)/DCa-free] x 100%, where D is the diameter of 
the vessel in calcium-containing (DCa) and calcium-free (DCa-free) Krebs.
The passive measurement percent distensibility was calculated at each pressure in 
completely relaxed vessels in calcium-free Krebs by determining diameter changes as a 
function of pressure, i.e., distensibility (%) = [(Dpressure/D5mmHg) – 1] x 100%, where Dpressure is 
the diameter of the vessel at a certain pressure and D5mmHg is the diameter of the vessel at 
5 mmHg.
Passive circumferential wall stress was calculated by the equation T/ω, where ω is 
wall thickness and T is circumferential wall tension. T is calculated as T=p x r, where p is 









Statistical analysis was performed using  SPSS for Windows 18. 
Differences in number and length of pups between P-CTL and P-endotoxin were 
assessed using Student’s t-tests. To determine the effect of pregnancy or endotoxin infusion, 
differences in body weight, wall thickness and wall-to-lumen ratio were determined by 
two-way ANOVA followed by a post hoc Bonferroni test for multiple comparisons where 
appropriate. Furthermore, linear regression analysis was performed to assess the slope of 
the myogenic tone curve of each experimental group and to determine whether this slope 
significantly differed from zero. This was executed in the intravascular pressure range of 
50-150 mmHg for PCA and 40-140 mmHg for MA.
To evaluate changes in active diameter for different pressures, repeated measures 
ANOVAs were performed for each experimental group. We tested whether active diameter 
changed with pressures below or above 75 mmHg for PCA or below or above 80 mmHg for 
MA, pressures that these vessels are exposed to under normotensive conditions.27,28 In PCA, 
the pressure at which the active diameter was significantly increased from the diameter at 
75 mmHg was defined as the pressure of FD.
To detect effects of pregnancy or endotoxin infusion on myogenic tone, passive 
diameter and distensibility curves, Areas Under the Curves (AUC) were calculated using 
GraphPad Prism for Windows (Version 4) and the effect of pregnancy or endotoxin infusion 
was evaluated using two-way ANOVA.




Table 1 shows the characteristics of all animals. As expected, both pregnant groups 
had higher body weights compared to the nonpregnant group with the same treatment 
(P<0.001). Endotoxin infusion did not affect body weight in nonpregnant animals but slightly 
increased body weight in pregnant rats (P<0.05).
Table 1
Animal characteristics
* P < 0.001 vs NP-CTL, † P<0.001 vs NP-endotoxin, ‡ P<0.05 vs P-CTL
NP-CTL, nonpregnant saline-treated; NP- endotoxin, nonpregnant endotoxin-treated; P-CTL, pregnant saline-treated; P-endotoxin, 
pregnant endotoxin-treated
NP-CTL (n=9) NP-endotoxin (n=9) P-CTL (n=9) P-endotoxin (n=10)
Body weight (g) 241.6 ± 6.6 247.2 ± 6.6 322.1 ± 7.0 * 345.8 ± 7.8 † ‡
No. of pups - - 12.4 ± 1.0 13.2 ± 0.9
Length of pups (mm) - - 32.36 ± 0.22 31.57 ± 0.22 ‡
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Figure 1A. Active diameter of posterior cerebral arteries at intravascular pressures from 50-175 
mmHg. Pregnant endotoxin-treated rats (P-endotoxin; black triangles) underwent forced dilatation 
at lower intravascular pressures than the other groups, i.e. nonpregnant saline-treated rats (NP-CTL; 
open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black circles) and pregnant saline-
treated rats (P-CTL; open triangles). * P<0.05 versus diameter at 75 mmHg from same group (repeated 
measures ANOVA)
Figure 1B. Percentage myogenic tone of posterior cerebral arteries at intravascular pressures from 
50-175 mmHg. Inserted bar graph: Area under the curve (AUC) of myogenic tone curves. Pregnancy 
or low-dose endotoxin treatment had no significant influence on myogenic tone. Nonpregnant 
saline-treated rats (NP-CTL; open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black 








Figure 2A. Passive diameter of posterior cerebral arteries at intravascular pressures from 5-175 
mmHg. Inserted bar graph: Area under the curve (AUC) of passive diameter curves. Pregnancy or 
low-dose endotoxin treatment had no significant influence on passive diameter. Nonpregnant saline-
treated rats (NP-CTL; open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black 
circles), pregnant saline-treated rats (P-CTL; open triangles) and pregnant endotoxin-treated rats 
(P-endotoxin; black triangles). 
Figure 2B. Passive distensibility of posterior cerebral arteries at intravascular pressures from 5-175 
mmHg. Inserted bar graph: Area under the curve (AUC) of passive distensibility curves. Pregnancy 
or low-dose endotoxin treatment had no significant influence on passive distensibility. Nonpregnant 
saline-treated rats (NP-CTL; open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black 
circles), pregnant saline-treated rats (P-CTL; open triangles) and pregnant endotoxin-treated rats 
(P-endotoxin; black triangles). 
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The number of pups and resorptions was similar for both pregnant groups. One 
animal of each group showed one resorption. However, pup length was significantly smaller 
in P-endotoxin compared to P-CTL rats (P<0.05).
PCA
Figure 1A shows the active diameter curves of PCA at intravascular pressures from 50 
to 175 mmHg, which were used to assess the pressure of FD. All four groups underwent 
FD at the higher end of the intravascular pressure range. In nonpregnant animals and in 
P-CTL animal, FD occurred between 150-175 mmHg. However, in the P-endotoxin group, FD 
occurred between 125-150 mmHg.
Figure 1B shows the percent myogenic tone at different intravascular pressures for 
PCA. Stable myogenic tone (i.e. the slope was not different from 0) was observed in PCA in 
all groups at intravascular pressures from 50 to 150 mmHg (Table 2). To assess the influence 
of both pregnancy and endotoxin infusion on myogenic tone, AUC were compared using 
two-way ANOVA. There was no significant influence of either pregnancy or endotoxin on 
myogenic tone. However, as demonstrated in figure 1A, loss of myogenic tone occurred in 
all groups at the higher end of the intravascular pressure range. 
To evaluate whether the differences in FD were due to differences in passive structure 
or diameter of PCA, we assessed the influence of both pregnancy and endotoxin infusion 
on passive diameters, wall thickness, wall-to-lumen ratio, wall stress and distensibility. 
For passive diameter and distensibility curves, AUC were compared between the groups 
using two-way ANOVA. This showed no significant effect of either pregnancy or endotoxin 
infusion on passive inner diameters of PCA (Figure 2A). Although NP-endotoxin animals 
appeared to have decreased distensibility compared to the other groups, no effect of 
either pregnancy or endotoxin was found (Figure 2B). Furthermore, passive wall thickness, 
wall-to-lumen ratio and wall stress were not significantly affected by either pregnancy or 
endotoxin infusion at any of the intravascular pressures from 5 to 175 mmHg. In table 3, 
passive wall thickness, wall-to-lumen ratio and wall stress are shown for the intravascular 
pressure of 75 mmHg, a pressure at which these vessels have been shown to operate under 
normotensive conditions.28 
Table 2
Slopes of myogenic tone curves of posterior cerebral (50 - 150 mmHg) and mesenteric (40 - 140 mmHg) arteries 
* P < 0.05 vs zero 














Slope myogenic tone PCA 0.017 ± 0.013 0.093 ± 0.010 0.054 ± 0.011 -0.018 ± 0.010







Figure 3A. Active diameter of mesenteric arteries at intravascular pressures from 40-160 mmHg. In 
nonpregnant saline-treated rats (NP-CTL; open circles) active diameter significantly decreased with 
increasing pressure. This was not observed in nonpregnant endotoxin-treated rats (NP-endotoxin; 
black circles), pregnant saline-treated rats (P-CTL; open triangles) and pregnant endotoxin-treated 
rats (P-endotoxin; black triangles). * P<0.05 versus diameter at 80 mmHg from same group (repeated 
measures ANOVA)
Figure 3B. Percentage myogenic tone of mesenteric arteries at intravascular pressures from 40-
160 mmHg.  Inserted bar graph: Area under the curve (AUC) of myogenic tone curves. Pregnancy 
decreased myogenic tone compared to nonpregnant animals at intravascular pressures from 120 to 
160 mmHg. Nonpregnant saline-treated rats (NP-CTL; open circles), nonpregnant endotoxin-treated 
rats (NP-endotoxin; black circles), pregnant saline-treated rats (P-CTL; open triangles) and pregnant 
endotoxin-treated rats (P-endotoxin; black triangles).* P<0.05 for pregnant vs nonpregnant (two-way 




To investigate whether pregnancy and experimental preeclampsia influence the cerebral 
and systemic circulation similarly, simultaneous experiments were performed in MA. 
In figure 3A the active diameter versus pressure curves are shown for all groups at 
intravascular pressures from 40 to 160 mmHg. Changes in active diameter at pressures 
below or above 80 mmHg were assessed using repeated measures ANOVA. In NP-CTL 
rats, as compared to 80 mmHg, active diameter significantly decreased with increasing 
pressures. This was not the case in the other three groups. Like in PCA, active diameter 
did not change below 80 mmHg in most groups, apart from P-CTL rats.
Figure 3B shows the level of myogenic tone of MA. Although MA from all groups 
developed myogenic tone, this appeared to be lower compared to PCA, which is in 
accordance with previous findings. Furthermore, in contrast to our findings in PCA, the 
slope of the myogenic tone curve of all groups of rats increased with increasing pressures 
between 40 and 140 mmHg (Table 2), indicating increasing myogenic tone over this pressure 
range. To assess the influence of both pregnancy and endotoxin infusion on myogenic tone, 
AUC were compared using two-way ANOVA. There was a significant effect of pregnancy 
on myogenic tone of MA with pregnant animals demonstrating decreased myogenic tone 
compared to nonpregnant animals (P<0.05). Endotoxin treatment did not affect myogenic 
tone in both nonpregnant and pregnant rats.
To assess whether decreased myogenic tone in MA during pregnancy was due to 
changes in passive diameter, passive pressure versus diameter curves of MA were evaluated 
(Figure 4A). As in PCA, AUC of passive inner diameters curves of MA were not significantly 
affected by pregnancy or endotoxin infusion at any of the intravascular pressures studied. 
















Wall thickness (um) 11.3 ± 1.0 10.6 ± 0.9 10.9 ± 0.7 10.6 ± 0.7
Inner diameter (um) 185.0 ± 6.1 183.0 ± 5.0 177.3 ± 10.1 184.8 ± 4.8
Wall-to-lumen ratio 0.061 ± 0.005 0.058 ± 0.004 0.064 ± 0.006 0.058 ± 0.005
Wall stress (dynes/cm2 x 106) 0.859 ± 0.062 0.897 ± 0.066 0.840 ± 0.074 0.914 ± 0.069
MA
80 mmHg
Wall thickness (um) 21.6 ± 1.9 21.3 ± 2.3 20.1 ± 1.4 21.6 ± 1.2
Inner diameter (um) 350.3 ± 13.7 358.8 ± 21.2 321.4 ± 10.5 349.9 ± 11.6
Wall-to-lumen ratio 0.062 ± 0.005 0.059 ± 0.005 0.062 ± 0.004 0.062 ± 0.004
Wall stress (dynes/cm2 x 106) 0.912 ± 0.090 0.949 ± 0.070 0.889 ± 0.070 0.882 ± 0.044
NP-CTL, nonpregnant saline-treated; NP-endotoxin, nonpregnant endotoxin-treated; P-CTL, pregnant saline-treated; P-endotoxin, 
pregnant endotoxin-treated
Table 3







Figure 4A. Passive diameter of mesenteric arteries at intravascular pressures from 5-160 mmHg. 
Inserted bar graph: Area under the curve (AUC) of passive diameter curves. Pregnancy or low-dose 
endotoxin treatment had no significant influence on passive diameter. Nonpregnant saline-treated rats 
(NP-CTL; open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black circles), pregnant 
saline-treated rats (P-CTL; open triangles) and pregnant endotoxin-treated rats (P-endotoxin; black 
triangles).
Figure 4B. Passive distensibility of mesenteric arteries at intravascular pressures from 5-160 mmHg. 
Inserted bar graph: Area under the curve (AUC) of passive distensibility curves. Pregnancy or low-
dose endotoxin treatment had no significant influence on passive distensibility. Nonpregnant saline-
treated rats (NP-CTL; open circles), nonpregnant endotoxin-treated rats (NP-endotoxin; black 




Furthermore, wall thickness, wall-to-lumen ratio and wall stress were evaluated 
in relaxed vessels and were not affected by either pregnancy or endotoxin infusion any 
of the intravascular pressures studied. In table 3, these measurements are shown for the 
intravascular pressure of 80 mmHg, a pressure to which  these vessels are exposed  under 
normotensive conditions.27 As in PCA, percent distensibility of MA tended to be decreased 
in NP-endotoxin animals compared to the other groups, however, no significant differences 
in AUC of distensibility curves were found (Figure 4B). 
Discussion
In the present study, we investigated the effect of pregnancy and low-dose endotoxin 
infusion, which is an established model for preeclampsia, on function and structure of Wistar 
rat PCA and MA. In PCA, we found that while normal pregnancy did not affect structure 
or function, low-dose endotoxin infusion decreased the pressure at which FD occurred 
compared to both normal pregnant and nonpregnant rats. Within the autoregulatory 
pressure range, myogenic tone was not affected by either pregnancy or low-dose endotoxin 
infusion. Our findings suggest that low-dose endotoxin infusion during pregnancy, and not 
pregnancy alone, may predispose the brain to autoregulatory breakthrough and edema 
formation when blood pressure is increased as seen in eclampsia. In MA, structure was 
unaffected by pregnancy or low-dose endotoxin. However, in contrast to PCA, pregnancy 
alone decreased myogenic tone of MA, with no additional effect of low-dose endotoxin 
infusion.
Prior studies evaluating the influence of pregnancy on the cerebrovasculature are 
relatively scarce and somewhat contradictory. In vitro studies by Cipolla et al showed 
diminished myogenic reactivity14 and earlier FD13 of PCA in late-pregnant versus nonpregnant 
Dahl salt-sensitive and Sprague-Dawley rats, respectively, suggesting that pregnancy alone 
would predispose to loss of autoregulation. However, others found no influence of pregnancy 
on myogenic reactivity of a different cerebral blood vessel (the middle cerebral artery) in 
Sprague-Dawley rats.29 Furthermore, an in vivo study showed autoregulatory breakthrough 
at similar pressures in late-pregnant and nonpregnant Sprague-Dawley rats.30 We used in 
vitro techniques comparable to those used by Cipolla et al and found no effect of pregnancy 
alone on PCA myogenic tone or pressure of FD. This difference might be explained by 
use of different rat strains as differences in mesenteric artery function during pregnancy 
have been described for Wistar versus Sprague-Dawley rats.31 Whether such inter-strain 
differences may also occur in cerebral arteries is currently unkown. Despite the fact that 
we found no effect of pregnancy on myogenic tone or FD in PCA, earlier FD was observed 
after low-dose endotoxin infusion in pregnant Wistar rats. Knowledge about effects of 
experimental preeclampsia on cerebral arteries is even more limited. Two studies using 
models of hypertension in pregnancy showed no differences in myogenic reactivity14 and 







Sprague-Dawley rats, respectively. However, middle cerebral arteries from experimental 
preeclamptic Sprague-Dawley rats, induced by reduced uterine perfusion, have decreased 
myogenic reactivity and increased brain water content compared to normal pregnant 
rats.29 In line with this study, our data also suggest that low-dose endotoxin infusion during 
pregnancy impairs cerebral autoregulation and thus may sensitise the brain for edema 
development and eclampsia. 
Earlier FD of PCA in preeclamptic rats appeared not to be due to structural changes 
of these arteries since neither pregnancy nor low-dose endotoxin did affect passive 
characteristics of PCA. These findings suggest the absence of pregnancy or experimental 
preeclampsia induced structural remodeling of PCA. It is well known that cerebral arteries 
from nonpregnant animals undergo structural remodeling in response to hypertension. 
This is thought to protect the downstream microcirculation from increased hydrostatic 
pressure.32,33 However, studies in two rat models of hypertensive pregnancies have shown 
that pregnancy prevented this remodeling in PCA14,15 and even reversed already established 
remodeling.34 The lack of remodeling in preeclamptic rat PCA in our study is in line with 
these earlier findings. Unfortunately, for various technical reasons it was not possible to 
measure blood pressure in the rats in our study. However, we expect a mild increase in 
blood pressure, mainly in the last few days of pregnancy.18-20,26 The lack of remodeling could 
also be due to this relatively mild hypertension, only at the end of pregnancy or to the 
short duration (one week) of hypertension. The mechanistic basis for forced dilatation at 
lower blood pressure in PCA from preeclamptic Wistar rats remains therefore unclear, but 
might be related to increased sensitivity of cerebral arteries to nitric oxide (NO). Recently, 
it was shown that low-dose endotoxin-treated Wistar pregnant rats showed enhanced 
sensitivity of PCA to the dilatory effect of the NO donor NONOate.16 In addition, expression 
of vascular inducible NO synthase (iNOS) was augmented in these animals16, which might 
increase NO levels. Whether similar changes occurred in the rats in our study remains to 
be studied, as the model of Cipolla et al, is different from our model in several aspects. 
Major differences  are infusion of a 1.5 times higher dose of endotoxin and infusion under 
isoflurane anesthesia, rather than under awake conditions.16 These differences may have 
affected the model, since our lab has previously demonstrated that infusion of endotoxin 
into pregnant animals under anesthesia did not result in hypertension (unpublished 
data). Additionally, the time frame between endotoxin infusion and the experiments was 
different; in the Cipolla study, rats were sacrificed 3 or 2 days prior to delivery, while in 
our study the rats were sacrificed 1 day prior to delivery.16  
To investigate whether pregnancy and low-dose endotoxin infusion similarly affect 
cerebral and peripheral resistance arteries, function and structure of MA were assessed. 
In contrast to PCA, pregnancy, regardless of infusion of low-dose endotoxin, appeared to 
decrease myogenic tone of MA due to a different response of active diameter to increasing 
intravascular pressure. Whereas, similar to other studies,35,36 MA active diameter in NP-
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CTL rats decreased in response to increasing pressure, they were relatively constant in 
pregnant animals. Our finding of decreased myogenic tone in MA of Wistar rats during 
pregnancy is not surprising in the face of the hemodynamic characteristics of normal 
pregnancy. Decreased myogenic tone may be one of the mechanisms underlying the 
decreased peripheral vascular resistance seen during pregnancy.37,38 However, earlier 
findings on myogenic behaviour of MA during pregnancy appear contradictory. While some 
studies have shown a similar decrease in myogenic tone in pregnant versus nonpregnant 
rats and mice,7,35 others did not.10,39 Furthermore, while we did not see an effect of low-dose 
endotoxin on myogenic tone, others have found increased myogenic reactivity in a model 
for preeclampsia induced by reduced uterine perfusion pressure in pregnant Sprague-
Dawley rats.11,40 These differences might be due to differences in rat strain, preeclampsia 
rat model or experimental techniques.
Similar to PCA, no effect of either pregnancy or low-dose endotoxin infusion 
was found on structural properties of MA suggesting that MA, like PCA, did not undergo 
structural remodeling. In addition, distensibility was not affected, suggesting no change in 
wall components.41 Only few studies have examined the influence of pregnancy on structural 
properties of MA. In contrast to our findings, they found increased distensibility41,42 and 
decreased wall thickness during pregnancy.42 However, both studies were performed in 
Sprague-Dawley rats, a different rat strain than used in our study. We also measured 
angiotensin II sensitivity and endothelial function in the aortas of these endotoxin infused 
pregnant rats and found increased angiotensin II sensitivity and endothelial dysfunction in 
the aortas of the pregnant endotoxin infused rats compared with control pregnant rats.23 
This suggests that, although we found no effect of endotoxin in pregnant animals on MA in 
the present study, peripheral vascular changes are apparent in these rats.
In conclusion, our study for the first time showed that low-dose endotoxin infusion, 
but not pregnancy alone, induced earlier FD in PCA. This could not be explained by 
structural remodeling of PCA. This earlier FD may predispose the brain to autoregulatory 
breakthrough and edema formation during states of increased blood pressure (e.g. 
eclampsia). In addition, myogenic tone of MA and PCA appeared to be differentially 
affected by pregnancy and low-dose endotoxin infusion. While pregnancy decreased 
myogenic tone of MA, independently of low-dose endotoxin infusion, myogenic tone of 
PCA was not affected. This might be due to functional difference between the mesenteric 
and cerebral vascular bed. Whereas the mesenteric vascular bed may show decreased 
myogenic tone in the light of the decreased systemic peripheral vascular resistance during 
pregnancy,37,38 the cerebral vascular system has to exert a tight autoregulatory blood flow 
control to prevent ischemia or hyperperfusion leading to blood-brain barrier disruption.43,44
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To assess brain damage using the neuroinflammation marker S100B in a preeclampsia rat 
model.
Methods
Non-pregnant and pregnant rats were infused with saline or low-dose endotoxin on day 
14 of pregnancy. S100B expression in the brain (immunohistochemistry) and S100B plasma 
concentrations (ELISA) were studied.
Results
No differences in S100B expression in brain tissue were observed between the four groups. 
Pregnant endotoxin-treated animals did not show increased levels of plasma S100B levels 
as compared with control pregnant rats, while significantly higher plasma S100B levels 
were found in non-pregnant endotoxin versus pregnant endotoxin infused rats.
Conclusion
Pregnancy nor experimental preeclampsia, alter S100B in rat brain, or in plasma. Increased 
plasma S100B in non-pregnant endotoxin-treated rats may indicate brain injury in these 




Pre-eclampsia is responsible for the world’s largest maternal mortality rates, mostly due 
to acute cerebral complications such as eclampsia (posterior reversible encephalopathy 
syndrome (PRES)), and intracerebral hemorrhage.1 PRES is thought to be caused by a failure 
of the brain’s autoregulatory response to increases in blood pressure in conjunction with 
endothelial cell dysfunction. It is associated with a loss of integrity of the blood–brain 
barrier; inflammatory cells and fluid can penetrate the brain and cause edema and cell 
death. Interruption of this delicate balance between capillary and cellular perfusion 
pressures may lead to the neurological complications of preeclampsia.1
S100B is an acidic calcium-binding protein, mainly expressed by astrocytes, 
oligodendrocytes and Schwann cells.2 Experimental and clinical studies have shown S100B 
to be involved in neuroinflammation.3 Because approximately 95% of S100B is located in 
the CNS, the results of several studies, both human and animal, have suggested that an 
increase in S100B levels in blood as well as increased expression in brain tissue could be 
a potential marker of neuronal injury indicating astrocytic death, reactive gliosis and/or 
blood–brain barrier dysfunction.4-7 
Neuroinflammation is a key component of various central nervous system 
(CNS) diseases, promoting both reparation and damage of neural tissue.3 The use of 
neuroinflammatory biomarkers (such as S100B) in hypertensive disease in pregnancy may 
represent a novel avenue for early diagnosis, and eventually prevention, of cerebrovascular 
complications in preeclamptic women who present with neurological signs and symptoms, 
but current data are limited.5-8
To assess the possible relationship between preeclampsia and neuronal brain 
damage, we investigated the brain injury marker S100B in brain tissue and plasma in a rat 
model for mild preeclampsia.
Materials and methods
Animals
Female Wistar outbred rats (200–220 g) were housed in standard conditions, in a temperature- 
and light-controlled room (12 h light–dark cycle), with free access to water and food. 
Vaginal smears were taken daily, and rats were rendered pregnant by housing them on 
proestrus with fertile male Wistar rats for one night. When spermatozoa were detected in 
the smear the next day, this day was designated day 0 of pregnancy. A permanent cannula 
was inserted in the right jugular vein in all rats under 2% isoflurane/oxygen anesthesia 








The ultra-low-dose endotoxin rat model for preeclampsia was used to simulate a 
preeclamptic state.10 This model is characterized by hypertension and proteinuria in the 
last week of pregnancy. Endotoxin, derived from Escherichia coli (E. coli, 0.55:B5, Whittaker 
MA Bioproducts, Walkerville, MD) was dissolved at a dose of 1.0 μg/kg body weight in 2 ml 
of pyrogen free saline solution. Endotoxin (or saline for control) was infused via the jugular 
vein cannula with an infusion rate of 2.0 ml/h for the duration of 1 h. Pregnant rats were 
infused at day 14 of pregnancy, nonpregnant rats 6 days prior to sacrifice. 
The rats were divided into four groups: (1) nonpregnant rats infused with saline 
(nonpregnant controls, n=5); (2) nonpregnant rats infused with low-dose endotoxin (n=7); 
(3) pregnant rats infused with saline (pregnant controls, n=7); and (4) pregnant rats infused 
with low-dose endotoxin (n=7). 
Because we were not able to obtain blood samples in all rats, the study population 
with regard to the ELISA consisted of: (1) nonpregnant rats infused with saline (n=5); (2) 
nonpregnant rats infused with low-dose endotoxin (n=5); (3) pregnant rats infused with 
saline (n=7); and (4) pregnant rats infused with low-dose endotoxin (n=6).
Preparation of brain tissue
At day 20 of pregnancy or 6 days after infusion in nonpregnant rats, rats were decapitated 
under isoflurane/oxygen anesthesia. Immediately after decapitation, trunk blood of the 
rat was collected in heparin tubes. Blood samples were centrifuged (562g, 10 min), blood 
plasma collected and centrifuged again (1083g, 10 min). Plasma was stored at -80 ºC until 
analysis. 
The brain was quickly removed and divided into forebrain, cerebellum and brain 
stem. Brain tissue was fixed in 4% paraformaldehyde for 24 h and, until embedding, stored 
in 70% ethanol. Before embedding in paraffin wax, tissue dehydrated by submitting to 
ethanol (96% and 100%) and finally xylol. Of the forebrain, cerebellum and brain stem, 
sections of 5 lm were cut and mounted on silane coated glass slides (Starforst adhesive 
grün, Knittel Gläser, Braunschweig, Germany).
Immunohistochemical staining of S100B in brain tissue
For immunohistochemical analysis, paraffin embedded sections were dewaxed in 
xylene and rehydrated in ethanol. S100B antigen was retrieved by heating sections in a 
trisaminomethane/ethylenediaminetetraacetic acid (Tris/EDTA) buffer (10 mM Tris/1 mM 
EDTA, pH 9.0) in a microwave oven (400 W) for 15 min. Sections were cooled in Tris/EDTA 
for 30 min and then washed in phosphate buffered saline (PBS) for 5 min. After incubation 
with normal rabbit serum (Dako, Glostrup, Denmark, 1:10, 30 min, room temperature (RT)), 
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the sections were incubated with the primary antibody (polyclonal rabbit anti-S100B (Dako, 
Glostrup, Denmark), 1:200, 60 min, RT). Endogenous peroxidase activity was blocked using 
0.075% hydrogen peroxide (H2O2) in PBS (30 min, RT). After incubation with a secondary 
antibody (swine anti-rabbit horseradish peroxidase labeled (Dako, Glostrup, Denmark, 
1:100, 30 min, RT)), the staining was finished by performing an 3-amino-9-ethyl carbazole 
(AEC)-staining (10 min, RT). Sections were counterstained with haematoxylin. 
Of each section of the forebrain, cerebellum and brain stem, 10 comparable fields 
were photographed with a computerized microscope (Leica DFC420C, Wetzlar, Germany) at 
a 400x magnification. Each photograph covers 0.06097 mm2. Of each section, the fields are 
comparable with fields in other sections with regard to anatomical location and estimated 
total number of cells. The hippocampus, a part of the forebrain, was also photographed. 
Because the hippocampus is a small structure, only five fields were photographed to avoid 
overlap. The hippocampus was not present in all sections: sections obtained in the lateral 
part of the forebrain did not contain hippocampal tissue. Hippocampal tissue was not 
present in one nonpregnant rat infused with saline, two nonpregnant rats infused with 
low-dose endotoxin, two pregnant rats infused with saline and two pregnant rats infused 
with low-dose endotoxin. Of each photograph, the total number of S100B-positive cells was 
scored blindly by two examiners. The average of the two examiners per photograph was 
calculated. The number of positive cells of all photographs of each section was added up, 
and expressed as number of positive cells/mm2. The fields photographed were compared 
with fields in the same brain region from other rats for differences in distribution of S100B-
positive cells and intensity of the S100B-staining.
ELISA to determine S100B concentrations in plasma
To determine the S100B concentration in rat plasma, we used a commercial available 
enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Heidelberg, Germany). All the 
procedures were performed according to the manufacturer’s protocol. All samples were 
measured in duplicates.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, USA). All results 
were expressed as mean ± standard error of mean (SEM). The effect of pregnancy or 








Figure 1. Representative microphotographs of the forebrain immunostained for S100B and 
counterstained with haematoxylin of nonpregnant and pregnant rats infused with saline or endotoxin. 
(a) Nonpregnant rat infused with saline, (b) pregnant rat infused with saline, (c) nonpregnant rat 
infused with endotoxin and (d) pregnant rat infused with endotoxin. In the forebrain, the S100B 
protein seems to be mainly localized in the glial cells (white arrow), but some neurons (black arrow) 
also contain S100B. S100B-positive cells are indicated by arrows: white arrow, glial cell; black arrow, 
neuronal cell. Magnification: 400x.
Figure 2. Representative microphotographs of the cerebellum immunostained for S100B and 
counterstained with haematoxylin of nonpregnant and pregnant rats infused with saline or endotoxin. 
(a) Nonpregnant rat infused with saline, (b) pregnant rat infused with saline, (c) nonpregnant rat 
infused with endotoxin and (d) pregnant rat infused with endotoxin. Different types of layers can 
be observed in these microphotographs: the granule cell layer (A) and the molecular layer (B) of the 
cerebellum. Between these two layers a layer of Purkinje cells (C) can be observed. S00B positive 
glial cells (white arrows) are mainly localized in the Purkinje cell layer; Purkinje cells (red arrow) are 
negative for S100B. Magnification: 400x.
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Figure 3. Representative microphotographs of the brain stem immunostained for S100B and 
counterstained with haematoxylin of nonpregnant and pregnant rats infused with saline or endotoxin. 
(a) Nonpregnant rat infused with saline, (b) pregnant rat infused with saline, (c) nonpregnant rat 
infused with endotoxin and (d) pregnant rat infused with endotoxin. In the brain stem, nerve tracts 
can be observed (D), surrounded by glial cells. S100B-positive glial cells are indicated by white arrows. 
Magnification: 400x.
Figure 4. Representative microphotographs of hippocampus immunostained for S100B and 
counterstained with haematoxylin of nonpregnant and pregnant rats infused with saline or endotoxin. 
(a) Nonpregnant rat infused with saline, (b) pregnant rat infused with saline, (c) nonpregnant rat 
infused with endotoxin and (d) pregnant rat infused with endotoxin. The dentate gyrus is shown in 
these photographs (E). The dentate gyrus is surrounded by both glial cells and neurons. S100B-positive 








S100B expression in brain tissue
To examine the expression of the S100B protein in brain tissue, we performed 
immunohistochemical staining of sections of the forebrain, cerebellum and brain stem.
Figs. 1–4 demonstrate representative microphotographs of the forebrain, cerebellum, 
brain stem and hippocampus, immunostained for the S100B protein.
In the forebrain, the S100B protein seems to be mainly localized in the glial cells, 
but some neurons also contain S100B. In the forebrain, no major differences between the 
four groups of rats with regard to the intensity of the S100B-staining were observed (Fig. 
1). Moreover, in all groups, the S100B-positive cells were diffusely distributed throughout 
the sections, and not grouped.
In Fig. 2, representative microphotographs of the cerebellum are shown. In all four 
groups, S100B-positive glial cells are mainly localized in the layer between the granule cell 
layer (A) and the molecular layer (B) of the cerebellum, which is called the Purkinje cell 
layer (C). The Purkinje cells are negative for the S100B protein. No major differences were 
observed with regard to the intensity of the S100B-staining in the cerebellum between the 
different groups.
Fig. 3 shows representative microphotographs of the brain stem. In these 
photographs, nerve tracts (D) can be observed. S100B-positive cells in the brain stem are 
mainly glial cells. With regard to the intensity of the staining of the sections of the brain 
stem, no major differences between the four groups could be observed. No difference in 
distribution of S100B-positive cells was observed. 
Representative microphotographs of the hippocampus are demonstrated in Fig. 4. 
The dentate gyrus (E) is shown in these photographs. Both neurons and glial cells contain 
S100B. No major differences between the four groups with regard to the intensity of the 
S100B-staining in the hippocampus could be observed. There were no differences with 
regard to the distribution of the S100B-positive cells between the four different groups in 
the hippocampus.
Table 1 demonstrates the number of S100B positive cells per mm2 in the different 
brain regions. No significant differences were detected in the number of S100B positive 
cells in the different brain regions between the nonpregnant controls and the pregnant 
controls, nor between the pregnant controls and the pregnant endotoxin group. Differences 
in nonpregnant endotoxin versus pregnant endotoxin and nonpregnant controls versus 
nonpregnant endotoxin were not observed either.
S100B concentration in plasma
No significant differences were observed between the nonpregnant controls and the 
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pregnant controls, nor between the pregnant controls and the pregnant endotoxin group 
(Fig. 5). In the nonpregnant endotoxin group, the S100B concentration in plasma was 
significantly higher when compared with the pregnant endotoxin group (P<0.05).
Discussion
This study demonstrates the expression of the S100B protein in different brain regions and 
plasma S100B concentrations in a preeclampsia rat model. No differences in S100B brain 
expression nor plasma concentrations were observed between pregnant and nonpregnant 
controls. Pregnancy per se, thus, does not influence the expression of the S100B protein in 
the rat brain nor S100B plasma concentrations. Moreover, no differences in S100B plasma 
concentrations nor S100B brain expression were detected between the pregnant controls 
and pregnant rats with experimental preeclampsia. Thus, in this mild preeclampsia rat 
model, we were unable to demonstrate evidence of brain injury. However, the S100B 
concentration in plasma was significantly higher in the nonpregnant endotoxin treated 
rats, when compared with the pregnant endotoxin treated rats (preeclampsia rat model). 
Pregnancy might have a protective effect on brain tissue after endotoxin infusion in rats.
In this study, we used the ultra-low-dose endotoxin preeclampsia rat model, which 
has been used for several years in preeclampsia research.10-14 The histopathological and 
clinical events in this model simulate the predominant features of mild human preeclampsia 
such as a significant increase in blood pressure and in urinary albumin excretion.10 The fact 
that we did not find evidence of brain injury in this model, may suggest that this mild 
preeclampsia rat model is not severe enough to induce cerebrovascular pathology. This 
may be in line with the fact that pregnant women with severe preeclampsia are more at 
risk for developing cerebrovascular pathology (PRES) when compared with women with 
mild preeclampsia.1 Therefore, it is possible that S100B plasma concentrations and brain 
expression are increased in animal models for severe preeclampsia, when compared with 
animal models for mild preeclampsia.
To our surprise, we observed increased concentrations of S100B in the plasma of 
nonpregnant endotoxin treated animals. In contrast, we did not find increased expression 
Table 1
Number of S100B positive cells per mm2 in the forebrain, cerebellum, brain stem and hippocampus in different 
groups of rats.
Group Brain regions (mean ± SEM)
Forebrain Cerebellum Brain stem Hippocampus
Nonpregnant saline 152.8 ± 11.6 (n=5) 182.9 ± 12.5 (n=5) 242.9 ± 46.1 (n=5) 192.9 ± 20.0 (n=4)
Nonpregnant endotoxin 151.1 ± 15.4 (n=7) 220.2 ± 17.1 (n=7) 300.8 ± 51.9 (n=7) 224.1 ± 20.4 (n=5)
Pregnant saline 165.6 ± 13.5 (n=7) 238.2 ± 20.0 (n=7) 260.9 ± 21.3 (n=7) 221.6 ± 8.5 (n=5)







of S100B in brain tissue of these animals. Our finding of increased plasma S100B is also in 
contrast to previous studies, in which we observed no effect of endotoxin in nonpregnant 
rats on various parameters.10-12 It may, however, be in line with several studies reporting 
neuroinflammation induced by endotoxin in rats.15-16 The dose of endotoxin used in our 
study, however, is much lower and given intravenously rather then intraperitoneally or 
via intracerebral injection. The high S100B plasma concentrations in the nonpregnant 
endotoxin-treated rats might thus be caused by endotoxin-induced neuroinflammation.
Little is known about S100B levels and their significance in the peripheral blood, 
and cerebrospinal fluid in human (pre)eclampsia. Schmidt et al. studied serum S100B 
concentrations in women with several forms and severity of hypertensive disease in 
pregnancy.5 This small study included 50 women. Of these women, 10 had experienced 
eclampsia, and 18 women had preeclampsia. No significant difference in serum S100B 
concentration could be demonstrated between the preeclamptic group and the 
normotensive group but serum S100B was significantly higher in eclampsia. Unfortunately, 
hardly any clinical characteristics of the study population with preeclampsia were provided, 
and therefore, no conclusions can be drawn with regard to the clinical relevance and 
utility of S100B serum levels. Whether the increased levels of plasma S100B only arise from 
the CNS in eclampsia remains to be established, since in pregnancy, S100B may also be 
found in fetal tissue. Tskitishvili et al. found the percentage of positively stained amniotic 
epithelial cells increased in preeclampsia compared with healthy pregnant controls, while 
in the amniotic fluid the S100B concentration was significantly higher in patients with 
preeclampsia, when compared with the healthy controls.8
Although little is known about S100B in preeclampsia, it has the potential to become 
an important clinical biomarker of central nervous system injury and neuroinflammation 
in pregnancy and preeclampsia.17 In various central nervous system disorder, such as 
Figure 5. Mean (±SEM) of S100B concentrations in plasma of nonpregnant (left set of bars) and 
pregnant rats (right set of bars) after infusion of saline (open bars) or endotoxin (black bars). *P<0.05 




subarachnoid hemorrhage, ischemic stroke and traumatic injury, the level of the S100B 
protein in peripheral blood samples is elevated.17 The expression of the S100B protein in 
brain tissue and S100B concentrations in peripheral blood have also been investigated in 
several animal models for brain injury. S100B expression in the stroke-prone hypertension 
rat model was increased compared with healthy, normotensive rats.6 Hippocampal 
S100B expression was increased in rats exposed to chronic cerebral hypoperfusion when 
compared with control rats.18 Lipcsey et al. demonstrated increased expression of the 
S100B protein in the pig brain, mainly in the astrocytes, in septic encephalopathy.19 Tanaka 
et al. demonstrated significant increases in serum S100B levels in a rat with cerebral 
hemorrhage when compared with rats without cerebral hemorrhage.20 These nonpregnant 
animal models demonstrate that brain injury (e.g. stroke and hypoperfusion) can cause a 
higher S100B expression in rat brain tissue and higher S100B concentrations in peripheral 
blood. Whether also in pregnancy S100B will be affected by brain injury, remains to be 
established. 
Concluding, this study demonstrates that pregnancy nor mild preeclampsia influenced 
the expression of the S100B protein in brain tissue and S100B plasma concentrations 
in the endotoxin rat model. Taking into account that the pathophysiology of PRES in 
(pre)eclampsia involves breakthrough of the blood–brain barrier and, eventually, ischemic 
damage to cells in the central nervous system, it is feasible that an increase in the S100B 
protein could be observed in preeclamptic women with impending PRES. To further 
elucidate the clinical utility of brain neuroinflammatory biomarkers animal studies with 
models for severe preeclampsia should be performed.
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This review aims to summarize existing information concerning visual disturbances in 
(pre)eclampsia that have been described in the literature. Preeclampsia is one of the leading 
causes of maternal and fetal morbidity and mortality worldwide. Visual disturbances in 
(pre)eclampsia seem to be frequent phenomena. Therefore, the obstetrician/gynecologist 
may encounter women with serious, and sometimes debilitating, pathology of the visual 
pathways. Established ophthalmic entities associated with (pre)eclampsia are cortical 
blindness, serous retinal detachment, Purtscher-like retinopathy, central retinal vein 
occlusions, and retinal or vitreous hemorrhages. Ensuing visual symptoms include blurry 
vision, diplopia, amaurosis fugax, photopsia, and scotomata, including homonymous 
hemianopsia. In general, aside from lowering the blood pressure and preventing (further) 
seizures with magnesium sulfate, no specific therapy seems indicated for (pre)eclamptic 
women who experience visual changes. Although in most cases visual acuity returns to 
normal within weeks to months after the onset of symptoms, rarely permanent visual 
impairment can occur. Health care providers such as emergency room physicians, 
obstetricians, family physicians, neurologists, and ophthalmologists should be aware that 
acute onset of visual symptoms in pregnant women can be the first sign of (pre)eclampsia. 
Given that visual changes are a diagnostic criterion for severe preeclampsia, obstetricians 
should appreciate the significance of these changes and discuss appropriate diagnostic 





A 24-year-old primigravid woman at 37 weeks’ gestation was brought to the emergency 
department by her family. The family stated that the woman had woken up that morning 
unable to see. The woman herself denied any visual disturbance but did complain of 
nausea and frontal headache. Her pregnancy had been uneventful before this time. On 
examination, she appeared confused and disoriented as to time. Her blood pressure was 
165/110 mm Hg, heart rate 128 beats per minute, and she had slight edema in her hands 
and feet. Neurologic and ophthalmic examination revealed no abnormalities, except 
hyperreflexia and severe impairment of vision, although the woman continued to disagree 
that she had visual impairment. Pupillary reflexes were intact and the motility undisturbed. 
Fundoscopic examination showed no abnormalities of the optic disc or macula. Laboratory 
testing revealed 3+ proteinuria and elevated uric acid. A T2-weighted magnetic resonance 
imaging (MRI) scan demonstrated bilateral hyperintense signals in the parieto-occipital 
lobes. Based on the signs and symptoms described earlier, the diagnosis made was 
preeclampsia complicated by cortical blindness.
Introduction
Pregnancy can affect multiple organs, including the eyes. For example, the pregnant 
state is associated with increased corneal thickness1,2 and curvature,3 and decreased 
corneal sensitivity.4 Furthermore, a decrease in intraocular pressure occurs during the 
third trimester of pregnancy.1,2,5 Preexisting ocular diseases (e.g., diabetic retinopathy and 
uveitis) can be exacerbated during pregnancy. In addition to these pregnancy-induced 
ocular changes, preeclampsia and its complications can be associated with a variety of 
visual changes.6–10 Because the obstetrician/gynecologist may occasionally be confronted 
with a preeclamptic woman who suffers visual disturbances, this review aims to summarize 
existing information described in the literature. The search strategy included a MEDLINE 
search through December 2011, limiting to articles published in English language and reports 
including humans. The following Medical Subject Headings terms were used: “pregnancy 
induced hypertension,” “(pre)eclampsia,” and “visual disorders.” Abstracts were reviewed 
for suitability. The references of the available articles were screened as well and were 
included when they represented a unique case report. This literature consisted mainly of 
isolated case reports or small case series. Not all single case reports we encountered were 
included in this review because often case reports described nearly identical features, 
and we decided to include reports that gave the most information on a particular case/ 









Some form of hypertension complicates 5% to 7% of all pregnancies and is one of the 
leading causes of maternal and fetal morbidity and mortality worldwide.11,12 Preeclampsia 
is a pregnancy-specific disorder, characterized by hypertension and proteinuria after 
midgestation. The exact pathophysiology of preeclampsia remains to be elucidated but 
is considered to entail reduced organ perfusion and endothelial dysfunction.13,14 Several 
maternal organs can be affected, including the brain in the form of eclampsia, which is 
marked by tonic-clonic convulsions. Accompanying symptoms include visual abnormalities, 
severe headache, nausea, vomiting, and altered mental state. Eclampsia occurs in 
approximately 0.5% of women with mild preeclampsia and in approximately 2% to 3% of 
those with severe preeclampsia.12 The HELLP syndrome is characterized by Hemolysis, 
Elevated Liver enzymes, and Low Platelet count, and this syndrome significantly increases 
the risk of preterm birth and perinatal mortality rate compared with isolated preeclampsia. 
Delivery remains the only cure for preeclampsia/HELLP syndrome with careful scrutiny 
regarding blood pressure control and seizure prophylaxis, as well as monitoring of fetal well-
being.13 Neurologic or ophthalmic entities that have been associated with (pre)eclampsia 
include cortical blindness, serous retinal detachment, Purtscher-like retinopathy, central 
retinal vein occlusions, and retinal or vitreous hemorrhages.8,9,15 Ensuing visual symptoms 
have been described to occur in approximately 25% of preeclamptic13 and 19% to 45% of 
eclamptic women,15,16 and include blurry vision, diplopia, amaurosis fugax, photopsia, and 
scotomata, including homonymous hemianopsia. The neurological and ophthalmic entities 
associated with (pre)eclampsia can arise from different parts of the visual pathway and are 
described in more detail in the following sections.
The visual pathway
The visual pathways emerge from the eye as the optic nerve, pass the optic chiasm adjacent 
to the pituitary gland, continue as the optic tract, move through the lateral geniculate 
nucleus of the thalamus, optic radiations, and end in the primary visual cortex (also known 
as V1 or striate cortex) (Fig. 1). The primary visual cortex is situated in the most posterior 
part of the occipital lobes and is the first cortical area to receive visual information. The 
primary visual cortex subsequently projects visual information via the secondary visual 
cortex (V2) to higher-order visual areas in the occipital, parietal, and temporal lobes (Fig. 
2). These higher-order visual areas are each involved in the processing of specific aspects 




Figure 1. Visual pathways from the eyes to the primary visual cortex.
Figure 2. Visual information streams from the primary visual cortex to the higher-order visual areas. 
The primary visual cortex (V1) projects visual information via the secondary visual cortex (V2) and 
the association visual cortex (V3) to higher-order visual areas in the occipital, parietal and temporal 
lobes using a dorsal and a ventral stream. The ventral stream passes V4 (in the ventral occipito-
temporal region) and ends up in high-order visual areas in the inferior temporal lobe (ITL). The dorsal 










Cortical blindness is one of the reported complications of (pre)eclampsia. Cunningham et al 
reported that 15% of eclamptic women were affected.19 The incidence of cortical blindness 
in preeclampsia without seizures is likely substantially lower. This type of blindness is 
caused by dysfunction of the optic radiations, primary and secondary visual cortexes, and 
high-order visual areas of the parieto-occipital lobes, hence its name.20,21 Cortical blindness 
is per definition associated with an intact pathway from the eye to the lateral geniculate 
bodies, and therefore, the pupillary light responses and ocular motility remain intact.21,22 
Normal ophthalmoscopic findings exclude an ophthalmic cause of blindness.19,23,24
Clinical manifestation
Cortical blindness has been described to occur not only several hours before or after 
eclamptic seizures but also, although rarely, for several days up to weeks postpartum.24–26 
The bilateral vision loss often begins with blurry vision and progresses within a couple of 
hours to bare light perception. Prodromal symptoms are similar to imminent eclamptic 
seizures and include nausea, vomiting, and severe (often frontal) headache. Blindness 
can also be the presenting symptom in preeclampsia.27 Cortical blindness is an anxiety-
provoking condition that fortunately resolves completely in most cases. Sometimes, and 
as presented in the case report, the patient is unaware of her blindness and feels that 
she can see (visual anosognosia or Anton syndrome), indicating involvement of the visual 
association cortex (Fig. 2).26,28
A computerized tomographic (CT) scan may show low-density areas (corresponding 
with cerebral edema) in both occipital lobes, which can extend to the frontoparietal and 
parietal lobes. On T2-weighted MRI, these areas appear hyperintense and are mainly 
located in the parieto-occipital lobes, but they can also occur in the frontal and temporal 
lobes and basal ganglia.24,29–31 Cases have been described in which the CT scan appeared 
normal, whereas major abnormalities were found on T2-weighted MRI,23,29,32 emphasizing 
the superiority of MRI for the evaluation of sudden bilateral vision loss in (pre)eclampsia. 
Delefosse et al reported an interesting case of a woman who had had preeclampsia, and 
whose hypertension recurred 3 weeks postpartum.24 This case illustrated an uncommon 
evolution of severe preeclampsia with secondary onset of neurologic symptoms, including 
cortical blindness, which the authors determined to be associated with intrauterine 
retention of placental products. After curettage and removal of the placental fragments, 
the woman was able to distinguish bright light within 12 hours. Visual acuity returned to 




Cortical blindness in (pre)eclampsia is usually related to the occurrence of the Posterior 
Reversible Encephalopathy Syndrome (PRES).33,34 PRES is a clinical-neuroradiological 
entity characterized by headache, vomiting, seizures, altered mental status, and visual 
abnormalities (including blurry vision, homonymous hemianopsia, visual neglect, cortical 
blindness, and visual anosognosia), together with cranial imaging findings consistent 
with vasogenic edema.33,34 PRES is thought to be due to loss of cerebral autoregulation 
in the context of endothelial dysfunction.35–38 Increased blood pressure overcomes the 
cerebrovascular autoregulation, resulting in hyperperfusion and vasogenic edema.36,37,39 
This edema is presumably the cause of the neurologic symptoms of PRES, including cortical 
blindness, when the edema affects the primary visual cortex in the occipital lobes. 
The occipital lobes seem more susceptible to autoregulation breakthrough and 
subsequent hyperperfusion than other regions.19,28,29,40 This may be explained by differences 
in innervation: the internal carotid system is better supplied with sympathetic nerves 
than the vertebrobasilar system.40 With acute hypertension, protective sympathetic 
nerves enhance vascular autoregulation.8 Severe autoregulation breakthrough can cause 
fibrinoid necrosis of the vessel wall and subsequent extravasation leading to accumulation 
of extracellular fluid, hypoperfusion of affected areas by increased hydrostatic pressure, 
and petechial hemorrhages.19,28,41
Prognosis 
Lowering blood pressure and preventing seizures with magnesium sulfate are the primary 
objectives in (pre)eclamptic patients with cortical blindness. Women typically regain 
normal vision within a couple of hours or days after the onset of treatment. Complete 
resolution of the high-intensity signals (cerebral edema) on MRI can usually be expected 
as well.19,42 However, residual symptomatic visual field defects and visuospatial deficits 
have been described in patients with concomitant presence of multiple bilateral parieto-
occipital hemorrhages.25,43 Although most women can expect full recovery, the combination 
of (pre)eclampsia-related cortical blindness and involvement of the eye (often a retinal 
detachment and/or Purtscher-like retinopathy) has been described to result in permanent 
visual impairment, and even blindness, in a few case reports.19,44–46 In such cases, the 
bilateral retinal detachments and Purtscher-like retinopathies were accompanied by brain 
infarcts.44,45 Murphy and Ayazifar reported diffuse optic disc and intraretinal and cerebral 
hemorrhages in a woman with eclampsia and HELLP syndrome who subsequently suffered 
permanent visual deficits.46
Balint’s syndrome







usually associated with cerebral infarction or neurodegenerative diseases. This triad is 
characterized by simultanagnosia (inability to integrate complex visual scenes), ocular 
apraxia (inability to voluntarily control gaze), and optic ataxia (inability to benefit from 
visual guidance in reaching an object). Balint’s syndrome is believed to be the result of a 
bilateral dysfunction of the dorsal stream in the parieto-occipital cortices (Fig. 2).47 To date, 
only 2 reports have described the development of this syndrome in an eclamptic woman.48,49 
The second case report was written in Italian, but it has an English abstract. Because of 
the rarity of Balint’s syndrome in eclampsia, this case report is included in this review. In 
both reports, bilateral parieto-occipital infarcts were seen on CT scanning, which might 
reflect infarction of the cerebral posterior border zone region. Both women experienced 
improvement in object recognition and other higher-order visual functions after several 
months. One of the few existing studies evaluating neurologic functioning in eclampsia 
examined 30 women for the presence of simultanagnosia.50 This evaluation took place in the 
first hours after eclamptic convulsion(s), after magnesium sulfate administration but before 
MRI scanning. All but one appeared to experience simultanagnosia. However, none of these 
women had ocular apraxia or optic ataxia to complete Balint’s syndrome. Unfortunately, 
whether these women were symptomatic was not indicated in this article. In 87% of 
the women, diffusion weighted imaging showed reversible bilateral focal hyperintensity 
lesions, which correlated well with the simultanagnosia. On repeat examination (after 3–5 
days), simultanagnosia had resolved in all cases. 
Serous retinal detachment
Epidemiology
Serous retinal detachment is a well-documented ocular manifestation occasionally seen 
with (pre)eclampsia. The occurrence in women with preeclampsia varies from <1% to 3%. 
In eclamptic patients, this rate is 5 to 10 times higher.51–55 Routine ophthalmic examination 
in 71 women admitted with severe preeclampsia/eclampsia revealed a prevalence of 32%.56 
Of the 3 cases presented in more detail by the authors, only one woman reported visual 
symptoms. Unfortunately, whether the 71 studied women experienced visual symptoms 
was not mentioned in the article. 
Clinical manifestation
Preeclampsia-related serous retinal detachment has been described to occur before, during, 
or after delivery.57–62 In an interesting case report, bilateral serous retinal detachment 
was reported to reveal an occult pregnancy.63 The onset of preeclampsia-related serous 
retinal detachment is sudden, the main symptoms are a visual field defect and loss of 
visual acuity. Photopsia and floaters, which are usually present in rhegmatogenous retinal 
detachment, are absent.9,52,53,61,64–66 Retinal detachments in preeclampsia are often bilateral, 
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but unilateral detachment can also occur. Occasionally, retinal detachments coexist with 
cortical edema. Fundoscopy reveals, in addition to the detached retina, retinal and/
or macular edema, exudates, hemorrhages, and cotton wool spots (retinal nerve fiber 
swelling due to ischemia).9,52,53,58,64,67,68
Pathophysiology
The retinal pigmented epithelium (RPE) facilitates the exchange of water, salts, nutrients, 
and metabolites between the retina and the choroid, and prevents the accumulation of 
fluid in the subretinal space, which is a potential space in healthy eyes. Tight junctions 
between the RPE cells form the blood-retinal barrier,53 which can be disturbed by conditions 
such as severe acute hypertension, inflammation, infection, neoplasm, hypoproteinemic 
states, and subretinal neovascularization.69 One or more of these processes is likely at play 
in preeclampsia.70 Some reports suggest hormonal involvement (by releasing endogenous 
vasoconstrictors).8,62 Vasospasm, generalized or localized, is seen in the choroidal arterioles 
and the central retinal and posterior ciliary arteries.8,9,68 Intense spasm of the choroidal 
arterioles results in choroidal ischemia, and this increases vascular permeability.53 
Subsequently, serous fluid accumulates in the subretinal space, separating the retina 
from the RPE.71 Photoreceptors located in the retina become devoid of nutrients and stop 
functioning.53 
Fluorescein angiography in (pre)eclamptic women with serous retinal detachment 
demonstrates areas of choroidal hypo- and nonperfusion (Elschnig spots).9,68,71 Abnormalities 
in preeclamptic women may also be found by multifocal electroretinography and optical 
coherence tomography.66,72,73 Changes in ocular blood flow, indicating vasospasm, can 
be found with color flow Doppler ultrasonography.9,74 As an alternative to the vasospasm 
theory, it is suggested that hyperperfusion and breakthrough in autoregulation of orbital 
vessels, especially choroidal arterioles, increase permeability of retinal and choroidal 
arterioles, causing retinal edema and serous detachment. Systemic magnesium sulfate 
therapy has been described to significantly increase retinal perfusion. Simultaneously, 
headache and visual symptoms resolve.74 This effect of magnesium sulfate could explain 
why systemic treatment of (pre)eclampsia is more effective in reducing visual symptoms 
than specific ocular treatment.
Prognosis
In general, the visual acuity gradually improves and the visual field defects disappear 
within 3 months postpartum, and the patients regain normal vision.8,53,59,61,71,73 Within 1 
week from the initial ophthalmoscopic examination, three-quarters of the serous retinal 
detachments will have resolved.56 







in most patients, a small percentage will show retinal abnormalities during follow-up weeks 
to 1-year postpartum with subtle changes in visual acuity. None of the reviewed articles 
mentioned accompanying visual symptoms in the following months; therefore, it is likely 
that the subtle visual changes have no consequences in daily life.
Purtscher-like retinopathy
Purtscher’s retinopathy, first reported by Otmar Purtscher in 1910, is a specific 
appearance of the fundus characterized by multiple areas of retinal whitening and 
intraretinal hemorrhages, usually caused by trauma.44,75 Systemic conditions, including 
acute pancreatitis, renal failure, fat embolism syndrome, connective tissue disorders, and 
(pre)eclampsia, have been associated with the same specific appearance of the fundus, and 
which is therefore named Purtscher-like retinopathy.75 Only a few case reports of Purtscher-
like retinopathy in (pre)eclamptic patients could be retrieved from the literature,44,45,76–78 
suggesting that it is an extremely rare complication of (pre)eclampsia.
Clinical manifestation
In the 6 (pre)eclamptic patients with Purtscher-like retinopathy described in the literature, 
visual abnormalities developed in the first 24 hours after urgent cesarean section.44,45,76–78 
Complaints included blurry vision, floaters, and complete bilateral vision loss. On ophthalmic 
examination, the visual acuity ranged from light perception to 20/400 and was bilateral in 
all cases.44,45,76–78 In all patients, fundoscopic examination revealed multiple, discrete areas 
of retinal whitening, so-called Purtscher flecken, mostly within the macula and around the 
optic disc.44,45,76–78 In addition, small, characteristic, flame-shaped hemorrhages were found 
in 4 of the patients.44,45,76,77 Fluorescein angiography revealed capillary nonperfusion in 
areas of retinal whitening, and narrowing or occlusion of retinal arterioles.44,76
Pathophysiology
Agrawal and McKibbin postulate that, considering the specific appearance of the fundus, 
Purtscher flecken may be caused by embolic occlusion of the precapillary arterioles of 
the retina by fat, air, platelets, or leukocyte aggregates.75 The latest hypothesis is the 
formation of leuko emboli by complement activation.44,77 Previous reports suggest a role 
of amniotic fluid in activating complement and inducing leuko-embolization, which may 
contribute to complications of late pregnancy, such as Purtscher-like retinopathy.44,45,77
Prognosis
Improvement of visual acuity can be seen within a couple of weeks after the initial 
insult. Some recovery of visual acuity is accompanied by partial resolution of the retinal 
whitening and delayed filling of the retinal vasculature.44,76,77 Apart from treating the 
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underlying systemic condition, no specific treatment is available, although it has been 
suggested that highdose steroids might be effective.75 Unfortunately, none of the reported 
6 (pre)eclampsia-related cases experienced complete recovery of visual acuity. In fact, 
one preeclamptic woman had unchanged visual acuity of 4/200 in both eyes 2 months 
postpartum.44 Another preeclamptic woman, who also suffered pancreatitis, experienced 
slight improvement from bare light perception in the acute phase to counting fingers at 1 
meter (i.e., a visual acuity of 1/60) in both eyes after 6 months.77
Central retinal vein occlusion
Two case reports describe sudden vision loss in preeclamptic women caused by central 
retinal vein occlusion (CRVO).79,80 Both women developed bilateral loss of vision 10 to 21 
days postpartum. At the onset of vision loss, blood pressure was normal in both cases. In 
both women, ophthalmologic examination revealed the classical picture of CRVO, that is, 
multiple retinal hemorrhages in all 4 quadrants, venous dilatation, and macular edema. 
In the next months, the hemorrhages resolved and macular edema reduced. Visual acuity 
improved significantly, but did not return to normal. The pathophysiology of CRVO in 
(pre)eclampsia is not fully understood. Although the name CRVO suggests otherwise, CRVO 
is primarily an arterial problem. Central retinal artery thickening is thought to cause 
compression of the central retinal vein thereby leading to venous occlusion. Interestingly, 
the risk factors for CRVO, hypertension, and coagulation disorders are also associated with 
preeclampsia.81
Retinal and vitreous hemorhages
Retinal and vitreous hemorrhages, preceding the presentation of preeclampsia, although 
rare, have been described each in the literature once. One case report described sudden 
vision loss in the left eye of a normotensive pregnant woman.82 Ophthalmologic examination 
revealed white-centered retinal hemorrhages (Roth spots). Within 48 hours, this previously 
healthy pregnant woman developed preeclampsia. During the first 6 months after delivery, 
visual acuity returned to normal, and the retinal hemorrhages resolved. The other case 
report described sudden vision loss in the left eye of a normotensive pregnant woman, 
resulting from a vitreous hemorrhage.83 This vitreous hemorrhage gradually resolved over 
the next 2 weeks. However, the woman developed preeclampsia with HELLP syndrome, 
another 2 weeks later, which may or may not have been coincidental.
Conclusions
Visual symptoms during preeclampsia are a frequent phenomenon. Therefore, the 
obstetrician/gynecologist can encounter women with serious, and sometimes debilitating, 







including cortical blindness, serous retinal detachment, Purtscher-like retinopathy, central 
retinal vein occlusion, and retinal and vitreous hemorrhages. Unfortunately, the existing 
literature largely consists of single case reports or small case series. Routine follow-up with 
standardized history taking of visual complaints/ symptoms and standardized ophthalmic 
examination, was not necessarily performed or described. Moreover, the frequency of 
occurrence of the reported visual manifestations in uncomplicated pregnancy and in the 
healthy young population is largely unknown. All this hampers drawing firm conclusions 
regarding the etiology of visual disturbances in preeclampsia and the existence of a causal 
relationship. 
In general, aside from lowering blood pressure and preventing (further) seizures 
with magnesium sulfate, no specific therapy seems indicated for (pre)eclamptic women 
who experience visual changes. When not rapidly transient, ophthalmic evaluation 
is helpful in distinguishing the underlying pathology. MRI may be helpful in delineating 
features of cerebral edema/ PRES in the occipito-parietal lobes. In most cases, visual 
acuity returns to normal within weeks to months after the onset of symptoms. Rarely, 
permanent visual impairment in (pre)eclamptic women has been described to occur, 
generally associated with occipital hemorrhages or brain infarcts, alone or in combination 
with retinal hemorrhages (e.g., Purtscher-like retinopathy). 
The follow-up in the described case reports typically included ophthalmoscopic 
examination and, in some cases, an MRI scan. However, a few articles report visual 
symptoms experienced by the formerly (pre)eclamptic women. The fact that most articles 
do not mention any visual symptoms during follow-up may tentatively lead to the conclusion 
that most women with visual disturbances during (pre)eclampsia experience no permanent 
visual symptoms. 
Health care providers such as emergency room physicians, obstetricians, family 
physicians, neurologists, and ophthalmologists should be aware that acute onset of visual 
symptoms in pregnant women can be the first sign of (pre)eclampsia. An ophthalmologist 
or neurologist faced with such a woman should consult an obstetrician or refer the woman 
without delay. Given that visual changes are a diagnostic criterion for severe preeclampsia, 
obstetricians should appreciate the significance of these changes and discuss appropriate 
diagnostic options with the ophthalmologist. Affected women can be reassured that most 
cases are transient. In addition, obstetricians should refer pregnant women with persistent 
visual symptoms to an ophthalmologist, as some ophthalmic entities may require specific 
therapy (e.g., central retinal vein occlusion) or follow-up by an ophthalmologist.
Continuation vignette
The patient was administered magnesium sulfate for seizure prevention, and her blood 
pressure was lowered with intravenous antihypertensive medication. Labor was induced, 
and she spontaneously delivered a healthy female infant of 2850 g. In the 3 days after 
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delivery, she gradually regained complete vision. MRI obtained 6 weeks postpartum 
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Complete neurocognitive recovery after eclampsia has been questioned with the expression 
of neurocognitive deficits by affected women and demonstration of cerebral white matter 
lesions on magnetic resonance imaging years after eclampsia. We hypothesized that 
formerly eclamptic women may experience impaired vision-related quality of life (QOL) 
and visual field loss as a result of the presence of such lesions in the cerebral visual areas. 
Methods
Using the National Eye Institute Visual Function Questionnaire-39/Nederlands questionnaire, 
vision-related QOL was compared between formerly eclamptic women and control 
participants after normotensive pregnancies. Furthermore, in formerly eclamptic women, 
visual fields were assessed using automated perimetry, and presence of white matter lesions 
was evaluated using cerebral magnetic resonance imaging. Presence of a relationship 
between these lesions and National Eye Institute Visual Function Questionnaire-39/
Nederlands scores was estimated.
Results 
Forty-seven formerly eclamptic women and 47 control participants participated 10.1 ± 5.2 
and 11.5 ± 7.8 years after their index pregnancy, respectively. Composite scores and 4 out 
of 12 National Eye Institute Visual Function Questionnaire-39/Nederlands subscale scores 
were significantly lower in formerly eclamptic women than in control participants (P<.01 
for composite scores). This could not be explained by visual field loss, because all formerly 
eclamptic women who underwent perimetry (n=43) demonstrated intact visual fields. 
White matter lesions were present in 35.7% of formerly eclamptic women who underwent 
magnetic resonance imaging (n=42) and were associated with lower vision-related QOL 
scores (P<.05 for composite scores). 
Conclusion 
Formerly eclamptic women express lower vision-related QOL than control participants, 
which seemed at least partly related to the presence of white matter lesions. However, 
such women do not have unconscious visual field loss. Vision-related QOL impairment 





Visual disturbances are relatively common during the acute phase of eclampsia, including 
transient cortical blindness, scotomata, visual neglect, and blurred vision, and can often 
be attributed to the presence of cerebral edema.1 Although the exact pathophysiology of 
eclampsia remains to be elucidated, it is considered to be an expression of the posterior 
reversible encephalopathy syndrome.2 As its name suggests, this syndrome is thought to 
be a completely reversible condition. However, the reversibility of this syndrome, and 
eclampsia in particular, has been questioned lately.3 In previous studies, one-fourth of 
eclamptic women showed persistent cerebral white matter lesions and brain tissue loss on 
magnetic resonance imaging (MRI) 6 weeks postpartum.4,5 Furthermore, several years after 
eclampsia, such lesions are more prevalent in formerly eclamptic women compared with 
women with normotensive pregnancies.6 
In general, visual disturbances expressed by patients with posterior reversible 
encephalopathy syndrome or eclampsia are known to be transient. However, permanent 
visual field abnormalities, in particular hemianopia, but also permanent blindness, have 
been described and are thought to be related to persistent lesions in the visual cortex.3,7 
Moreover, in a Scandinavian follow-up study, 11% of formerly eclamptic women reported 
persistent visual disturbances.8 However, median follow-up time of these studies was 
relatively short, being less than 1 year. 
When located in the visual pathway from the optic nerve to optic radiation, white 
matter lesions may cause (un)conscious visual field defects or impairment of higher-order 
visual functions such as visual perception and spatial orientation. Visual disturbances 
might be a contributing factor related to persistent complaints described by some 
formerly eclamptic women such as poor concentration and limited attention span.8,9 We 
hypothesized that years after eclampsia decreased vision-related quality of life (QOL) and 
visual field loss may be experienced as a result of the presence of white matter lesions in 
the cerebral visual areas. We choose to use a validated vision-related QOL questionnaire 
to evaluate these women’s own perception of daily functioning in relation to vision. The 
questionnaire determines the influence of visual disability and visual symptoms on generic 
health domains such as emotional well-being and social functioning in addition to task-
oriented domains related to daily visual functioning. Subsequently, the relationship of this 
self-perceived vision-related QOL with the prevalence of visual field defects and cerebral 
white matter lesions was assessed.
Material and methods
Women with a diagnosis of eclampsia in their medical history between 1988 and 2008 
were identified in the University Medical Center Groningen, VU University Medical Center 
Amsterdam and Isala Clinics Zwolle. These hospitals are teaching hospitals that serve as 







to the definition of the International Society for the Study of Hypertension in Pregnancy.10 
Exclusion criteria included pre-existing glaucoma or other conditions known to be 
related to visual field defects, epilepsy or other neurological disorders including a known 
cerebrovascular accident, intracranial infections, or a history of any cranial neurosurgical 
procedure. Also, current pregnancy and an age of younger than 18 years were used as 
exclusion criteria. 
In the three participating hospitals, electronic admission, diagnosis, and delivery 
databases are kept up to date, which were used to identify eligible study participants 
(Fig. 1). In total, 133 women were diagnosed with eclampsia in these three hospitals 
between 1988 and 2008. In addition, six women who delivered in other hospitals than the 
participating clinics and who had heard about this study requested to participate in the 
current study, which was allowed. 
Medical records were reviewed for accuracy of diagnosis of eclampsia and to extract 
clinical and demographic characteristics. On review, one woman was excluded because a 
diagnosis of eclampsia could not be confirmed. Three women were described as having had 
generalized myoclonic twitches while remaining conscious. Because these twitches suggest 
cerebral involvement, these women were not excluded from the study although they had 
Figure 1. Flow diagram illustrating the inclusion and exclusion process of study participants. A. The 
selection of formerly eclamptic women. B. The selection of control participants. *Forty-two of these 
women returned the National Eye Institute Visual Function Questionnaire-39 (NEI-VFQ-39/NL). †Forty-
one of these women returned the NEI-VFQ-39/NL.
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not experienced tonic–clonic seizures. Four women had died in the interim, two of whom 
as a result of cerebral complications resulting from eclampsia, one resulting from breast 
cancer, and one attributable to cervical cancer years after her pregnancy. Four other 
women were excluded, two women as a result of a current pregnancy, one because of a 
cerebrovascular accident, and one because she did not speak Dutch. 
This resulted in 130 formerly eclamptic women who were eligible to participate. 
These women received a written invitation for participation in this study. Of these women, 
47 women could be reached and were willing to participate. Several women, who decided 
not to take part in the study, mentioned travel distance and time commitment as the main 
reason for nonparticipation. Some other women did not want to be confronted with their 
medical history. 
In addition to these formerly eclamptic women, 47 parous control women who had 
normotensive pregnancies participated in this study (Fig. 1). These women were recruited 
among hospital personnel of the University Medical Center Groningen. In total, 80 such 
women were randomly selected and invited to participate, of which 50 decided to take 
part in the study. One of them was excluded as a result of a history of hypertension in 
pregnancy. An additional two had to be excluded as a result of ophthalmologic conditions 
known to be associated with visual field impairment. 
Both formerly eclamptic and control participants filled out a questionnaire related 
to their obstetric and current and past medical history. Approval for this project was 
obtained from the Medical Ethics Committee of the University Medical Center Groningen, 
and informed consent was obtained from the participants.
Vision-specific health-related QOL was compared between formerly eclamptic 
and parous control participants using the validated Dutch translation of the National 
Eye Institute Visual Function Questionnaire-39/Nederlands.11 The English version of this 
questionnaire was developed at RAND Health under the sponsorship of the National Eye 
Institute and was designed to measure the dimensions of self-reported vision targeted 
health status. 
The National Eye Institute Visual Function Questionnaire-39/Nederlands consists of 
a base set of 25 questions and 14 additional questions generating the following vision-
targeted subscales: general health, general vision, near and distance activities, driving 
difficulties, peripheral vision, color vision, ocular pain, vision-related role function, vision-
related dependency, vision-related social functioning, and vision-related mental health. 
Each question was scored on a 0 to 100 scale with 0 being the worst and 100 being the best 
possible score. Each subscale score was calculated by averaging the scores of the questions 
that constitute that particular subscale. The composite score was calculated by averaging 
all vision-targeted subscale scores, excluding the general health subscore. 
The National Eye Institute Visual Function Questionnaire-39/Nederlands was filled 
out by 46 formerly eclamptic women, of which 42 had participated in visual field testing. 







Three women filled out the questionnaire but did not participate in visual field testing as 
a result of travel distances. Results were compared with scores from 47 parous control 
women, who participated in vision-related QOL assessment only.
The prevalence of visual field defects was assessed in 43 formerly eclamptic women 
at the Department of Ophthalmology of the University Medical Center Groningen using 
automated perimetry. The control group did not undergo visual field testing as a result 
of an expected very low prevalence of visual field defects in these participants. This 
presumption was based on data from the Rotterdam Study, which showed a prevalence of 
visual field loss of 3% in the general elderly population (55–64 years).12 In our group of healthy 
women of on average 40 years old, the prevalence of visual field defects would likely be 
less than 3% and probably even closer to 1%. Based on literature indicating approximately a 
50% prevalence of visual field defects in patients with former stroke,13 we anticipated that 
at least 25% of formerly eclamptic women who demonstrate cerebral white matter lesions 
would experience some degree of visual field loss. Although a formal power calculation 
could not be performed as a result of lack of available data in the literature, we considered 
the number of 43 formerly eclamptic women to evaluate whether the prevalence of visual 
field loss in such women is clinically relevant. 
An assistant of the Department of Obstetrics and Gynecology was trained by 
a certified technician in conducting automated perimetry using the Humphrey Field 
Analyzer. The visual field was tested with a 52-point suprathreshold test that covered the 
central visual field with a radius of 24°, a test identical to the test used in the Rotterdam 
Study.14 Visual field loss was defined as nonresponse to a light stimulus of 6 dB above a 
threshold-related estimate of the hill of vision in at least three contiguous test points or 
four including the blind spot. 
Visual field testing was performed on one eye at a time with the contralateral 
eye covered. The patient was asked to look straight ahead while lights were projected at 
different places in the perimeter. Participants were instructed to click a button every time 
they noticed a projected light. 
Test reliability was evaluated using the reliability indices for false-positive and false-
negative answers; fixation stability was observed by the perimetrist. In case of visual field 
loss or an unreliable test result (more than 33% false-positive or false-negative catch trials 
or poor fixation as observed by the perimetrist), the test was repeated in the same session 
after a break. Visual field loss on an initial test is, as a result of a learning effect, quite 
common and should always be confirmed or falsified.15
Cerebral MRI was performed in 42 of the 47 formerly eclamptic participants as part 
of an ongoing follow-up study assessing white matter lesions after eclampsia.6 These MRI 
scans were made on a 3-Tesla MRI system using the following sequences: T1, T2, proton 
density, and fluid-attenuated inversion recovery. The presence of white matter lesions was 
rated by an experienced neuroradiologist as previously described.6,16 Briefly, such lesions 
were considered present if hyperintense on T2- and proton densityweighted images and 
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not hypointense on T1-weighted images. The presence of subcortical white matter lesions 
was evaluated for the following locations: frontal, parietal, temporal, occipital and insular 
lobe, brain stem, and cerebellum. To correct for inclusion of partial volume, women with 
two small white matter lesions or less were considered as negative. Descriptive statistics 
such as demographic information and scores on the National Eye Institute Visual Function 
Questionnaire-39/Nederlands were presented as means±standard deviations for continuous 
variables and percentages for dichotomous variables. 
Demographic data and National Eye Institute Visual Function Questionnaire-39/
Nederlands subscale and composite scores were compared between formerly eclamptic 
and control women using Fisher’s exact test, independent Student’s t test, or Mann-
Whitney U tests, where appropriate. The relation between National Eye Institute Visual 
Function Questionnaire-39/Nederlands scores and presence of white matter lesions was 
assessed using Mann-Whitney U tests. Differences were considered statistically significant 
at P≤.05. Data analyses were performed using SPSS for Windows 18.
Results
In this study, 47 formerly eclamptic women participated. Of these women, 46 completed 
the National Eye Institute Visual Function Questionnaire-39/Nederlands, 43 underwent 
perimetry, and 42 underwent cerebral MRI. In total, 47 parous control women who did not 
experience a hypertensive pregnancy filled out the National Eye Institute Visual Function 
Questionnaire-39/Nederlands. 
Table 1 shows baseline characteristics of the study participants. Mean age and 
elapsed time since index pregnancy at the time of participation were similar for both 
groups. Also, the percentage of white women and nulliparity at the time of index pregnancy 
were comparable between the groups. However, as may be expected, birth weight and 
estimated gestational age at delivery were significantly lower in formerly eclamptic women 
compared with parous control participants. 
Vision-related QOL may be influenced by visual field defects and impairment of 
higher-order visual functions and therefore was assessed in formerly eclamptic women 
Table 1
Characteristics of formerly eclamptic and parous control participants
Eclampsia (n=47) Control (n=47) P value
Age (y) 40.3 ± 7.0 41.7 ± 8.1 .362
White 91.5 (83.5–99.5) 100.0 (100.0–100.0) .117
Elapsed time since index pregnancy (y) 10.1 ± 5.2 11.5 ± 7.8 .631
Nulliparous 87.2 (77.7–96.8) 80.9 (69.7–92.1)   .574
Estimated gestational age at delivery (wk) 33.9 ± 4.7 39.8 ± 1.9 <.001
Birth weight of child (g) 2,022 ± 1,054 3,522 ± 544   <.001







and parous control participants. Compared with parous control participants, formerly 
eclamptic women had significantly lower composite scores as well as lower scores on all 
subscales. This difference was significant for the composite of the National Eye Institute 
Visual Function Questionnaire-39/Nederlands and for four of 12 subscales, specifically, 
general health, vision-related social functioning, driving, and peripheral vision (Table 2). 
For the subscales general vision, ocular pain, near and distance activities, vision-related 
mental health, vision-related role function, vision-related dependency, and color vision, 
the differences did not reach significance (Table 2). 
Automated perimetry was performed in 43 formerly eclamptic women. At the first 
examination, nine of these women showed abnormal test results in at least one eye and 
one had an unreliable test result. On the repeat test, all had a reliable test result and none 
showed visual field defects. 
In total, 42 formerly eclamptic participants underwent MRI, of which 15 (35.7%, 
95% confidence interval [CI] 21.2–50.2%) demonstrated white matter lesions. All but two 
of these women (86.7%, 95% CI 69.5–100.0%) had these lesions in the frontal lobe and 
some in the parietal lobe (n=4; 26.6%, 95% CI 4.2– 49.0%), insular lobe (n=3; 20.0%, 95% CI 
0.0–40.2%), or cerebellum (n=1; 6.7%, 95% CI 0.0–19.4%). No lesions were observed in the 
occipital, temporal lobe, or brain stem. Five formerly eclamptic women demonstrated 
white matter lesions in multiple brain regions (33.3%, 95% CI 9.5–57.2%). 
Magnetic resonance imaging scans were available for 41 of the formerly eclamptic 
participants who also filled out the National Eye Institute Visual Function Questionnaire-39/
Nederlands. For three women, no scans were available as a result of general contraindications 
Table 2
National Eye Institute Visual Function Questionnaire-39 subscale and composite scores of formerly eclamptic
and parous control participants
Data are mean±standard deviation unless otherwise specified.
Eclampsia (n=46) Controls (n=47) P
General Health 67.3 ± 15.8 74.7 ± 14.0 .027
General Vision 80.5 ± 11.2 83.3 ± 9.3 .175
Ocular Pain 86.1 ± 17.1 90.2 ± 12.8 .380
Near Activities 93.2 ± 9.4 94.9 ± 6.1 .508
Distance Activities 92.9 ± 10.4 96.5 ± 4.1 .362
Social Functioning 98.3 ± 5.1 100.0 ± 0.0 .006
Mental Health 90.2 ± 12.1 93.5 ± 7.5 .181
Role Function 92.4 ± 12.8 95.9 ± 7.1 .327
Dependency 98.9 ± 3.0 99.5 ± 2.9 .142
Driving 75.6 ± 14.8 85.9 ± 11.1 .001
Color Vision 98.4 ± 8.2 100.0 ± 0.0 .151
Peripheral Vision 90.8 ± 17.0 98.4 ± 8.1 .002
Composite Score 90.9 ± 7.8 94.5 ± 3.5 .005
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for MR scanning and another two participants waived participation in MRI scanning as a 
result of travel distance. Fourteen (34.1%, 95% CI 19.6–48.6%) formerly eclamptic women 
who participated in the National Eye Institute Visual Function Questionnaire-39/Nederlands 
demonstrated white matter lesions. These women had lower subscale scores compared 
with formerly eclamptic women without lesions, except for the subscale color vision 
(Table 3). This difference was significant for the subscales general vision, near activities, 
vision-related role function, and peripheral vision. In addition, formerly eclamptic women 
with white matter lesions had a significantly lower composite score compared with those 
without lesions.
Discussion
Women who have experienced eclampsia report lower vision-related QOL on average 
10 years after the index pregnancy compared with parous control participants who had 
normotensive pregnancies. In formerly eclamptic women, lower vision-related QOL was 
associated with the presence of cerebral white matter lesions. Because visual fields of 
these women were intact when examined by perimetry, this suggests that lower vision-
related QOL was not the result of (un)conscious visual field loss related to white matter 
lesions. 
Visual disturbances are relatively common during the acute phase of eclampsia, 
attributed to the presence of reversible cerebral vasogenic edema, mainly in the 
Table 3
National Eye Institute Visual Function Questionnaire-39 subscale and composite scores of formerly eclamptic
women with and without white matter lesions








General Health 62.5 (32.5-100.0) 65.0 (32.5-100.0) .173
General Vision 75.0 (60.0-85.0) 85.0 (60-100.0) .010
Ocular Pain 87.5 (37.5–100.0) 87.5 (50.0–100.0) .530
Near Activities 91.7 (70.8–100.0) 95.8 (50.0–100.0) .037
Distance Activities 91.7 (66.7–100.0) 100.0 (58.3–100.0) .115
Social Functioning 100.0 (91.7–100.0) 100.0 (70.0–100.0) .192
Mental Health 90.0 (70.0–100.0) 95.0. (45.0–100.0) .175
Role Function 90.6 (56.3–100.0) 100.0 (50.0–100.0) .028
Dependency 100.0 (93.8–100.0) 100.0 (87.5–100.0) .460
Driving 66.7 (58.3–91.7) 75.0 (50.0–100.0) .377
Color Vision 100.0 (75.0–100.0) 100.0 (50.0–100.0) .659
Peripheral Vision 87.5 (50.0–100.0) 100.0 (25.0–100.0) .045







(sub)cortical parieto-occipital and temporal regions.17,18 The fact that a substantial 
percentage of formerly eclamptic women expresses persistent neurocognitive deficits and 
demonstrates white matter lesions6 stimulated us to examine the possibility that these 
lesions could be associated with (un)conscious visual field loss. 
Unawareness of visual field loss is a commonly described phenomenon19,20 and can be 
attributed to occurrence of perceptual filling-in, in which missing information of a visual 
field defect is inferred from the surrounding intact visual field.21 In addition, several animal 
studies have shown a marked potential for brain plasticity in response to both retinal and 
cortical lesions.22,23 Interestingly, also human studies show evidence for (partly) functional 
recovery of visual field loss after cerebral scotomata.24–26 Therefore, although formerly 
eclamptic women in our study did not demonstrate visual field loss on perimetry, one could 
hypothesize that small visual field defects might have been present in the period directly 
after the acute phase of eclampsia. We assessed visual fields years after eclampsia, a 
timeframe that might have allowed for rearrangement of visual pathways affected by 
white matter lesions. Hence, especially small visual field defects may have shrunken to 
undetectable abnormalities.27 
Absence of identifiable lesions in the visual pathway from the optic nerve to optic 
radiation of our participants can obviously also explain a true absence of visual field 
defects after eclampsia. It seems plausible that white matter lesions after eclampsia are 
mainly located in the parieto-occipital region because vasogenic edema during the acute 
phase of eclampsia is most commonly observed here.2 This edema, when severe enough, 
has been suggested to decrease regional cerebral perfusion pressure and blood flow to 
ischemic levels leading to areas of cytotoxic edema and infarction.28 However, this study 
demonstrated only a few women with parietal white matter lesions and absence of such 
lesions in both the occipital and temporal lobe. Interestingly, white matter lesions were 
located in the frontal lobe in the majority of women with lesions. Because the primary 
visual cortex is located within the occipital lobe, these results can well explain the absence 
of visual field loss in formerly eclamptic women. Furthermore, the location of white matter 
lesions suggests a different or additional etiology of these lesions other than ischemia 
resulting from vasogenic edema. As a result of the relatively small group of lesion-positive 
women, further research addressing lesion location and its etiology after eclampsia is 
required. 
Vision-related QOL was assessed using the National Eye Institute Visual Function 
Questionnaire-39/Nederlands, a commonly used questionnaire in the field of ophthalmology. 
A broad spectrum of ocular conditions has been shown to potentially alter vision-related 
QOL as measured by the National Eye Institute Visual Function Questionnaire-39/Nederlands, 
including glaucomatous and poststroke visual field loss,29,30 congenital cataract,31 and 
diabetic retinopathy.32 In contrast with the objective visual field assessment as a measure 
of visual function, the National Eye Institute Visual Function Questionnaire-39/Nederlands 
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comprises aspects of daily functioning in relation to vision strictly from a participant’s 
perspective. In addition to lower National Eye Institute Visual Function Questionnaire-39/
Nederlands composite scores in formerly eclamptic women, subscale scores related to 
general health, driving, peripheral vision, and vision-related social functioning were lower 
as well. This lower vision-related QOL appeared to be at least partly related to the presence 
of white matter lesions in formerly eclamptic women because women who demonstrated 
such lesions had a lower composite score as well as lower scores on one-third of the 
subscales compared with those without lesions. It should be noted that additional smaller, 
but still relevant, differences in subscale scores between the groups may have been missed 
as a result of insufficient power. However, although the number of women evaluated in this 
project may appear limited, in the context of the rare incidence of eclampsia, this study 
is considered sizeable. 
The underlying mechanism by which white matter lesions might lead to lower vision-
related QOL is still speculative at this moment because visual fields were intact. A possible 
explanation is that these lesions may interfere with neurocognitive functioning pertaining 
to higher-order visual functions, which might subsequently result in lower vision-related 
QOL and commonly reported complaints of formerly eclamptic women such as difficulties 
with reading texts. The majority of lesions in formerly eclamptic women appeared to be 
located in the frontal and parietal lobe, which are involved in higher-order visual functions, 
including visual memory and visuospatial processing.33–35 Future research is needed to 
objectively assess such higher-order functions in formerly eclamptic and control women 
using a detailed neurocognitive test battery. 
A few limitations of the current study should be noted. First, as a result of the 
retrospective nature of this study, no data are available on visual functioning before the 
index pregnancy. However, a prospective study design seems unfeasible in view of the 
rare incidence of eclampsia. Second, management and outcome of eclamptic women may 
have changed in the period during which our participants had eclampsia. However, this 
long period was required to obtain a sizeable study population, especially because the 
participation rate of eclamptic women was relatively low. 
In conclusion, formerly eclamptic women have lower vision-related QOL, which 
seemed associated with the presence of cerebral white matter lesions. Because these 
lesions did not appear to induce visual field loss, further research is needed to unravel 
the underlying mechanism of lower vision-related QOL and its relationship with white 
matter lesions. However, our results are in line with the current doubts about the complete 
reversibility of eclampsia. In addition to earlier proposed long-term sequelae pertaining 
to self-perceived neurocognitive functioning, eclampsia may also affect visual functioning 
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Women with a history of (pre)eclampsia demonstrate an increased prevalence of cerebral 
white matter lesions (WML) compared to women who had normotensive pregnancies 
years following the index pregnancy. The pathophysiology of these WML is unclear but 
may be related to the predisposition for cerebro-/cardiovascular disease in such women 
and/or the occurrence of the posterior reversible encephalopathy syndrome (PRES) while 
pregnant. Assessing the distribution of WML in these women may give insight into both 
the pathophysiology as well as the possible consequences of these lesions and is therefore 
subject of this study. 
Methods
Presence, severity and location of WML were determined in cerebral MRI scans of 64 
formerly eclamptic, 74 formerly preeclamptic and 75 parous control women. 
Results
Compared to parous controls, formerly (pre)eclamptic women demonstrated WML more 
often (35.0% versus 21.3%; P<0.05) and more severe (0.07 versus 0.02 mL; P<0.05). In all 
groups, the majority of WML was located in the frontal lobes, followed by the parietal, 
insular and temporal lobes.
Conclusion
Regional WML distribution was similar for all three groups and does not correspond to the 
typical occipito-parietal edema distribution observed in PRES. The frontal lobe distribution 
of WML in formerly (pre)eclamptic women may be a reflection of their predisposition for 
cerebro-/cardiovascular disease. Whether a history of PRES plays an additional role in this 
relation still remains speculative but seems less likely. The clinical implications of the 
presence and distribution of WML in our relatively young cohort remain so far unknown and 




The prevalence of cerebral white matter lesions (WML) is increased in formerly 
(pre)eclamptic women compared to women following normotensive pregnancies.1, 
2 Although the pathogenesis of these lesions remains to be elucidated, the increased 
propensity for cerebro-/cardiovascular disease in women with a history of preeclampsia3 
may be an associated factor in the development of WML.
In the elderly population WML are associated with cognitive decline and dementia4 
and such lesions are mainly located in the frontal lobe, followed by the parietal, temporal 
and occipital lobe.5, 6 Although impaired subjective cognitive functioning in formerly 
eclamptic women has been previously reported,7, 8 no significant differences were found for 
objective measures of sustained attention and executive functioning following eclampsia.9 
Therefore, the clinical implications of WML in formerly (pre)eclamptic women remain so far 
unclear and are subject of further investigation.
We hypothesize that an episode of posterior reversible encephalopathy syndrome 
(PRES), which is considered the underlying cause of the neurologic symptoms in eclamptic 
as well as some preeclamptic patients, may play an additional role in the development of 
WML.10 In PRES, vasogenic edema has been suggested to potentially progress to such an 
extent that regional cerebral perfusion decreases and blood flow diminishes to ischemic 
levels leading to areas of cytotoxic edema and infarction and the development of WML in 
the long-term.11, 12 This theory is supported by recent follow-up studies which have shown 
persistent neuroimaging abnormalities in a substantial part of former non-obstetric as well 
as obstetric PRES patients.1, 11, 13-16 In addition to WML, various other imaging abnormalities 
have been observed in former PRES patients including infarction, atrophy, hemorrhage, 
and laminar necrosis. Moreover, permanent clinical symptoms have been found in some 
of these patients, including impaired self-perceived as well as objective neurocognitive 
functioning and visual disturbances.7, 8, 17-19 Part of these clinical sequelae is thought to 
be related to permanent cerebral lesions. The exact relationship between neuroimaging 
findings and clinical symptoms following an episode of PRES remains, however, largely 
unknown.
Assessing the distribution of WML in formerly eclamptic and preeclamptic women 
may give insight into both the pathophysiology as well as the possible consequences of 
these lesions. Therefore, this study aimed to assess the distribution of WML in women 
who suffered eclampsia or preeclampsia compared to women who had normotensive 
pregnancies several years prior. 
Materials and methods
Study participants
Participants were enrolled in this study as part of ongoing follow up studies assessing 







functioning.1,2 Three groups of women were recruited for these studies, i.e. formerly 
eclamptic, formerly preeclamptic and parous control women. 
Women with a diagnosis of eclampsia in their medical history between 1988 and 
2005 were identified from the electronic admission, diagnosis, and delivery databases 
of the University Medical Center Groningen (UMCG). Recruitment and selection criteria 
have been published previously.1, 2 In the meantime, additional formerly eclamptic women 
have been recruited to participate in our follow-up studies through collaboration with two 
other tertiary referral centers; the VU University Medical Center Amsterdam (VUmc) and 
Isala Clinics Zwolle. In addition, six women who delivered in other hospitals and who had 
heard about this study requested to participate in the current study, which was allowed. 
Recruitment and selection criteria of participating women with a diagnosis of preeclampsia 
or normotensive pregnancies in their medical history were reported previously.2
Briefly, medical records of formerly eclamptic and preeclamptic women were 
reviewed for accurateness of diagnosis and to extract clinical and demographic 
characteristics. Both eclampsia and preeclampsia were defined according to the definition 
of the International Society for the Study of Hypertension in Pregnancy (ISSHP).20 For parous 
controls, records were evaluated to confirm that the pregnancy was indeed normotensive. 
Exclusion criteria included contra-indication for MR scanning, pre-existent epilepsy, a 
known cerebrovascular accident, demyelinating disorders, intracranial infections, a history 
of any cranial neurosurgical procedure, or the inability to understand Dutch. Only women 
who did not meet any of the exclusion criteria were invited to participate in the current 
study by mail. 
Following the MRI procedure and after a period of rest blood pressure was measured 
manually using a sphygmomanometer. Subjects with a systolic blood pressure of ≥ 140 
mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or currently using antihypertensive 
medication were diagnosed with current hypertension.21
 Approval for this project was obtained from the Medical Ethics Committee of the 
UMCG and all participants signed informed consent.
Cerebral MR imaging protocol
Detailed MRI study protocols have been previously described.1 Briefly, participants 
underwent MRI on a 3 Tesla MRI system (Philips Intera, Best, the Netherlands) using the 
following sequences: T1, proton density, T2, and fluid attenuated inversion recovery (FLAIR). 
Slice thickness was 5 mm with a 20% interslice gap. The presence, size and number of WML 
were rated by an experienced neuroradiologist, who was blinded for patient category as 
previously described.1, 22 WML were considered present if hyperintense on FLAIR, T2- and 
proton density-weighted images and not hypointense on T1-weighted images. Subcortical 
WML were categorized according to their largest diameter as small (< 3 mm), medium 
(3-10 mm) or large (> 10 mm). The number of WML was evaluated per size category for 
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the following locations; frontal, parietal, temporal, occipital, insular, brainstem and 
cerebellum. Considering them spherical with a fixed diameter per size category, a total 
approximated volume for subcortical WML was determined. 
For evaluation of prevalence and mean volume of WML in each group, correction 
for inclusion of partial volume was performed as previously described.2 Briefly, for each 
participant two small lesions were subtracted from the total number of small WML. This 
means that women with only two small lesions or less were considered as WML negative. 
Correction for partial volume was not possible for evaluation of regional distribution since 
it is not feasible to determine from which brain region(s) the partial volume correction, i.e. 
two small WML, should be subtracted if a woman demonstrates small WML in more than 
one region. Therefore, prevalence of WML according to brain region was evaluated in WML 
positive women only with inclusion of all lesions, i.e. without correction of partial volume.
Data analysis
Descriptive statistics, such as demographic information, are presented as means ± standard 
deviations for continuous variables and percentages for dichotomous variables.
Demographic data were compared between formerly eclamptic, preeclamptic 
and control women using ANOVA for normally distributed data, or Kruskall-Wallis test 
for not normally distributed data. Dichotomous variables, i.e. presence of WML, current 
hypertension and nulliparity, were compared between the groups using Chi-square, with 
pair wise Chi-square as post-hoc test. WML volume between formerly (pre)eclamptic and 
control women was compared using Mann Whitney test.
Differences were considered statistically significant at P ≤ 0.05. Data analyses were 
performed using SPSS statistical package for Windows Version 18 (SPSS, Chicago, IL).
Results
Participant characteristics
The inclusion process of the formerly preeclamptic women (n=74) and the women who 
had normotensive pregnancies (n=75) has been published before.2 Because the group of 
formerly eclamptic women has been expanded in the mean time, we now provide detailed 
description of the recruitment of the entire group of women who suffered eclampsia. In 
total, 137 formerly eclamptic women were identified. Six of these women were excluded. 
One because diagnosis of eclampsia could not be confirmed, another because of a 
history of a cerebrovascular accident and a third due to inability to understand Dutch. In 
addition, three women had died in the interim; two of whom due to cerebral complications 
resulting from eclampsia, and one due to cervical cancer. Of the remaining 131 formerly 
eclamptic subjects, 69 women could be reached and were willing to participate. Six of 
them were subsequently excluded due to contra-indications for MR scanning. Three of the 







clonic seizures. These three, however, were described as having experienced generalized 
myoclonic twitches while conscious, suggesting cerebral involvement. Therefore, for 
this study we describe the MRI findings of a total of 63 formerly eclamptic, 74 formerly 
preeclamptic and 75 parous control participants.
Table 1 shows baseline characteristics of the study participants. Mean age at time 
of participation was similar for all groups; all groups were in their late thirties. However, 
elapsed time since index pregnancy was longer for the formerly eclamptic women (7.6 ± 4.7 
years) compared to both formerly preeclamptic women (5.2 ± 4.1 years) and parous controls 
(5.0 ± 3.3 years). Furthermore, the percentage of nulliparous women differed between the 
groups, with most nulliparous women in the formerly eclamptic group (82.5%), followed by 
formerly preeclamptic (67.6%) and control women (46.7%). In addition, as expected, birth 
weight of the child was about 45% lower in the formerly eclamptic and preeclamptic group 
than the control group. Also estimated gestational age at delivery was more than six weeks 
shorter in formerly eclamptic and preeclamptic women compared to parous controls.
Current weight was comparable between the three groups. Both systolic and diastolic 
blood pressures were higher for formerly eclamptic and preeclamptic women compared 
to the parous controls. Additionally, formerly eclamptic and preeclamptic women were 
currently hypertensive or using antihypertensive medications four times more often than 
parous controls.
Subcortical WML
Formerly eclamptic (n=20, 31.7%) and preeclamptic women (n=27, 36.5%) had subcortical 
WML more often compared to parous controls (n=16, 21.3%). When the presence of WML 
was compared between the three groups, these differences did not reach significance. 
However, when formerly eclamptic and preeclamptic women were grouped together, to 
Controls (n=75) Preeclampsia (n=74) Eclampsia (n=63)
Current age (y) 36.9 ± 6.1 36.6 ± 6.2 38.2 ± 6.3
Elapsed time (y) 5.0 ± 3.3 5.2 ± 4.1 7.6 ± 4.7 *
EGA at delivery (wk) 40.1 ± 1.1 ** 33.2 ± 5.1 33.5 ± 4.5
Birth weight of child (g) 3464 ± 462 ** 1848 ± 1169 1923 ± 1008
Nulliparous (n) 46.7% (35) § 67.6% (50) † 82.5% (52)
Current SBP (mmHg) 116 ± 12 ** 127 ± 12 126 ± 14
Current DBP (mmHg) 74 ± 9 ‡ 82 ± 11 79 ± 10
Current hypertension (n) 5.6% (4) ‡ 24.3% (18) 20.8% (10)
Current weight (kg) 70.8 ± 10.5 76.1 ± 17.7 73.9 ± 14.9
Table 1
Participant characteristics
Data are presented as mean and SD or percentage with the number of women in parentheses.
* P < 0.01 versus controls and preeclampsia, ** P < 0.001 versus preeclampsia and eclampsia, § P < 0.01 versus preeclampsia and P < 
0.001 versus eclampsia, † P < 0.05 versus eclampsia, ‡ P < 0.01 versus preeclampsia and P < 0.05 versus eclampsia
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enhance statistical power, and compared to parous controls, the (pre)eclamptic group had 
WML significantly more often than parous controls (35.0 versus 21.3%; P < 0.05). In addition, 
WML were more severe in formerly (pre)eclamptic women than in controls as indicated by 
a larger WML volume. Mean WML volume for the (pre)eclamptic group was 0.07 mL (range 
0.00 – 2.35 mL), and for the control group this was 0.02 mL (range 0.00 – 0.13 mL, P < 0.05). 
The cerebral regional distribution of lesions in WML positive women was comparable 
for all groups (Figure 1). In all three groups, the majority of WML was located in the frontal 
lobes. In the formerly preeclamptic group, all women with WML (n=27) demonstrated these 
in the frontal lobes. Eighty-five percent (n=17) of the formerly eclamptic women with 
WML had these lesions in the frontal lobe, for control participants this was 87.5% (n=14). 
The parietal lobe was the second most affected region by WML, i.e. in 35% of formerly 
eclamptic (n=7), 29.6% of formerly preeclamptic (n=8) and 25% of control women (n=4). 
In addition, three formerly preeclamptic women (11.1%) and one control woman (6.3%) 
demonstrated WML in the temporal lobes. The insular lobes were affected by WML in four 
formerly eclamptic women (20.0%) and two controls (12.5%). One formerly eclamptic woman 
(5.0%) had a WML located within the cerebellum. WML in more than one brain region were 
observed in 40.0% of the formerly eclamptic (n=5), 33.3% of formerly preeclamptic (n=9), 
and 25.0% of control women (n=4). In all subjects, except for three formerly eclamptic 
and two controls, WML in the parietal, temporal or insular lobe and cerebellum were 
accompanied by WML in the frontal lobes. None of the participants showed involvement of 
the occipital lobe or brainstem.
Periventricular WML
Periventricular WML were present in only one formerly eclamptic woman. She did not 
demonstrate any subcortical WML. In five formerly preeclamptic women, periventricular 
WML were observed. These women all demonstrated subcortical WML in addition. None of 
the control women had periventricular WML. In all women demonstrating periventricular 
WML, these lesions were considered mild; pencil thin lining surrounding only part of the 
ventricles.
Infarcts
In the formerly eclamptic group, one woman demonstrated a lacunar infarct and two 
women had cortical infarcts. Two of these women also demonstrated subcortical WML. 
In the formerly preeclamptic group, two women had lacunar infarcts and one woman 
demonstrated a cortical infarct. These three women all had subcortical WML in addition to 









Several years following the index pregnancy formerly (pre)eclamptic women had cerebral 
white matter lesions (WML) more often and more severe compared to parous controls 
with normotensive pregnancies. The distribution of such WML was similar for formerly 
eclamptic, formerly preeclamptic and parous control women in that the majority of WML 
was located in the frontal lobes, followed by the parietal, insular and temporal lobes. 
The pathophysiology of WML in formerly (pre)eclamptic women remains speculative 
and by assessing their distribution we aimed to provide further insight into their development. 
Previously, we have hypothesized that WML in formerly (pre)eclamptic women may be 
related to the occurrence of the posterior reversible encephalopathy syndrome (PRES).1, 2 
In PRES, an acute increase in blood pressure may cause loss of cerebral autoregulation and 
forced dilatation of cerebral arteries, resulting in blood-brain barrier disruption, vasogenic 
edema formation and the neurologic symptoms of PRES.23-25 It has been suggested that the 
vasogenic edema in the acute phase of PRES, when severe enough, may reduce regional 
cerebral perfusion and blood flow to ischemic levels resulting in areas of cytotoxic edema.11 
These areas may later appear as infarctions or WML on MRI.11, 12 When reviewing the few 
existing follow-up studies in obstetric and non-obstetric PRES patients, doubts have been 
raised concerning the complete reversibility of PRES. There is now evidence for persistent 
Figure 1. Regional distribution of cerebral WML in WML positive women.
Presence of WML per brain region for WML positive women in the parous control, formerly preeclamptic 




neuroimaging abnormalities in a substantial part of affected subjects such as infarction, 
gliosis, hemorrhage, atrophy and laminar necrosis.14, 15, 18 Studies that longitudinally evaluate 
eclampsia-related PRES cases with a follow-up between several days and more than seven 
years, mainly describe presence of WML consistent with gliosis but do not elaborate on 
their location.1, 11, 13, 16 We expected that the distribution of WML would be similar to that 
of the cerebral edema in the acute phase of PRES and suggested a causal relationship 
between an episode or PRES and the presence of WML. However, while the edema is 
typically located in the occipito-parietal lobes,26 the current study demonstrates that only 
few women had WML in the posterior brain regions. In fact, the majority of WML was 
located in the frontal lobes. Moreover, this distribution was similar between women who 
had PRES, i.e. the formerly eclamptic women, and women without PRES, i.e. the parous 
controls. Therefore, a direct causal relationship between the cerebral edema of PRES and 
WML in formerly (pre)eclamptic women is less likely. 
Alternatively, in the general population the presence of hypertension is associated 
with cerebral WML,27-29 which may also explain the higher prevalence of WML in our 
formerly (pre)eclamptic women. A history of preeclampsia has been associated with an 
increased risk for cardiovascular disease later in life, including hypertension, ischemic 
and hemorrhagic stroke, and ischemic heart disease.3 In this context, the cardiovascular 
and metabolic demands of normal pregnancy are considered to be a physiologic “stress 
test” which can provide insight into a woman’s future health.30 Predisposed women 
fail this “stress test” and develop preeclampsia during pregnancy, thereby revealing 
their increased risk for cerebro-/cardiovascular disease later in life.  In this scheme, an 
underlying predisposition for cardiovascular disease may result in development of both 
WML and (pre)eclampsia, without the presence of a direct causal relationship between the 
two. Our results are in line with this “stress test” theory and epidemiologic findings, with a 
higher prevalence of current hypertension in formerly (pre)eclamptic women compared to 
women who had normotensive pregnancies. Moreover, the regional distribution of WML in 
formerly (pre)eclamptic women is similar to what has been found in other conditions that 
are associated with cerebro-/cardiovascular disease, such as dementia and migraine.5, 6, 31 
WML in dementia have been related to ischemic changes32 and migraine is associated with 
an increased risk for ischemic stroke.33 Whether a merely subcortical or periventricular 
WML distribution is related to the pathophysiological mechanism underlying these lesions 
remains to be elucidated.22, 34, 35
In the elderly, the presence and severity of WML is associated with stroke, cognitive 
decline and dementia.4 The clinical implications of such lesions in our relatively young 
cohort of formerly (pre)eclamptic women are currently unknown as reports on WML in this 
group do not exist. Whether cognitive functioning may sooner or later also be affected 
in formerly (pre)eclamptic women who have WML, especially since the WML distribution 







Since a role for PRES in the development of WML cannot be completely ruled out, also 
clinical follow-up of former PRES patients is of interest. In a rather small percentage of 
such patients, persistent neurocognitive complaints have been described in addition to 
abnormalities on cerebral imaging. Self-perceived cognitive functioning is impaired in 
formerly eclamptic women.7, 8 Furthermore, cases of diminished objective neurocognitive 
functioning, visual disturbances and epilepsy have been described after both eclampsia-
related as well as non-obstetric PRES.17-19, 36 However, comprehensive longitudinal studies 
concerning neurocognitive functioning following PRES are lacking.
A few limitations of the current study should be noted. First, since neuroimaging is 
not a standard procedure during the acute phase of (pre)eclampsia, the location of cerebral 
edema in the acute phase of PRES cannot be individually related to the distribution of 
WML years later. Second, for evaluation of presence of WML per brain region in WML 
positive women, it was technically not feasible to correct for inclusion of partial volume. 
Therefore, we might have slightly overestimated the prevalence of WML per brain region. 
To our knowledge, this is the first study describing the regional distribution of 
WML in a relatively large group of formerly (pre)eclamptic women as well as seemingly 
healthy parous women who never exhibited pregnancy-related hypertension. The regional 
distribution of WML, mostly in the frontal lobe, may be a reflection of the predisposition 
for cerebro-/cardiovascular disease in such women. Whether a history of PRES plays 
an additional role in this relation remains speculative but is less likely. These findings 
may add to the existing literature concerning the importance of evaluation of cerebro-/
cardiovascular risk factors in formerly (pre)eclamptic women. Future research is needed to 
examine the progress of WML and their clinical implications.
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Following the general introduction in Chapter 1, this thesis consists of two parts. In 
Part One, animal studies assessing the influence of pregnancy and preeclampsia on the 
maternal cerebral circulation are presented. Part Two of this thesis is focused on visual 
functioning in both the acute phase of (pre)eclampsia as well as on the long-term follow-up 
after eclampsia. In addition, neuroimaging data evaluating regional distribution of cerebral 
lesions following (pre)eclampsia is presented in this second part.  
Part I - Animal studies
A previous study has shown that pregnant and nonpregnant animals demonstrated 
breakthrough of cerebral autoregulation at similar pressures. However, only pregnant 
animals developed cerebral edema in response to autoregulatory breakthrough. In Chapter 
2, we investigated the underlying mechanism by which pregnancy may predispose to 
cerebral edema during acute hypertension. We hypothesized that pregnancy enhances 
cerebral endothelial cell permeability in response to increased hydrostatic pressure. 
Therefore, permeability coefficients to Lucifer Yellow (LY) and hydraulic conductivity 
(Lp; permeability to water), were compared in PCA from nonpregnant and pregnant rats 
(N=7 for both groups). The permeability coefficient to LY was increased in pregnant 
versus nonpregnant animals (P<0.05), an effect that may predispose the brain to edema 
formation during acute hypertension. However, pregnancy did not increase Lp, suggesting 
that pregnancy differentially affects blood-brain barrier permeability to LY and water. To 
assess whether the increased permeability coefficient to LY was due to elevated estrogen 
levels during pregnancy, experiments concerning permeability to LY were also performed 
in ovariectomized (n=6) and estrogen treated ovariectomized rats (n=7). Interestingly, 
estrogen treatment prevented an increase of the permeability coefficient in ovariectomized 
animals (P<0.05), suggesting that estrogen is protective of BBB permeability and that 
pregnancy increases BBB permeability by a mechanism other than elevated estrogen.
Cerebral aquaporins (AQPs) may have a role in cerebral edema formation and resolution 
during pathological states such as eclampsia. Therefore, in Chapter 3 real-time quantitative 
polymerase chain reaction was used to assess the expression of AQP1, 4 and 9 in the rat brain 
during pregnancy and the postpartum state. We found that all three AQPs were expressed 
in the anterior and posterior cerebrum, cerebellum and brainstem of nonpregnant (N=5), 
midpregnant (N=5), late-pregnant (N=6) and postpartum (N=5) rats. During pregnancy, 
the expression of AQP1 and 9 was decreased in the posterior cerebrum and cerebellum. 
Decreased AQP1 expression in the cerebellum was also observed in postpartum versus 
nonpregnant animals. In contrast to pregnancy-related decreased expression of AQP1 and 
9 in the posterior cerebrum and cerebellum, AQP4 expression was increased in these brain 
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regions in pregnant compared to nonpregnant animals. However, AQP4 expression in the 
anterior cerebrum was lower in the postpartum than the nonpregnant state. Since the 
exact role of AQPs in the brain has not been elucidated yet, the implication of our findings 
remained so far speculative but may affect edema resolution and/or seizure threshold. 
In Chapter 4, the influence of preeclampsia, in addition to that of normal pregnancy, on 
myogenic activity and structure of cerebral resistance arteries was assessed in pregnant rats 
infused with low-dose endotoxin, which has been shown to be a model for preeclampsia. 
In this model, endotoxin is considered to induce a low grade systemic inflammatory 
response, resulting in hypertension, proteinuria, disseminated intravascular coagulation 
and endothelial activation similar to human preeclampsia. In addition to cerebral arteries, 
mesenteric resistance arteries were investigated to assess whether these peripheral 
vessels were similarly affected. Nonpregnant and pregnant rats were infused with either 
saline (N=9 in both groups) or low-dose endotoxin (N=9 in nonpregnant, N=10 in pregnant 
group). On day 20 of pregnancy, or 6 days after infusion in nonpregnant rats, the posterior 
cerebral arteries (PCA) and mesenteric arteries (MA) were used to assess myogenic activity, 
pressure of forced dilatation and structural properties. In PCA, we found that while normal 
pregnancy and low-dose endotoxin infusion did not affect structure or myogenic tone 
within the autoregulatory pressure range, low-dose endotoxin decreased the pressure 
at which forced dilatation occurred compared to both normal pregnant and nonpregnant 
rats. These findings suggested that not pregnancy alone, but low-dose endotoxin infusion 
during pregnancy, which has been shown to be a model for preeclampsia, may predispose 
the brain to autoregulatory breakthrough and edema formation when blood pressure is 
increased as seen in eclampsia. In MA, structure was also unaffected by pregnancy or 
low-dose endotoxin. However, in contrast to PCA, pregnancy alone decreased myogenic 
tone of MA, with no additional effect of low-dose endotoxin. These different results with 
respect to myogenic tone in PCA and MA might be explained by the functional difference 
between the peripheral mesenteric and cerebral vascular bed. The mesenteric arteries 
show decreased myogenic tone. This could possibly play a role in the decreased peripheral 
resistance seen during pregnancy.  The PCA do not show a decreased myogenic tone during 
pregnancy. This may be due to the fact that the cerebral vascular system needs to exert 
a tight autoregulatory blood flow control to prevent ischemia or hyperperfusion. This may 
be especially important during pregnancy, in the face of the increased plasma volume and 
cardiac output.
To study whether these changes in PCA function were related to other forms of injury in 
the brain, we assessed the presence and extent of brain injury in the low-dose endotoxin-







S100B in the brain and the peripheral circulation in Chapter 5. No difference in S100B 
expression in the brain was found between nonpregnant saline-treated (N=5), nonpregnant 
endotoxin-treated (N=7), pregnant saline-treated (N=7) and pregnant endotoxin-treated 
(N=7) rats. Furthermore, plasma levels of S100B were similar in pregnant endotoxin- 
and saline-treated rats. From these results, we concluded that pregnancy nor low-dose 
endotoxin (experimental preeclampsia) affected S100B brain expression and plasma levels 
suggesting the absence of brain injury in this model.
Part II – Human studies
Chapter 6 reviews the literature concerning visual disturbances in patients with 
preeclampsia, eclampsia and HELLP-syndrome. Visual disturbance is a relatively common 
phenomenon in (pre)eclamptic patients, therefore, obstetricians may encounter women 
with serious, and sometimes debilitating, pathology of the visual pathways. Several 
ophthalmologic entities are associated with (pre)eclampsia, which include cortical 
blindness, serous retinal detachment, Purtscher-like retinopathy, central retinal vein 
occlusions, and retinal or vitreous hemorrhages. Ensuing visual symptoms experienced 
by these patients are blurry vision, diplopia, amaurosis fugax, photopsia and scotomata, 
including homonymous hemianopsia. In general, aside from lowering the blood pressure 
and preventing (further) seizures, no specific therapy seems indicated for (pre)eclamptic 
women who experience visual disturbances. In most cases, visual acuity returns back 
to normal after the preeclamptic pregnancy. However, permanent visual impairment in 
(pre)eclamptic women has incidentally been described and related to persistent cerebral 
lesions consistent with infarction and/or retinal abnormalities. 
As brain white matter lesions have been described in formerly (pre)eclamptic women, and 
might be related to visual impairment, especially when located in the cerebral visual areas, 
in Chapter 7 we sought to determine whether formerly eclamptic women experience 
lower vision-related quality of life. Therefore, formerly eclamptic women (N=46) and 
controls following normotensive pregnancies (N=47) completed the vision-related quality 
of life questionnaire (NEI-VFQ-39/NL). Composite scores and 4 out of 12 subscale scores of 
the NEI-VFQ-39/NL, in specific, general health, vision-related social functioning, driving 
and peripheral vision, were significantly lower in formerly eclamptic women compared to 
controls (P<0.01 for composite scores). To assess whether these lower scores in formerly 
eclamptic women could be explained by visual field loss due to white matter lesions (WML), 
these women underwent formal visual field assessment (N=43). All visual fields appeared 
intact, suggesting that lower vision-related quality of life scores in formerly eclamptic 
women were independent of visual field loss. However, WML were present in 35.7% of 
formerly eclamptic women who underwent MRI (N=42) and these WML were associated 
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with the lower NEI-VFQ-39/NL composite scores and 4 out of 12 subscale scores, in specific, 
general vision, near activities, vision-related role function and peripheral vision (P<0.05 for 
composite scores). Therefore, these lower composite and subscale scores in the subgroup 
of formerly eclamptic women with WML might be related to impaired higher-order visual 
functioning due to the presence of WML in cerebral areas involved in these functions.
In Chapter 8 we aimed to gain further insight into the possible consequences and 
pathogenesis of the cerebral WML following eclampsia described in the previous chapter. 
We assessed the regional distribution of these lesions on MRI scan in women years following 
eclampsia (N=63) and normotensive pregnancies (N=75) and also included formerly 
preeclamptic women (N=74). We found, in accordance with previous studies, that formerly 
(pre)eclamptic women more often demonstrated WML than women who had normotensive 
pregnancies (35.0% versus 21.3%; P<0.05). Moreover, WML in the (pre)eclamptic group 
were more severe than in the group with normotensive pregnancies (0.07 versus 0.02 mL; 
P<0.05). In all groups, the majority of WML was located in the frontal lobes, and to a lesser 
extent in the parietal, insular and temporal lobes. This led to the conclusion that the 
regional WML distribution was similar for all three groups. Interestingly, this distribution 
corresponded to the distribution observed in conditions that are associated with cerebro-/
cardiovascular disease, such as migraine and dementia. Therefore, WML in formerly (pre)
eclamptic women may be a reflection of the predisposition for cerebro-/cardiovascular 
disease in these women. These findings may add to the existing literature concerning the 
importance of evaluation of cerebro-/cardiovascular risk factors in formerly (pre)eclamptic 
women. Furthermore, it has been suggested that a history of the posterior reversible 
encephalopathy syndrome (PRES), which is considered the underlying cause of the 
neurological symptoms in the acute phase of (pre)eclampsia, may play an additional role in 
the development of WML. Although this seems less likely in view of the WML distribution, 
future studies should address the possible relation between PRES and WML. 
General discussion
Pathophysiology of eclampsia
The brain during pregnancy
Although the exact pathophysiology of eclampsia still remains to be elucidated, the 
general thought is that eclampsia develops in preeclamptic women when, in the presence 
of endothelial dysfunction, the blood pressure rises beyond the upper limit of cerebral 
autoregulation. Interestingly, however, eclamptic women often do not reach blood pressure 
values generally known to be in this upper limit range.1, 2 This suggests that pregnancy, 
and preeclampsia in particular, somehow predisposes the brain to autoregulatory 







group have therefore focused on the question whether pregnancy induces a leftward 
shift of the cerebral autoregulation curve. If such a shift occurs, lower blood pressures 
may induce loss of autoregulation. In our ex vivo study, we were unable to demonstrate 
an effect of pregnancy on the blood pressure at which forced dilatation occurred in 
posterior cerebral arteries of Wistar rats, suggesting no leftward shift of the upper limit 
of autoregulation (Chapter 4). However, this may be strain dependent since in Sprague 
Dawley rats a decreased pressure at which forced dilatation occurred was demonstrated 
during pregnancy.3 These above mentioned studies evaluated aspects of autoregulation in 
isolated arteries which lack the influence of several factors involved in autoregulation in 
vivo. Examples of such factors are perivascular innervation, circulating substances in blood 
and shear stress due to blood flow.4, 5 In vivo experiments in Sprague Dawley rats, in fact, 
demonstrated forced dilatation at similar blood pressures in nonpregnant and pregnant 
animals.6 Interestingly, in this latter study, while the pressure at which breakthrough of 
autoregulation occurred appeared to be similar in pregnant and nonpregnant rats, only 
pregnant rats developed brain edema in response to this breakthrough.6 Furthermore, 
blood-brain barrier permeability for both 70,000 MW dextran and sodium fluorescein was 
increased in pregnant rats during a period of acute hypertension compared to nonpregnant 
rats.7 These findings suggest that it may not be a shift of the autoregulatory curve but rather 
an increased susceptibility for blood-brain barrier disruption, and edema formation, that 
underlie the cerebrovascular adaptation of pregnancy. Several mechanisms may underlie 
this susceptibility during pregnancy and have been the focus of studies in the Cipolla lab.
First, pregnancy seems to affect barrier properties of the cerebral endothelium 
thereby enhancing blood-brain barrier permeability. In rat posterior cerebral arteries, 
both increased permeability to dextran8 and Lucifer Yellow (Chapter 2) and enhanced 
pinocytosis (i.e. transcellular transport) were observed in response to increased pressure 
during pregnancy.8 However, permeability to water (i.e. hydraulic conductivity) appeared 
unaffected (Chapter 2). This differential effect of pregnancy on permeability to water 
versus solutes such as Lucifer Yellow and dextran suggests that pregnancy enhances 
transcellular transport without increasing hydraulic conductivity. The implications 
of this differential effect as well as the exact mechanistic basis of pregnancy-induced 
increased blood-brain barrier permeability remain so far elusive. The elevated estrogen 
levels during pregnancy appeared unrelated to this enhanced permeability (Chapter 2). 
Future studies should focus on other possible candidates contributing to or responsible for 
inducing increased arterial blood-brain barrier permeability during pregnancy, including 
progesterone or other pregnancy hormones, and angiogenic factors.  
Secondly, aquaporins, in particular aquaporin 4 as the most abundant cerebral 
aquaporin, have been suggested to play a role in the vulnerability towards cerebral edema 
formation during pregnancy.9 Given the localization of aquaporin 4 in the astrocytic 
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endfeet bordering the cerebral vasculature,10 this aquaporin may have a function in uptake 
of water that has entered the brain after blood-brain barrier disruption. In this scheme, 
aquaporin 4 may contribute to resolution of cerebral vasogenic edema. This is supported 
by studies using a freeze injury model of vasogenic edema, which showed increased brain 
water content in aquaporin 4 knockout mice compared to wild type mice.11, 12 A role in 
vasogenic edema formation seems less likely since aquaporin expression in the cerebral 
endothelium is doubtful.10, 13-15 As pregnant animals are more sensitive to formation of 
edema, one would hypothesize that the expression of aquaporin 4 would be decreased in 
pregnant animals. However, in contrast, we found increased expression mRNA of aquaporin 
4 in the posterior cerebrum and the cerebellum in pregnant versus nonpregnant rats 
(Chapter 3). In addition, aquaporin 4 protein expression was shown to be increased during 
pregnancy.16 The implications of these pregnancy-induced increases in cerebral aquaporin 
4 expression remain so far speculative. For example, the increased expression of aquaporin 
4 may represent a protective mechanism against the vulnerability of this brain region for 
vasogenic edema by its role in edema resolution. Alternatively, this altered aquaporin 4 
expression may influence susceptibility to seizures during pregnancy since mice lacking 
aquaporin 4 had higher seizure threshold.17 
Finally, a pregnancy-induced decrease in cerebrovascular resistance during pregnancy 
with subsequent increased hydrostatic pressure on the downstream microcirculation may 
enhance blood-brain barrier permeability. This is illustrated by the fact that pregnancy 
induced outward remodeling of rat penetrating brain arterioles, which appeared associated 
with decreased cerebrovascular resistance and hyperperfusion during acute hypertension, 
compared to the nonpregnant state.7 Furthermore, increased cerebral capillary density 
during pregnancy may also result in diminished cerebrovascular resistance. In situations 
accompanied by hypertension, this may lead to hyperperfusion and increased pressure on 
the downstream microcirculation.7 From this study, it therefore appeared that pregnancy 
may indeed enhance vulnerability of the blood-brain barrier by decreased cerebrovascular 
resistance when blood pressure is increased.
While the above mentioned studies have focused on cerebral arteries, the primary 
site of blood-brain barrier disruption might not reside in the cerebrovasculature’s arterial 
tree. In fact, blood-brain barrier disruption during acute hypertension is primarily 
described in cerebral veins,18, 19 making the influence of pregnancy on venous blood-brain 
barrier permeability of interest. A recent study showed that nonpregnant rat cerebral 
veins that were exposed to plasma from pregnant women had increased blood-brain 
barrier permeability compared to veins that were not exposed to plasma.20 Although this 
study may suggest that pregnancy-related circulating plasma factors may increase venous 
permeability, another study in cerebral veins demonstrated no difference in permeability 
when nonpregnant veins were perfused with nonpregnant plasma and compared to 







pregnancy protects against increases in blood-brain barrier permeability related to vascular 
endothelial growth factor (VEGF) or placental growth factor (PLGF) by increased levels of 
soluble fms-like tyrosine kinase-1 (sFlt-1).21 Additional future studies are needed to further 
elucidate the influence of pregnancy and circulating pregnancy factors on cerebral venous 
blood-brain barrier permeability.
In conclusion, although it has been the focus of several studies, a complete picture of 
the pregnancy-induced adaptation of the cerebral vasculature is lacking. Results from the 
above mentioned animal studies in pregnancy suggest a predilection for development of 
cerebral edema during, possibly even mild, increases in blood pressure. While a pregnancy-
related shift of the cerebral autoregulation curve seems less likely, other mechanisms 
such as a decrease in cerebrovascular resistance and/or enhanced blood-brain barrier 
permeability during pregnancy may be in place. To further elucidate such adaptations, 
more studies focusing on cerebral autoregulation and the blood-brain barrier in relation to 
pregnancy are required.
  
The brain during preeclampsia
Although studies in normal pregnancy may certainly add to our understanding of the 
cerebrovascular pathophysiology of preeclampsia, the influence of preeclampsia on the 
cerebral circulation is of particular interest. We raised the question whether preeclampsia 
further increases the tendency for cerebral edema formation, in addition to the effects of 
pregnancy per se. In this context, we hypothesized that preeclampsia decreases the blood 
pressure at which loss of autoregulation occurred (Chapter 4), thereby increasing the 
likelihood of edema formation at lower blood pressures. We used the low-dose endotoxin-
infused pregnant rat as experimental model for preeclampsia. This model is characterized 
by hypertension, proteinuria, intravascular disseminated coagulation, generalized 
activation of the inflammatory response as well as endothelial activation.22-25 The 
development of the preeclamptic-like syndrome in this model is considered to result from 
a systemic inflammatory response induced by endotoxin.23, 25, 26 Moreover, the syndrome 
is exclusively seen in pregnant animals, i.e. identically treated non-pregnant rats did not 
show the above mentioned signs.22-24 Given the severity of these symptoms and the limited 
effects on the fetuses, this model is considered a model of mild preeclampsia.22, 23 Even 
in this mild model of preeclampsia, we found that posterior cerebral arteries underwent 
forced dilatation at lower pressures compared to healthy pregnant rats. The mechanistic 
basis for forced dilatation at lower blood pressure during preeclampsia is so far unclear 
but might be related to increased sensitivity of cerebral arteries to nitric oxide, since it 
was recently shown that cerebral arteries from low-dose endotoxin-treated pregnant rats 
showed enhanced sensitivity to the dilatory effect of a nitric oxide donor27 and increased 
vascular inducible nitric oxide synthase,27 which might both explain the forced dilatation 
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at lower pressures. Whether similar changes occurred in the rats in our study remains 
to be studied, as the model of Cipolla et al, is different from our model, since a slightly 
higher dose of endotoxin was infused under isoflurane anesthesia, rather than under awake 
conditions.27 In addition, we did not measure blood pressure and thus direct comparisons 
cannot be made. The fact that even mild preeclampsia in our study decreased the pressure 
of forced dilatation, may suggest that in more severe models of preeclampsia, the pressure 
at which forced dilatation occurs might even be further decreased, thereby enhancing the 
predisposition for loss of autoregulation and cerebral edema formation.
In addition to a decreased pressure of forced dilatation in experimental preeclampsia, 
studies in hypertensive pregnancy models have shown that pregnancy prevents, and 
even reverses, protective remodeling of posterior cerebral arteries in response to 
hypertension.28-30 Since hypertensive remodeling attenuates the increased pressure on the 
downstream vasculature, it is considered a protective mechanism against the effects of 
an episode of acute hypertension.31 Lack of this remodeling may, therefore, lead to earlier 
forced dilatation at lower pressures and increased vulnerability of the blood-brain barrier 
to disruption. Our findings of lack of remodeling of cerebral arteries in experimental 
preeclamptic rats are in line with these previous findings of prevention of hypertensive 
remodeling during pregnancy (Chapter 4). Unfortunately, it was technically not possible 
to measure blood pressure in the rats in our study. From previous studies, we expect a 
mild rise in blood pressure (from about 110-120 to 130-140 mmHg), mainly in the last few 
days of pregnancy.22, 24, 32 The lack of remodeling could be due to this mild hypertension. 
Alternatively, the lack of blood pressure data does also leave the possibility that our rats 
did not reach hypertensive values, which may also explain lack of hypertensive remodeling.
In addition to these altered features pertaining to autoregulation, barrier properties 
of the cerebral endothelium seem also further impaired during preeclampsia. Exposure 
of cerebral rat veins to human preeclamptic plasma significantly increased blood-brain 
barrier permeability compared to exposure to plasma of normotensive pregnant women.20 
Whether this is also true for arteries, is unknown. While vascular endothelial growth factor 
(VEGF) is held responsible for this increase,21 several other factors may be involved in blood-
brain barrier permeability during (pre)eclampsia. For example, oxidative stress, histamine, 
nitric oxide, bradykinin and pro-inflammatory cytokines, such as tumor necrosis factor, 
interleukins and growth factors, all seem to increase blood-brain barrier permeability.33 
Since preeclampsia is also associated with oxidative stress and increased circulating 
proinflammatory cytokines in association with endothelial dysfunction, these factors might 
as well increase blood-brain barrier permeability changes during preeclampsia.34, 35 
Results from the above mentioned animal studies suggest that preeclampsia, in 
addition to the suggested pregnancy-induced adaptation, may further sensitize the brain 
to cerebral edema formation in face of increased blood pressure. They suggest that 







as changes in blood-brain barrier properties might play a role. However, these studies 
should just be considered the first pieces of the puzzle. Much more research is needed to 
unravel the influence of preeclampsia on the brain so that eventually brain involvement in 
preeclampsia can be prevented and/or adequately treated. In this light, studies focusing 
on neuroinflammatory markers of blood-brain barrier disruption are highly interesting. 
Such markers might be used to diagnose brain involvement in preeclamptic women in an 
early stage, during which clinical signs of brain involvement are still absent or indistinct. 
Use of these markers, such as S100B, glial fibrillary acidic protein (GFAP) and neuron-
specific enolase (NSE), seems promising in diagnosing brain damage and blood-brain barrier 
dysfunction in various neuropathologic states. Examples include cerebral hemorrhage, 
ischemic stroke, traumatic injury and iatrogenic blood-brain barrier disruption.36-38 Since 
these markers might also be useful in recognizing brain involvement in preeclamptic 
patients, we aimed to gain insight in S100B brain expression and plasma levels during 
experimental preeclampsia in de rat. Using the low-dose endotoxin-treated rat as model 
for preeclampsia, we found no effects of preeclampsia on both S100B brain expression 
and plasma levels (Chapter 5), suggesting that experimental preeclampsia did not induce 
brain injury. However, since women with severe preeclampsia are more at risk for cerebral 
involvement than women with mild preeclampsia,39 our findings might be explained by the 
fact that we used a model for mild preeclampsia. It is therefore possible that S100B brain 
expression and plasma levels are increased in animal models of more severe preeclampsia.
Long-term consequences of (pre)eclampsia
Neuroimaging findings
While the obstetrical literature and textbooks used to state that (pre)eclamptic 
women could expect full recovery, the persistent complaints by such women suggests 
otherwise. Years following (pre)eclampsia a substantial number of these women report 
impaired physical and mental well being.40, 41 Examples of common complaints include 
headache, visual disturbances, tiredness and loss of concentration or memory.40, 41  In 
addition, persistent abnormalities on cerebral imaging have been observed. Both formerly 
preeclamptic and eclamptic women demonstrate cerebral white matter lesions more 
often than women who had normotensive pregnancies (Chapter 8).42, 43 These reports 
hypothesized that such lesions were related to an episode of the posterior reversible 
encephalopathy syndrome (PRES), which is considered the underlying cause of the cerebral 
edema and neurological symptoms in eclamptic as well as some preeclamptic patients.2, 9 
This syndrome can also be encountered in several other patient categories, for example in 
patients with renal inflammatory conditions, chemotherapy and immunosuppression after 
organ transplantation.44, 45 Although follow-up studies in such non-obstetric PRES patients 
are largely lacking, the few available results have also shown persistent neuroimaging 
abnormalities in a substantial part of these patients, including white matter lesions.45-47 
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Subsequently, questions concerning the pathogenesis as well as the clinical implications of 
these lesions arose, which will be discussed below.
 While previous studies were not designed to provide insight into the pathogenesis 
of white matter lesions, it was deemed plausible that the vasogenic edema in PRES was 
responsible for inducing white matter lesions. With regards to this, vasogenic edema may 
progress to such an extent that regional blood flow and cerebral perfusion decreases to 
ischemic levels leading to areas of cytotoxic edema and the development of white matter 
lesions in the long-term.48, 49 The fact that more severe eclampsia, in terms of number of 
seizures, appeared related to a higher lesion load supported this hypothesis.42 However, 
with our demonstration of a mainly frontal localization of white matter lesions (Chapter 8), 
a direct causal relationship between the vasogenic edema of PRES and white matter lesions 
in the long-term seems doubtful since the edema in PRES is mainly located in the posterior 
brain regions.44 The distribution rather suggests that these lesions are an expression of 
the predisposition of formerly (pre)eclamptic women for cerebro-/cardiovascular disease. 
In accordance with this hypothesis, lesion distribution in conditions commonly associated 
with cerebro-/cardiovascular disease, such as migraine and vascular dementia, appear 
similar to that found following (pre)eclampsia.50, 51
 As stated, epidemiologic research in recent years has revealed an association 
between a history of preeclampsia and cerebro-/cardiovascular disease later in life.52 
Formerly preeclamptic women have an increased risk for development of systemic 
hypertension, ischemic and hemorrhagic stroke, ischemic heart disease and venous 
thromboembolism. Furthermore, these women have unfavourable cardiovascular risk 
profiles.53, 54 Though the mechanistic basis of the increased risk for cerebro-/cardiovascular 
disease in women who had preeclampsia remains elusive so far, many risk factors are 
shared by both conditions,53, 54 suggesting that both conditions are an expression of the 
same underlying predisposition. Examples of such common risk factors are hypertension, 
insulin resistance, hyperlipidemia and obesity.53, 54 In this context, the cardiovascular and 
metabolic demands of normal pregnancy are considered to be a physiologic “stress test” 
which can provide insight into a woman’s future health.55 Predisposed women fail this “stress 
test” and develop preeclampsia during pregnancy, thereby revealing their increased risk for 
cerebro-/cardiovascular disease later in life. In this scheme, an underlying predisposition 
for future cerebro-/cardiovascular disease may result in development of both cerebral 
white matter lesions and (pre)eclampsia earlier in life, without the obvious presence of a 
definite causal relationship between the two. An episode of PRES may in this light be seen 
as the death blow.
Clinical implications of cerebral white matter lesions
The clinical implications of cerebral white matter lesions in women who previously had 







neurocognitive functioning and visual disturbances on clinical follow-up after pregnancy-
related and non-obstetric PRES.56, 57 Part of these clinical sequelae was thought to be related 
to permanent cerebral lesions. However, the exact relationship between neuroimaging 
findings and clinical symptoms after PRES remains largely unknown.
White matter lesions are not only observed in former PRES patients. One-fifth of 
our healthy parous control women also demonstrated such lesions (Chapter 8). This is in 
line with a previous study which also reported a rather high prevalence of white matter 
lesions in relatively young healthy cohorts.58 The exact clinical importance of this lesion 
burden in a young cohort, as in our study, is not clear and may be related to the normal 
process of ageing. Concerning, though, is the fact that in the elderly there is evidence 
that the presence, and particularly the severity, of white matter lesions are risk factors 
for the development of cognitive impairment, vascular dementia, Alzheimer’s disease 
and stroke.59 One could therefore hypothesize that white matter lesions in our formerly 
(pre)eclamptic women may also be associated with impairment of cognitive functioning 
and might even predispose to dementia. Even though this remains rather speculative as 
of 2012, it is of particular interest since preeclampsia and Alzheimer’s disease appear to 
share (epi)genetic features, namely expression of the STOX1 gene.60 In preeclampsia, this 
placentally-expressed gene has been proposed to be involved in trophoblast dysfunction, 
whereas in Alzheimer’s disease cerebral STOX1 expression may have a role in amyloid 
deposition, a key event in the pathogenesis of Alzheimer’s disease.61, 62 However, sizeable 
studies concerning the causal relationship between white matter lesions and impaired 
cognitive functioning are not yet available. Small studies, however, indicate that self-
reported cognitive functioning seems lower in women who had eclampsia,63 while we have 
now shown that white matter lesions in formerly eclamptic women seemed associated 
with decreased vision-related quality of life (Chapter 7). The latter might be related to 
impaired higher-order neurocognitive functions involved in vision since visual fields of 
these women were intact. Studies regarding objective neurocognitive functioning following 
(pre)eclampsia have so far been inconclusive.64-66 
Further studies regarding cognitive functioning following (pre)eclampsia and 
its relationship with white matter lesions are required to answer the ominous question 
whether a history of (pre)eclampsia might be related to cognitive impairment and even 
dementia later in life. But, since white matter lesions following (pre)eclampsia may be 
considered an expression of a predisposition to future cerebro-/cardiovascular disease, 
this stresses the importance of evaluation of cerebro-/cardiovascular risk factors in such 
women. In this context, postpartum lifestyle interventions seem hope giving, since such 





Animal studies in this thesis found that pregnancy increased blood-brain barrier permeability 
of cerebral arteries to Lucifer Yellow in response to rising pressure. This increase in blood-
brain barrier permeability may predispose to cerebral edema formation during acute 
hypertension and appeared unrelated to elevated estrogen levels during pregnancy. The 
mechanism underlying the increase in blood-brain barrier permeability should therefore 
be the focus of future studies. Furthermore, pregnancy and the postpartum state induce 
changes in cerebral aquaporin expression. While these changes may relate to altered edema 
resolution and seizure threshold, the implication remains to be elucidated. In addition to 
these pregnancy-related adaptations of the cerebrovasculature contributing to vulnerability 
for cerebral edema formation during acute hypertension, preeclampsia seemed to further 
increase this vulnerability. In an animal model of preeclampsia, posterior cerebral arteries 
underwent forced dilatation at lower pressure compared to normal pregnancy, suggesting 
a possible leftward shift of the upper limit of autoregulation. Despite these suggested 
effects on autoregulation, preeclamptic animals did not demonstrate signs of brain injury 
as assessed by the neuroinflammatory marker S100B, which might be explained by the fact 
that we used a model for mild preeclampsia. In conclusion, these studies have expanded 
our current knowledge about pregnancy-related adaptation of the cerebral vasculature 
and how such adaptation may enhance the vulnerability of the brain to cerebral edema 
formation during acute hypertension, as in eclampsia. Additionally, this thesis suggests 
that preeclampsia may even further increase this vulnerability.
Human studies in this thesis demonstrated the presence of long-term brain 
involvement following (pre)eclampsia. Formerly eclamptic women reported lower 
vision-related quality of life several years following eclampsia, which appeared at least 
partly related to the presence of cerebral white matter lesions. Since these women 
had intact visual fields, decreased vision-related quality of life compared to women 
following a normotensive pregnancy might be due to impairment of higher-order visual 
functions. Furthermore, formerly (pre)eclamptic women demonstrate a higher prevalence 
of cerebral white matter lesions than women who had normotensive pregnancies. The 
regional distribution of these lesions suggests a relationship with a propensity towards 
cerebro-/cardiovascular disease rather than a direct causal relation with a prior episode 
of PRES. These studies add to the existing evidence that (pre)eclampsia should not be 
conceptualized as a completely reversible condition, from which women can expect full 
recovery. In addition, they emphasize the importance of evaluation and reduction of 








Cerebrovascular changes in pregnancy and preeclampsia
Several animal studies have focused on the adaptation of the brain to pregnancy. However, 
how pregnancy affects cerebral autoregulation and the blood-brain barrier has still not 
completely been unraveled. Future studies in both animal models and the human should 
gain further insight into pregnancy-induced adaptation of both the arterial and venous 
circulations of the brain. Moreover, studies evaluating whether and how preeclampsia 
additionally affects the cerebral circulation should be continued. Such studies should 
make use of different experimental animal models of preeclampsia, such as models 
based on reduced uterine perfusion pressure (RUPP) or soluble fms-like tyrosine kinase-1 
(sFlt1) infusion.68 This will not only answer the question whether study results are model-
dependent but may also give insight into cerebrovascular functioning in relation to severity 
of preeclampsia. In studies using such models, it would be highly interesting to focus on 
the underlying mechanism by which pregnancy and preeclampsia enhance vulnerability of 
the blood-brain barrier. While estrogen seemed unrelated to increased blood-brain barrier 
permeability during pregnancy, the role of several other factors should be assessed.  For 
example, effects of endothelial dysfunction and the various circulating factors, such as pro-
inflammatory cytokines and (anti)angiogenic substances, pertaining to this preeclampsia-
related vulnerability should be assessed. When such mechanisms become unraveled, the 
next step would be to shift the focus towards studies assessing methods to protect the 
blood-brain barrier. 
Recognition of impending brain involvement in preeclampsia 
To aid in the diagnosis of (impending) cerebral involvement during preeclampsia, future 
studies should be directed towards the identification and usefulness of neuroinflammatory 
markers in preeclampsia. These markers, such as S100B and neuron-specific enolase (NSE), 
may be increased in serum and/or cerebrospinal fluid before clinical symptoms of brain 
involvement become apparent. Early recognition of cerebral involvement in preeclamptic 
women may eventually lead to prevention of progression to eclampsia/PRES or other 
devastating complications such as hemorrhage. Therefore, both animal and clinical studies 
in healthy pregnant and preeclamptic subjects should be designed to determine levels 
of several neuroinflammatory markers in serum and cerebrospinal fluid. These studies 
should compare levels between normal pregnant and preeclamptic subjects and assess the 
relation between these levels and cerebral involvement.
Long-term consequences of (pre)eclampsia 
While impaired cognitive functioning has been suggested following (pre)eclampsia, 
objective neurocognitive studies are needed to further evaluate cognitive functioning in 
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such women and to assess whether higher-order visual functions are impaired. The presence 
of a relation between results from these neurocognitive tests and cerebral neuroimaging 
findings should be investigated. In these analyses not only presence and severity of cerebral 
lesions should be taken into account, but also their regional distribution as this may give 
clues towards their clinical sequelae.
To further elucidate the role of PRES in the pathogenesis of cerebral white matter 
lesions and long-term consequences following (pre)eclampsia, additional studies are 
warranted that include patient categories with non-obstetric PRES. Neuroimaging and 
neurocognitive follow-up data from these non-obstetric PRES patients should be compared 
to data from (pre)eclamptic PRES patients.
Concerning the future clinical implications of cerebral white matter lesions in our 
cohorts of formerly (pre)eclamptic women, studies with extensive follow-up periods should 
be designed. These studies may give answer to the questions whether these women are at 
increased risk for developing future cognitive impairment, or even dementia, and cerebro-/
cardiovascular disease and whether this is related to white matter lesions earlier in life. 
Since women within this group are probably not homogeneous with respect to these future 
sequelae, an emphasis should be placed on the identification of women with the highest 
risk for developing cerebro-/cardiovascular disease. In addition to long-term follow-up 
studies, retrospective studies in cohorts of women with dementia may give insight in the 
possible relation with preeclampsia earlier in life. 
Interventions for formerly (pre)eclamptic women 
In view of the increased risk for future cerebro-/cardiovascular disease in formerly 
(pre)eclamptic women, studies are needed that focus on the development and establishment 
of effective and feasible lifestyle intervention programs for formerly (pre)eclamptic 
women. Such interventions may reduce risk factors, such as overweight, cholesterol levels 
and blood pressure, in those women who are prone to developing cerebro-/cardiovascular 
disease later in life. In addition to interventions addressing cardiovascular risk factors, 
attention should be paid towards investigating therapeutic and counseling modalities for 
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Pre-eclampsie is een zwangerschapsgerelateerde aandoening die optreedt bij 
5 tot 7% van de zwangerschappen. De aandoening is gedefinieerd als het optreden van 
hypertensie en proteïnurie tijdens de tweede helft van de zwangerschap bij een voorheen 
normotensieve vrouw. Pre-eclampsie is een systemische aandoening waarbij onder andere 
de lever en nieren betrokken kunnen raken. Ook de hersenen kunnen aangedaan zijn in de 
vorm van eclampsie, het optreden van tonisch-clonische insulten bij een vrouw met pre-
eclampsie zonder andere aanwijsbare oorzaak. Naast eclamptische insulten kunnen andere 
neurologische verschijnselen voorkomen, waaronder hoofdpijn, misselijkheid en braken, 
en visusstoornissen. Hoewel hersenbetrokkenheid bij pre-eclampsie weinig voorkomt, is 
het verantwoordelijk voor een substantieel deel van de maternale sterfte in de westerse 
wereld en zo ook in Nederland. 
Om eclampsie adequaat te kunnen voorkomen, behandelen, en eventuele 
langetermijngevolgen te begrijpen is kennis over het ontstaan van eclampsie essentieel. 
In Hoofdstuk 1 wordt ingegaan op de pathofysiologie van eclampsie. Omdat de cerebrale 
circulatie hierbij een cruciale rol speelt, worden in dit hoofdstuk verschillende aspecten 
van de cerebrale circulatie besproken, te weten cerebrale autoregulatie en de bloed-
hersenbarrière. Deze cerebrale autoregulatie, middels aanpassing van de diameter van 
de bloedvaten, zorgt ervoor dat de cerebrale bloeddoorstroming gelijk blijft ondanks 
veranderingen in bloeddruk. Wanneer de bloeddruk echter boven de maximale grens van 
de cerebrale autoregulatie stijgt, zoals bij eclampsie wordt aangenomen het geval te 
zijn, ontstaat er geforceerde dilatatie van de bloedvaten. De huidige opvatting over de 
pathofysiologie van eclampsie is dan ook dat een acute bloeddrukstijging, in combinatie 
met endotheeldysfunctie, leidt tot geforceerde dilatatie van de cerebrale vasculatuur. Dit 
resulteert vervolgens in cerebrale hyperperfusie, gevolgd door beschadiging van de bloed-
hersenbarrière. Hierdoor kunnen water, eiwitten en electrolyten uit de bloedvaten treden 
en wordt vasogeen oedeem gevormd. Dit oedeem veroorzaakt vervolgens het zogenaamde 
‘posterior reversible encephalopathy syndrome’ (PRES). Het is echter nog grotendeels 
onbekend waarom de hersenen tijdens zwangerschap, en pre-eclampsie in het bijzonder, 
vatbaar zijn voor het ontwikkelen van PRES/eclampsie. In Deel 1 van dit proefschrift wordt 
daarom in diermodellen gekeken naar de invloed van zwangerschap en pre-eclampsie op 
de cerebrale circulatie. 
 Tot voor kort werd gedacht dat in geval van eclampsie, wanneer de bloeddruk 
normaliseert, het hersenoedeem verdwijnt en de patiënte volledig herstelt. Recentelijk 
is men dit volledige herstel echter in twijfel gaan trekken, zoals in Hoofdstuk 1 wordt 
besproken. Veel vrouwen melden neurocognitieve klachten na het doormaken van 
eclampsie, waaronder problemen met geheugen en concentratie. Daarnaast vertonen 
zij jaren na het doormaken van eclampsie vaker wittestoflaesies op MRI scans van de 
hersenen. In Deel 2 van dit proefschrift wordt gekeken naar de regionale verdeling van 
deze laesies en mogelijke langetermijngevolgen op het visueel functioneren. Daarnaast 
worden in deel 2 visusstoornissen in de acute fase van eclampsie besproken.
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Deel I - Dierexperimentele studies
Uit eerder onderzoek is gebleken dat bij zwangere en niet-zwangere ratten doorbraak van 
de cerebrale autoregulatie plaatsvond bij vergelijkbare drukken. Echter, alleen zwangere 
ratten ontwikkelden cerebraal oedeem in respons op deze doorbraak. In Hoofdstuk 2 wordt 
gekeken naar het onderliggende mechanisme waarop zwangerschap de hersenen vatbaarder 
maakt voor het ontwikkelen van oedeem tijdens acute hypertensie. De hypothese was dat 
de permeabiliteit van het cerebrale endotheel in respons op hydrostatische druk toeneemt 
tijdens zwangerschap. Om dit te onderzoeken werden de permeabiliteitscoëfficiënten van 
Lucifer Yellow (LY) en de hydraulische conductiviteit (Lp; permeabiliteit voor water) in de 
arteria cerebri posterior (ACP) van niet-zwangere en zwangere ratten vergeleken (n=7 in 
beide groepen). De permeabiliteitscoëfficiënt van LY was toegenomen in zwangere versus 
niet-zwangere proefdieren (P<0.05). Dit zou de hersenen mogelijk vatbaarder kunnen 
maken voor oedeemvorming tijdens acute hypertensie. Tijdens zwangerschap nam L p 
echter niet toe, wat suggereert dat zwangerschap een verschillend effect heeft op bloed-
hersenbarrière permeabiliteit voor LY en water. 
Om te onderzoeken of de toegenomen permeabiliteitscoëfficiënt voor LY een gevolg 
was van verhoogde oestrogeenspiegels tijdens zwangerschap, werd de permeabiliteit 
voor LY tevens onderzocht in ratten die een ovariëctomie hadden ondergaan en 
vervolgens behandeld werden met oestrogeen (n=7) of placebo (n=6). Hierbij bleek dat 
oestrogeenbehandeling toename van de permeabiliteitscoëfficiënt kon tegengaan na 
ovariëctomie (P<0.05). Dit suggereert dat oestrogeen een beschermend effect heeft op 
de bloed-hersenbarrière permeabiliteit en dat de toename van deze permeabiliteit tijdens 
zwangerschap niet wordt veroorzaakt door toegenomen oestrogeenspiegels.
Cerebrale aquaporines (AQPs) spelen mogelijk een rol bij cerebrale oedeemvorming en 
-resolutie tijdens pathologische condities zoals eclampsie. Daarom werd in Hoofdstuk 
3 met behulp van real-time quantitative polymerase chain reaction gekeken naar de 
expressie van AQP1, 4 en 9 in rattenhersenen tijdens zwangerschap en de postpartum 
periode. Hierbij werd expressie van alle drie AQPs gevonden in zowel het anterieure en 
posterieure cerebrum, het cerebellum alsmede de hersenstam. Dit gold voor zowel de 
niet-zwangere (n=5) en postpartum (n=5) ratten als ook proefdieren halverwege (n=5) en 
aan het eind (n=6) van de zwangerschap. Tijdens zwangerschap was de expressie van 
AQP1 en 9 in het posterieure gedeelte van de hersenen en het cerebellum afgenomen. 
Ook was er lagere AQP1-expressie in het cerebellum van postpartum versus niet-zwangere 
ratten. In tegenstelling tot de zwangerschapsgerelateerde afname van de AQP1- en 
9-expressie in het posterieure cerebrum en cerebellum, was de AQP4-expressie in deze 
gebieden toegenomen in zwangere versus niet-zwangere ratten. Echter, AQP4-expressie in 
het anterieure cerebrum was lager in postpartum dan in niet-zwangere ratten. Omdat de 
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exacte rol van AQPs in de hersenen nog niet is opgehelderd, zijn de implicaties van deze 
bevindingen nog speculatief. Mogelijk hebben AQPs invloed op oedeemresolutie en/of de 
drempel tot het ontstaan van een insult waarbij ook de anatomische locatie een rol speelt.
In Hoofdstuk 4 is gekeken naar de invloed van pre-eclampsie, naast dat van gezonde 
zwangerschap, op de myogene activiteit en opbouw van cerebrale weerstandsarteriën. 
Hiervoor werd gebruik gemaakt van een diermodel voor pre-eclampsie, waarin zwangere 
ratten behandeld werden met een lage dosis endotoxine. Deze endotoxine veroorzaakt een 
laaggradige systemische inflammatoire respons die leidt tot symptomen die worden gezien 
in humane pre-eclampsie, namelijk hypertensie, proteïnurie, gedissemineerde intravasale 
stolling en gegeneraliseerde endotheelactivatie. Naast cerebrale arteriën werden tevens 
mesenteriale weerstandsarteriën onderzocht om te bekijken of pre-eclampsie een 
vergelijkbaar effect had op de perifere vasculatuur.
Niet-zwangere en zwangere ratten werden behandeld met fysiologisch zout (n=9 
in beide groepen) of een lage dosis endotoxine (n=9 in de niet-zwangere en n=10 in de 
zwangere groep). Op dag 20 van de zwangerschap, of 6 dagen na behandeling bij niet-
zwangere ratten, werden de myogene activiteit, de druk waarbij geforceerde dilatatie 
plaatsvond en de structurele eigenschappen onderzocht van de arteria cerebri posterior 
(ACP) en arteria mesenterica (AM). Het bleek dat zowel gezonde zwangerschap als 
endotoxine-infusie geen invloed hadden op de structuur en myogene tonus van ACP zolang 
de drukken binnen de autoregulatoire range bleven. Echter, endotoxinebehandeling 
leidde bij zwangere ratten tot verlaging van de druk waarop geforceerde dilatatie 
ontstond vergeleken met gezonde zwangere en niet-zwangere ratten. Dit suggereert dat 
pre-eclampsie, maar niet de gezonde zwangerschap, predisponeert tot doorbraak van 
cerebrale autoregulatie en oedeemvorming tijdens bloeddrukstijging zoals bij eclampsie. 
Ook in AM hadden zwangerschap en endotoxinebehandeling geen effect op de structuur 
van deze vaten. Echter, in tegenstelling tot in ACP, veroorzaakte zwangerschap een afname 
van myogene tonus van MA, zonder bijkomende invloed van endotoxine. Dit verschil in 
bevindingen in myogene tonus tussen ACP en AM kan mogelijk verklaard worden door de 
functionele verschillen tussen het perifere mesenteriale en cerebrale vaatbed. De afname 
van myogene tonus van AM zou mogelijk een rol kunnen spelen in de afgenomen perifere 
vasculaire weerstand die tijdens zwangerschap optreedt. De ACP liet geen afname van 
myogene tonus zien. Dit zou verklaard kunnen worden door het feit dat in het cerebrale 
vaatbed strikte autoregulatie van bloeddoorstroming nodig is om ischemie of hyperperfusie 
te voorkomen. Mogelijk is dit tijdens zwangerschap des te meer van belang, gezien het 
toegenomen plasmavolume en hartminuutvolume.
Om te onderzoeken of bovengenoemde veranderingen in ACP-functie waren 
gerelateerd aan andere vormen van schade in de hersenen, is in Hoofdstuk 5 gekeken naar 
de aanwezigheid van hersenschade in met endotoxine behandelde zwangere ratten, een 
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model voor pre-eclampsie. In dit onderzoek werd de aanwezigheid van S100B, een marker 
voor neuroinflammatie, gemeten in de hersenen en de perifere circulatie. Hierbij werden 
geen verschillen in cerebrale S100B-expressie gevonden tussen niet-zwangere ratten 
behandeld met fysiologisch zout (n=5) of endotoxine (n=7) en zwangere ratten behandeld 
met fysiologisch zout (n=7) of endotoxine (n=7). Ook plasmaspiegels van S100B waren 
vergelijkbaar bij zwangere ratten die waren behandeld met endotoxine of fysiologisch zout. 
Uit deze resultaten concludeerden we dat zwangerschap en experimentele pre-eclampsie 
de cerebrale expressie en plasmaspiegels van S100B niet beïnvloeden. Dit suggereert dat 
er geen sprake was van betrokkenheid van de hersenen in ratten met experimentele pre-
eclampsie.
Deel II - Humane studies
In Hoofdstuk 6 wordt een overzicht gegeven van de bestaande literatuur over 
visusstoornissen bij patiënten met (pre-)eclampsie en HELLP-syndroom. Aangezien 
visusstoornissen relatief vaak voorkomen bij (pre-)eclampsie patiënten, kunnen obstetrici 
regelmatig geconfronteerd worden met pathologie van het visuele systeem. Naast dat de 
meeste symptomen onverklaard blijven en van voorbijgaande aard zijn, zijn verschillende 
oogheelkundige afwijkingen nadrukkelijk geassocieerd met (pre-)eclampsie, waaronder 
corticale blindheid, sereuze retinaloslating, retinopathie van Purtscher, veneuze 
stamocclusie en bloedingen in de retina of het glasvocht. Visuele symptomen die als gevolg 
van deze afwijkingen door patiënten kunnen worden geuit zijn wazig zien, amaurosis fugax, 
fotopsie en scotomen, waaronder homonieme hemianopsie. Over het algemeen is, behalve 
het verlagen van de bloeddruk en voorkomen van insulten, geen specifieke behandeling 
geïndiceerd voor patiënten met pre-eclampsie en visusstoornissen. In het merendeel 
van de gevallen herstelt de gezichtsscherpte zich na de zwangerschap. Permanente 
visusstoornissen na (pre-)eclampsie zijn echter incidenteel beschreven en zijn gerelateerd 
aan persisterende cerebrale laesies, infarcering, en/of afwijkingen van de retina.
Jaren na het doormaken van (pre-)eclampsie zijn bij deze vrouwen cerebrale 
wittestoflaesies beschreven. Mogelijk zijn deze laesies gerelateerd aan visusproblemen, 
voornamelijk wanneer ze gelegen zijn in de cerebrale visuele gebieden. Daarom was 
het doel van Hoofdstuk 7 om te onderzoeken of voormalig eclamptische vrouwen een 
lagere visusgerelateerde kwaliteit van leven ervaren. Voormalig eclamptische vrouwen 
(n=46) en controles die (een) normotensieve zwangerschap(pen) hadden doorgemaakt 
(n=47) vulden een gevalideerde visus-gerelateerde kwaliteit van leven vragenlijst (NEI-
VFQ-39/NL) in. Samengestelde scores en 4 van de 12 subschaalscores van de NEI-VFQ-39/
NL, te weten algemene gezondheid, visusgerelateerd sociaal functioneren, autorijden en 
perifere zien, waren significant lager voor voormalig eclamptische vrouwen vergeleken 
met controles (P<0.01 voor samengestelde scores). Om te bekijken of deze lagere 
170
scores van voormalig eclamptische vrouwen verklaard zouden kunnen worden door 
gezichtsvelduitval als gevolg van wittestoflaesies, werd bij hen een gezichtsveldonderzoek 
verricht (n=43). De gezichtsvelden van alle vrouwen bleken intact, wat suggereert dat de 
lagere visusgerelateerde kwaliteit van leven niet was geassocieerd met gezichtsvelduitval. 
Echter, bij 35,7% van de voormalig eclamptische vrouwen die een MRI ondergingen (n=42) 
waren wittestoflaesies aanwezig, en deze laesies waren geassocieerd met lagere NEI-
VFQ-39/NL samengestelde scores en 4 van de 12 subschaalscores, te weten algemeen 
gezichtsvermogen, dichtbij zien, visusgerelateerde rolproblemen en perifere zien (P<0.05 
voor samengestelde scores). Deze lagere scores in de subgroep van voormalig eclamptische 
vrouwen met wittestoflaesies zouden gerelateerd kunnen zijn aan verminderd functioneren 
van hogere orde visuele functies als gevolg van wittestoflaesies in de cerebrale gebieden 
die bij deze functies betrokken zijn.
Hoofdstuk 8 had tot doel om inzicht te krijgen in de mogelijke pathogenese en 
consequenties van cerebrale wittestoflaesies na eclampsie, die werden beschreven in het 
vorige hoofdstuk. Hiervoor werd gekeken naar de regionale verdeling van deze laesies 
op MRI-scans van vrouwen jaren na het doormaken van eclampsie (n=63), pre-eclampsie 
(n=74) en normotensieve zwangerschappen (n=75). Dit liet, in overeenstemming met eerder 
onderzoek, zien dat voormalig (pre-)eclamptische vrouwen vaker wittestoflaesies hadden 
dan vrouwen die normotensieve zwangerschappen hadden gehad (35.0% versus 21.3%; 
P<0.05). Bovendien waren deze laesies ernstiger in de (pre-)eclampsie groep vergeleken 
met de groep met normotensieve zwangerschappen (0.07 versus 0.02 mL; P<0.05). In alle 
groepen was het merendeel van de wittestoflaesies gelegen in de frontale kwab, gevolgd 
door de pariëtale, insulaire en temporale kwabben. Hieruit werd geconcludeerd dat de 
regionale verdeling van wittestoflaesies vergelijkbaar was voor alle drie groepen. Opvallend 
is dat deze verdeling overeenkomt met de verdeling van wittestoflaesies bij condities die 
geassocieerd zijn met cerebro-/cardiovasculaire ziekte, zoals migraine en dementie. De 
wittestoflaesies bij voormalig (pre-)eclamptische vrouwen zouden daarom mogelijk een 
uiting kunnen zijn van de predispositie van deze vrouwen voor cerebro-/cardiovaculaire 
ziekte. Deze bevindingen benadrukken, naast de reeds bestaande literatuur, het belang 
van evaluatie van cerebro-/cardiovaculaire risicofactoren bij voormalig (pre-)eclamptische 
vrouwen. Daarnaast is gesuggereerd dat het doormaken van ‘posterior reversible 
encephalopathy syndrome’ (PRES), het onderliggende mechanisme achter de neurologische 
symptomen in de acute fase van (pre-)eclampsie, mogelijk ook een rol speelt bij het 
ontstaan van wittestoflaesies. Gezien de regionale verdeling van wittestoflaesies, veel 
meer frontaal dan posterieur, lijkt dit echter minder waarschijnlijk.
Tot slot worden in Hoofdstuk 9 een algemene discussie, conclusies en mogelijkheden 
voor toekomstig onderzoek gegeven. Uit de dierstudies wordt geconcludeerd dat 
zwangerschap, en pre-eclampsie in het bijzonder, verschillende facetten van de hersenen 
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en cerebrale circulatie beïnvloedt en dat dit mogelijk leidt tot een toegenomen vatbaarheid 
van de hersenen voor ontwikkeling van oedeem tijdens acute bloeddrukstijging. Zowel 
de tijdens zwangerschap gevonden toegenomen permeabiliteitscoëfficient van cerebrale 
vaten voor Lucifer Yellow als de veranderde aquaporine-expressie kunnen invloed 
hebben op cerebrale oedeemvorming en/of –resolutie. De exacte implicaties van deze 
zwangerschapsgerelateerde cerebrale adaptatie zouden in toekomstig onderzoek verder 
moeten worden onderzocht. Naast de invloed van gezonde zwangerschap, lijkt pre-
eclampsie de kwetsbaarheid voor cerebrale oedeemvorming verder te doen toenemen. 
Pre-eclampsie leidde in hersenvaten namelijk tot geforceerde dilatatie bij lagere drukken 
dan in gezonde zwangerschap. Dit suggereert een toegenomen kwetsbaarheid voor bloed-
hersenbarrièredoorbraak en vervolgens oedeemvorming. Deze kwetsbaarheid lijkt niet 
geassocieerd te zijn met andere vormen van hersenbetrokkenheid, zoals werd onderzocht 
met de neuroinflammatoire marker S100B.
 Met betrekking tot de klinische studies wordt in aanvulling op eerder onderzoek 
geconcludeerd dat (pre-)eclampsie niet langer als een compleet reversibele aandoening 
kan worden beschouwd waarvan vrouwen geheel genezen. Jaren na het doormaken van 
eclampsie hebben vrouwen namelijk een lagere visusgerelateerde kwaliteit van leven 
dan vrouwen die een normotensieve zwangerschap doormaakten. Hierbij lijkt er een 
relatie te zijn met aanwezigheid van cerebrale wittestoflaesies, die vaker voorkomen na 
(pre-)eclampsie dan na een normotensieve zwangerschap. Voorts suggereert de regionale 
verdeling van deze wittestoflaesies een verband met een constitutionele aanleg voor 
cerebro-/cardiovasculaire ziekte die voormalig (pre-)eclamptische vrouwen hebben. 
Hiermee wordt het belang van evaluatie en reductie van cerebro-/cardiovasculaire 
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